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Myxomatous mitral valve disease (MMVD) is one of the most common degenerative 
cardiac diseases affecting humans and dogs; however, its pathogenesis is not 
completely understood. This study focussed on developing tissue-engineered fibrin 
based canine mitral valve constructs, which can be used as an in vitro platform to 
study the pathogenesis of MMVD.  
Prior to three dimensional (3D) construct fabrication, primary canine mitral valve 
endothelial cells (VECs) and valve interstitial cells (VICs) were isolated, cultured 
and characterized utilising a variety of techniques. Moreover, preliminary 
experiments were carried out to optimise the purity of VEC cultures.  
It is uncertain if canine MMVD is initiated by long term shear stress damage to the 
valve endothelium or from abnormalities of VICs. To investigate both hypotheses, 
three types of models were produced using fibrin/based 3D culture techniques: 
healthy VEC-VIC co-culture (Type 1); healthy VEC-diseased VIC co-culture (Type 
2); healthy VEC-VIC co-culture with endothelial damage during culture (Type 3). 
Histological examination demonstrated partial native tissue-like morphology of the 
3D constructs. Results suggest that current static cultured constructs express MMVD 
markers irrespective of using healthy or diseased VICs. Simple mechanical 
stimulation was found to regulate VIC activity in the 3D models. Endothelial damage 
resulting in VIC phenotypic activation (a change typically observed in MMVD), and 
decreased mechanical tension appeared to be a negative regulator of this effect. 
Moreover, there appears to be heterogeneity in the activated VIC population.  
Additionally, distinct advanced glycation end product (AGE) carboxymethyllysine 
(CML) expression was found in canine MMVD valves, which suggesting this 
biochemical compound (known to affect long living protein) might be a putative 
regulator of MMVD pathogenesis. The role of CML in MMVD can be further 
investigated utilizing current 3D static mitral valve construct model in future studies. 
Lastly a prototype dynamic tubular construct and a customised bioreactor system 




fabrication and endothelialisation, which provides foundation for future dynamic 
conditioning experiments and will allow examination of the role of endothelial shear 
stress in triggering MMVD.  
In summary, this project successfully developed fibrin based canine mitral valve 
constructs. It is believed they are promising models for MMVD research, allowing 
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Chapter 1: Introduction 
1.1 Mitral Valve Biology 
1.1.1 Gross Anatomy  
The mitral valve, also called bicuspid valve, is a connective tissue structure between 
the left atrium and left ventricle which functions to separate the two heart chambers 
and to prevent the blood flow from left ventricle back to left atrium. This delicate 
structure closes and opens more than 2 billion times during the average human life. 
The mitral valve was named by Andreas Vesalius, an anatomist in the 16
th
 century 
(Walmsley, 1929), because the shape of the valve is similar to a bishop’s mitre. The 
term mitral valve complex usually refers to the annulus, the leaflets, chordae 
tendineae and papillary muscles (Fenoglio et al., 1972; Frater and Ellis, 1961; 
Silverman and Hurst, 1968). Some literature has suggested that the left atrial and left 
ventricular myocardium should be considered part of the mitral apparatus as well 
since myocardial performance is associated with mitral valve regurgitation (Perloff 
and Roberts, 1972). All these components interact with each other and determine the 
overall mitral valve function. Among them are the annulus, leaflets and chordae 
tendineae and these are discussed in detail below. 
 Annulus 1.1.1.1
The annulus is the fibrous junction where the two mitral valve leaflets anchor, at the 
confluence of the left atrial and left ventricular walls (Fox, 2012; Silverman and 
Hurst, 1968). It is a discontinuous fibrous ring containing collagen, elastin and scant 
cartilage in dogs (Evans, 1993; Fenoglio et al., 1972; Silverman and Hurst, 1968). 
The mitral annulus comprises the anterior and posterior portions in accordance with 
anterior and posterior leaflets. The anterior part of the annulus consists of a left 
fibrous trigone and a right fibrous trigone (Evans, 1993). The left fibrous trigone lies 
in the triangular confluence of anterior mitral valve-aortic valve juncture. The right 
trigone is situated between the left and right atrioventricular (AV) orifice. The left 
and right fibrous trigones are united at the central fibrous body (Evans, 1993; 
Silverman and Hurst, 1968). It is a dynamic structure with capacity to alter shape and 




points for valve leaflets and atrial and ventricular muscle, the annulus is essential to 
modulate dilation of the valve orifice. Annulus dilation, if it occurs, is associated 
with increased valve regurgitation (Grewal et al., 2010) and altered shear stress 
distribution on the mitral valve leaflet surface (Misfeld and Sievers, 2007; Salgo et 
al., 2002). 
 Mitral Valve Leaflets 1.1.1.2
The major components of the mitral valves are two leaflets: anterior and posterior 
leaflets. Normally they are thin and translucent membrane-like structures without 
nodules or evidence of thickening (Whitney, 1967). The leaflets attach to the annulus 
and the chordae tendineae and form a coordinated unit. There are two zones present 
on the leaflet surface: rough zone, which is near the valve free edge where the 
chordae tendineae insert while the smooth zone is localized near the annular junction 
(Connell et al., 2012). Comparing the atrial surface to the ventricular aspect, the 
former is smooth and relatively transparent while the latter is more rough and 
irregular and serves as attachment point for the chordae tendineae (Fox, 2012). It has 
been shown that the leaflet surface area is greater than the mitral orifice area, which 
indicates that the two leaflets must have contact with each other close to the end of 
systole (Borgarelli et al., 2011; Kunzelman et al., 1994; Pohost et al., 1975).  
The two mitral leaflets are not completely identical. The anterior leaflet is adjacent to 
the aortic valve, and is also called the aortic leaflet of the mitral valve or septal 
leaflet. It is anchored by the fibrous region of the continuity of the aortic annulus. 
The anterior leaflet is longer than posterior leaflet, and has more chordae tendineae 
attachment (Borgarelli et al., 2011; Frater and Ellis, 1961; Hadian et al., 2007; Han et 
al., 2010). The posterior leaflet, also called the mural leaflet is smaller and more 
compliant compared to the anterior leaflet (Fox, 2012; Richards et al., 2012). 
Healthy mitral valves are usually considered as avascular. In canine mitral valves, 
vascular components have been found restricted to the proximal portion of the cusps 
(Fenoglio et al., 1972; Sonnenblick et al., 1967). Similar to the vascularization, 
innervation of canine mitral valves occurs predominately in the proximal part of the 




and there is a dramatic reduction of innervation with advancing aging (Culshaw et 
al., 2010). Some evidence suggests innervation may be associated with valve 
function (Bassett et al., 1976; Woollard, 1926). In degenerative mitral valve disease 
in dogs, however, there is no alteration of innervation pattern or density (Culshaw et 
al., 2010). 
 Chordae Tendineae 1.1.1.3
Chordae tendineae are columnar structures unique to AV valves which link the valve 
leaflets and papillary muscle or occasionally are directed to the ventricular walls 
(Fox, 2012; Frater and Ellis, 1961; Richards et al., 2012). They can transmit the 
contractility of the left ventricle to the valve leaflet and are arranged in an ‘arcade’ 
like fashion (Misfeld and Sievers, 2007). Based on different sites of insertion on 
valve leaflets, several subtypes of mitral valve chordae tendineae are classified, each 
of which exhibit differential mechanical properties and functions (Liao and Vesely, 
2003; Nielsen et al., 2003; Obadia et al., 1997). In dogs, first order (marginal) 
chordae tendineae and second order (basal) chordae tendineae are typically seen 
(Frater and Ellis, 1961). The first order chordae tendineae attach to the free edge of 
the valve leaflet and are normally thin. They are stiff and bearing high stress, which 
is essential to maintain mitral valve function: prevent mitral valve leaflet prolapse 
and insufficiency (Frater and Ellis, 1961; Kunzelman and Cochran, 1990; Obadia et 
al., 1997). The second order chordae tendineae insert at the junction of the smooth 
and rough zone of the leaflet ventricular aspect, and are usually thicker in size (Frater 
and Ellis, 1961). Compared to first order chords, they are more elastic and bearing 
less stress (Kunzelman and Cochran, 1990). They are not responsible for leaflet 
function but for promoting valve-ventricle interaction which is crucial for left 
ventricular geometry and systolic function (Lomholt et al., 2002; Nielsen et al., 
2003). Intact chordae tendineae are essential to optimize valve function as well as 
reduce the stress on the valve (Yacoub and Cohn, 2004).  
1.1.2 Mitral Valve Embryonic Development 
During mammalian embryonic development, the heart begins with a primary heart 
tube originating from mesodermal tissue of the late gastrulation. After bending to the 




separated by the AV canal. The superior and inferior endocardial cushions are 
formed from the ventricular wall and grow towards each other on the same plane as 
the AV canal. The anterior leaflet of the mitral valve is thereafter formed by the 
fused superior and inferior endocardial cushions. Whereas the mural leaflets of the 
mitral valve development is based on the AV myocardium protrusion. The mural 
valve leaflet mesenchyme is formed on the surface of the myocardium and the 
underneath myocardium undergoes apoptosis in later development. Different from 
valve leaflets, the papillary muscle is transformed from trabeculae of the muscular 
ridge, which was separated from the left ventricular wall. Simultaneously to papillary 
muscle formation, the myocardium is detached from the valve leaflets and the 
tendinous cords are formed by the cushion tissue of the ventricular layer. By then, 
the two valve leaflets are completely formed and attached to chordae tendineae and 
further anchored to the papillary muscle. The whole mitral apparatus complex 
achieves mature morphology and only increases in size in later development 
(Anderson et al., 2003; de Lange et al., 2004; Harvey, 2002; Kanani and Deanfield, 
2003; Oosthoek et al., 1998). 
1.1.3 Mitral Valve Histology 
Histologically, the typical mitral leaflet has been described as having three distinct 
layers: atrialis, spongiosa and fibrosa from the atrial side to the ventricular side 
(Black et al., 2009; Fenoglio et al., 1972). The aortic valve has an additional 
ventricularis layer, and more recently a thin distinct layer at the ventricular aspect of 
the MV has been suggested and is also termed ventricularis (Aupperle et al., 2009a). 
The atrialis contains a monolayer of endothelial cells with elastic fibres and a few 
collagen fibres lying underneath. Valve interstitial cell (VIC) population is also 
present in the atrialis (Aupperle et al., 2009a). In the sub-endothelium layer of the 
anterior leaflet, there is a smooth muscle cell layer originating from left atrium 
occupying one fifth the cross sectional thickness of the proximal valve portion 
(Gross and Kugel, 1931). These myocardial fibres extended from atrial to mitral 
valve leaflets are thought to contribute to valve closure and competency as they are 
found to affect mitral valve three dimensional shape and dynamic geometry 




consists of proteoglycan (PG) and glycosaminoglycan (GAG) with some loose 
collagen and elastic fibres interpersed with VICs (Aupperle et al., 2009a; Fenoglio et 
al., 1972). It extends from the annulus to the free edge of the leaflets. Towards the 
distal end, the spongiosa layer merges with the fibrosa layer. Spongiosa is more 
prominent in the posterior leaflet and in the free edge of the anterior leaflet. It has 
been found water binding PG versican and GAG hyaluronan are rich in the 
compression load-bearing region (posterior leaflets and distal edge of the anterior 
leaflets) (Grande-Allen et al., 2004). This suggests they play an important role in 
buffering shear strain during valve opening and closure. Small PGs such as decorin 
and biglycan are also detected in the mitral valve and they have been found to co-
localize with collagen and elastin fibres in a tension bearing region (central area of 
anterior leaflets) (Grande-Allen et al., 2004; Yang et al., 2012). They may play a part 
in regulating collagen fibrillogenesis and elastic fibre formation (Reed and Iozzo, 
2002; Reinboth et al., 2002). The fibrosa layer has been considered as a dense 
collagenous skeleton of the valve which contains predominantly bundles of collagen 
fibres with scattered VICs (Aupperle et al., 2009a; Fenoglio et al., 1972). This well- 
organized collagen-based structure is crucial to maintain tension as well as decrease 
overall bending stress on valve leaflets (Kunzelman et al., 1993). The final layer is 
the ventricularis. In the canine mitral valves, it has been described as thin collagen 
layer between ventricular endothelium and fibrosa layer (Aupperle et al., 2009a). It is 
a similar layer to the atrialis but generally has shorter and thinner elastin fibres and is 
without smooth muscle cells (Fox, 2012). Chordae tendineae have similar histology 
to the mitral valve leaflets: a monolayer of squamous endothelial cells, a basal 
lamina containing loosely organized collagen and elastin (so called elastic sheath) 
and, a central core formed by densely packed and aligned collagen bundles (Fenoglio 
et al., 1972; Kunzelman et al., 1993). The alignment of the collagen fibres is parallel 
to the long axis of the chordae tendineae and in the direction of flow and the major 
stem of this collagen cord has been considered to contribute to the fibrosa of the 
leaflet (Fenoglio et al., 1972). Similar to the central region of the anterior leaflets, 
biglycan and decrorin are present in chordae tendineae (Grande-Allen et al., 2004). It 




1.1.4 Mitral Valve Cells and Extra Cellular Matrix 
 Mitral Valve Endothelial Cells 1.1.4.1
Valve endothelial cells (VECs) have the basic endothelial features such as detecting 
the environmental change of the blood tissue surface, responding to hemodynamic 
stress and cytokine stimulation and building up a protective barrier to defend the 
structures underneath (Balachandran et al., 2011; Butcher et al., 2004; Chalajour et 
al., 2004; Leask et al., 2003; Paranya et al., 2001). The endothelial characteristics of 
VECs have been demonstrated as being close cell-cell contact, expressing a variety 
of cell surface marker such as platelet endothelial cell adhesion molecule (PECAM-
1) also called CD31, and metabolically having ability to take up acetylated low 
density lipoproteins (Cuy et al., 2003; Gould and Butcher, 2010; Paruchuri et al., 
2006; Wylie-Sears et al., 2011). However, there are some unique characteristics 
found in VECs when compared with endothelial cells from other anatomic sites. 
Previous studies have shown that the aortic VECs respond to shear stress differently 
from vascular endothelial cells, the former aligned perpendicular to the flow while 
the latter aligned parallel to the flow (Butcher et al., 2004). Moreover, phenotypic 
differences of VECs have been observed between the inflow surface and outflow 
surface of the aortic valves. Compared to the ventricular side, VECs of the aortic side 
are more predisposed to becoming calcified, showing less inhibition of calcification 
and inflammation protection (Davies et al., 2004; Simmons et al., 2005). These 
findings suggest that the heterogeneity of the VECs may be a regulatory result of 
adapting to differential local environment.  
Recently, the communications between the VECs and other cell types has become a 
popular research topic in heart valve research. By using a VECs-VICs three 
dimensional (3D) co-culture model, Butcher et al. identified that the aortic VECs 
tend to stabilize the VIC behaviours including inhibition of the VIC activation and 
modulation of the VIC osteogenic differentiation (Butcher and Nerem, 2006; 
Richards et al., 2013). In other studies, the VECs have shown the potential to 
transform into VICs postnatally, known as endothelial mesenchymal transition 
(EndoMT) which happens in embryonic development. Adult VECs from aortic 




response to transform growth factor beta (TGF-β) treatment (Paranya et al., 2001). 
Osteogenic and chondrogenic propensity have also been detected in mitral VECs 
when cultured in specific differentiation medium, which suggest the differentiation 
plasticity of the adult VECs (Wylie-Sears et al., 2011). 
 Mitral Valve Interstitial Cells 1.1.4.2
The most dominant cell population in all heart valves are the interstitial cells, which 
are previously termed as ‘valve fibroblasts’ or ‘myofibroblasts’ (Mulholland and 
Gotlieb, 1996; Taylor et al., 2003). During embryonic development, a group of 
endothelial progenitor cells in endocardial cushion undergo EndoMT and migrate to 
cardiac jelly giving rise to the VICs (Markwald et al., 1977; Oosthoek et al., 1998; 
Patten et al., 1948). This distinct mesenchymal population is different from cells in 
any other organ and have more complexity and dynamic diversities than fibroblasts 
or smooth muscle cells. VICs are well known as maintaining normal valve structure 
and function. They are responsive to tensile mechanical tension (Kural and Billiar, 
2013; Stephens et al., 2011; Weston and Yoganathan, 2001), and are responsible for 
valve contractile activity (Filip et al., 1986; Lester et al., 1988), extracellular matrix 
synthesis (Dreger et al., 2006; Flanagan et al., 2006a), as well as valve repair and 
remodelling in disease condition (Disatian et al., 2008; Lester et al., 1993; Lester and 
Gotlieb, 1988; Rabkin et al., 2002).  
It has been widely accepted that the VICs are a heterogeneous population (Durbin 
and Gotlieb, 2002; Taylor et al., 2003). Liu et al. proposed a more detailed 
classification of VICs subtypes in 2007 (Liu et al., 2007). They summarized five 
subtypes of the versatile VICs: embryonic progenitor endothelial cells, quiescent 
VICs (qVICs), progenitor VICs (pVICs), activated VICs (aVICs) and osteoblastic 
VICs (obVICs). In normal adult valves, qVICs are the primary VIC phenotype which 
is characterized by expressing vimentin but lack of alpha smooth muscle actin (α-
SMA) expression (Han et al., 2008; Rabkin-Aikawa et al., 2004b; Rabkin et al., 
2001). It has been suggested the qVICs can maintain the normal heart valve structure 
and function and might have some role in extracellular matrix synthesis and 
degradation (Liu et al., 2007). Once in injury or disease conditions, there is a 




understanding valve disease pathogenesis (Black et al., 2005; Disatian et al., 2008; 
Han et al., 2008; Rabkin et al., 2001). Activated VICs have been described as 
myofibroblast-like but actually not smooth muscle cells (Flanagan et al., 2006a; 
Lester et al., 1988; Taylor et al., 2003). The α-SMA is a common marker for aVICs, 
but the α-SMA expression level may vary between different aVIC cultures 
depending on cell density, culture environment and composition of aVIC sub-
phenotypes (Blevins et al., 2006; Engler et al., 2006; Stephens et al., 2011; Xu et al., 
2012). Other phenotypic markers of aVICs include embryonic form non-smooth 
muscle myosin heavy chain (SMemb) (Disatian et al., 2008; Rabkin et al., 2001) and 
transgelin (SM22) (Della Rocca et al., 2000; Wiester and Giachelli, 2003). The VIC 
activation is believed to be associated with extracellular matrix (ECM) remodelling 
(Aupperle et al., 2009a; Aupperle et al., 2009b; Disatian et al., 2008; Han et al., 
2013; Han et al., 2010; Rabkin et al., 2001). TGF-β signalling is possibly the most 
important regulatory pathways involved in the VIC activation of myxomatous valves 
(Aupperle et al., 2008; Disatian and Orton, 2009; Obayashi et al., 2011). This 
pathway regulates aVIC proliferation, and also has an effect on increasing expression 
of α-SMA and can regulate ECM synthesis (Jian et al., 2002; Merryman et al., 2007; 
Walker et al., 2004). It has been hypothesized that TGF-β induced VIC activation 
and contractility may be the initiating step in the heart valve disease process as this 
contributes to alteration of valve mechanics (Walker et al., 2004). The pVICs are a 
group of cells which show stem cell features and can develop into activated VICs. 
This group is not well characterized to date but two types of cells were thought to 
belong to this phenotype: endothelial progenitor cells (EPC) and dendritic cells (DC) 
(Bischoff and Aikawa, 2011; Paruchuri et al., 2006; Skowasch et al., 2005). EPCs are 
characterized by expressing stem cell markers CD133 and CD34, whereas DCs are 
characterized by expressing S-100 protein (Skowasch et al., 2005). The valve 
resident pVICs could possibly originate from valve endothelial cells though the 
EndoMT process (Dal-Bianco et al., 2009; Paruchuri et al., 2006; Wylie-Sears et al., 
2011). The obVICs require osteogenic culture medium for differentiation in vitro. 
They are thought to play a crucial role in aortic valve calcification (Richards et al., 
2013; Wylie-Sears et al., 2011). It has been hypothesized that the degenerative valve 




the aortic calcification may share similar regulatory pathways with osteogenic 
development, while the myxomatous mitral valve disease may share signalling 
pathways with chondrogenesis (Caira et al., 2006; Combs and Yutzey, 2009; Orton et 
al., 2012). In vitro adult mitral valve clones also have shown chondrogenesis 
differentiation in chondrogenic medium culture (Wylie-Sears et al., 2011). Desmin 
positive chondrocyte-like cells have been detected in myxomatous mitral valves 
(Han et al., 2008). 
It should be noticed that the constitution of the VIC sub-populations is dynamic. 
Evidence of this is the VIC phenotypic modulation happening in the physiological 
valve wound healing process as well as in valve disease (Black et al., 2005; Han et 
al., 2013; Han et al., 2008; Rabkin-Aikawa et al., 2004b; Tamura et al., 2000). 
Apparently the VICs have the ability to establishing functional adaption once they 
are exposed to unusual environment/conditions.  
 Physiological Role of Valve Extracellular Matrix  1.1.4.3
Mitral valve ECM is synthesized mainly by VICs (Flanagan et al., 2006a; Latif et al., 
2005). As a predominant component of the valve, the ECM plays a key role in 
shaping the valves. Histologically, a typical canine mitral valve ECM contains 
collagen, elastin, PGs and GAGs, fibronectin, laminin and heparin sulphate 
(Aupperle et al., 2009a). Among them, elastin, collagen and PGs and GAGs are 
major matrix protein types which are predominant in layer of atrialis, fibrosa and 
spongiosa respectively (Bashey et al., 1992; Cole et al., 1984; Latif et al., 2005; 
Tamura et al., 1995). The disposition of these matrix proteins reflects differential 
mechanical behaviour of each tissue layer in the valve (Kunzelman et al., 1993). The 
elastin provides tissue elasticity, the collagen is responsible for tissue strength and 
internal force generation and, the PGs and GAGs give flexibility of valve spongiosa 
(Aupperle and Disatian, 2012; Kunzelman et al., 1993). The normal ECM 
composition is constantly dynamic to keep the balance between anabolism and 
catabolism (Dreger et al., 2002; Rabkin et al., 2001). The latter metabolic mechanism 
is accomplished by matrix metalloproteinase (MMP) family and their tissue 
inhibitors (TIMP) which are predominantly secreted by the VICs (Aupperle et al., 




from the physiological maintenance of normal valve structure and functions, the 
ECM is remodelled in the valve disease process which is an underlying cause of 
valve pathological lesions (Aupperle et al., 2009a; Cole et al., 1984; Gupta et al., 
2009a; Hadian et al., 2007; Han et al., 2010; Tamura et al., 1995). The detailed 
relationship between ECM and myxomatous valve disease will be discussed later in 
this chapter. 
1.2 Canine Myxomatous Mitral Valve Disease  
1.2.1 Epidemiology of Canine Myxomatous Mitral Valve 
Disease 
Myxomatous mitral valve disease (MMVD), also called mitral valve endocardiosis or 
chronic valvular disease is characterized by the progressive degenerative 
myxomatous change presenting in the mitral valve. So far, similar changes have been 
found in human, dogs, horses and pigs (Olsen et al.,, 2010). Dogs and humans seem 
to be more predisposed to it and present similar pathological changes (Kogure, 1980; 
Pedersen and Haggstrom, 2000; Pomerance and Whitney, 1970). It is the most 
common acquired cardiac diseases in dogs and approximately accounts for 75-80% 
of canine cardiac diseases. Risk factors for the disease progression from mild to 
severe include age, gender, breed, severity of valve lesion, left atrial enlargement, 
heart rate and arrhythmia (Olsen et al., 2010). Similar to human mitral valve 
prolapse, the severity of the diseases is strongly associated with age (Han et al., 
2010; Han et al., 2008; Pedersen and Haggstrom, 2000; Whitney, 1974). In contrast 
to low prevalence in young dogs, MMVD is common in old adult dogs. In fact it is 
more likely that all geriatric dogs have some evidence of the disease. This could due 
to the degenerative nature of the disease which usually requires several years to 
progress to be clinically significant. MMVD can occur in any breed but mainly 
affects small to medium sized breeds, particularly the Cavalier King Charles Spaniel 
(CKCS), in which the pathological change has been found even at an early age 
(Beardow and Buchanan, 1993). However, it would appear that the pathological 
changes (gross and cellular) in CKCS where the disease has an earlier onset are no 
different than that seen in other dogs, suggesting the inherited component of the 




Previous studies suggest polygenic inheritance may play a role in highly susceptible 
breed like CKCS and Dachshund (Olsen et al., 2003a; Swenson et al., 1996). A 
genome-wide association study on CKCS identified two potential loci associated 
with MMVD development (Madsen et al., 2011), but this was not confirmed on a 
further study (French et al., 2012). Some evidence suggests males have greater 
tendency of developing MMVD earlier and with more rapid progression than females 
(Fox et al., 1999; Olsen et al., 2003a; Smith et al., 2005). In humans, degenerative 
mitral valve disease has also been linked to some inherited connective tissue 
disorders, such as Marfan syndrome (Ng et al., 2004; Schoen, 2005). The 
degenerative changes of the valve are possibly an adaptive result of connective tissue 
weakness. 
For clinical features, many affected dogs remain asymptomatic during their lifetime. 
However, in the severely affected cases, as the disease progresses, it can eventually 
develop into congestive heart failure, which has a poor prognosis (Kittleson et al., 
1984; Olsen et al., 2010).  
1.2.2 Gross Morphological Changes 
On gross morphology, the MMVD is characterized by thickened, distorted and less 
transparent valve leaflets, nodule lesions on the valve surface especially the edge and 
it may affect the whole mitral valve apparatus, e.g. chordae tendineae thickening and 
rupture, in severe cases. In 1967, Whitney et al proposed a system to classify canine 
chronic heart valve disease based on gross morphological changes to the valve 
(Whitney, 1967). Grade 0 represents normal valves. From grade 1 to grade 4, the 
disease gradually progressed in pathological severity. Generally, the disease starts 
with a few small discrete nodules appearing on the edge of the leaflet, which might 
associate with irregular opacities of the more proximal region on the valve (Grade 1). 
As the disease become more advanced, the nodules are larger, numerous and 
coalescent. Irregular opacities might be observed in the proximal region of the valve 
(Grade 2). Chordae tendineae are not affected at this stage. Clinically, there is no 
valve incompetence in Grade 1 and Grade 2. In Grade 3, the entire valve is thickened 




irregular plaque-like deformities. The chordae tendineae are thickened as well. In the 
most severe cases (Grade 4), the edge of the valve has been described as ballooning 
or billowing (Behar et al., 1967; Bittar and Sosa, 1968). Because of the nodule or 
plaque formation, the leaflets are grossly distorted and usually rolled upward. The 
chordae tendineae are proximally thickened, elongated and can rupture eventually 
(Whitney, 1967). Alternative grading systems of canine MMVD have been proposed 
by Kogure et.al in 1980 and Disatian et.al in 2008. The former system is based on the 
progression of pathological changes on the affected leaflets particularly the ECM 
alteration (Kogure et.al., 1980). The other system is similar to the Whitney grading 
criteria but is more simplified. It is depending on the nodular thickening area of the 
valve leaflets and whether the attached chordae tendineae are affected (Disatian et 
al., 2008). For the purpose of this thesis the Whitney classification was used.  
1.2.3 Cellular Changes  
The cardinal microstructure alteration in MMVD comprises valve cellular changes 
and ECM remodelling (Aupperle et al., 2009a; Han et al., 2013; Han et al., 2010; 
Han et al., 2008). The most dramatic cellular changes are endothelium denudation 
and interstitial cells activation (Barth et al., 2005; Black et al., 2005; Corcoran et al., 
2004; Disatian et al., 2008; Disatian et al., 2010; Han et al., 2008; Mow and 
Pedersen, 1999; Prunotto et al., 2010; Rabkin-Aikawa et al., 2004b; Stein et al., 
1989). Endothelial cell loss has been found in both human and canine diseased 
valves by topographic studies (Black et al., 2005; Corcoran et al., 2004; Han et al., 
2013; Stein et al., 1989). The remaining endothelial cells are less organized than 
normal and the number of surface micro-appendages are increased which might 
indicate the cells are activated (Corcoran et al., 2004). Moreover, the endothelial cell 
denuding is associated with local sub-endothelial matrix degeneration (Han et al., 
2013). This suggests there is an interaction between valve endothelium and subjacent 
matrix which is possibly through nitric oxide (NO) or endothelin signalling pathway 
(Mow and Pedersen, 1999; Olsen et al., 2003b). It has been well accepted that the 
endothelium loss is likely to be a consequence of flow induced shear stress impact. 
Indeed the activity of shear mechanosensor nitric oxide synthases (NOS) has been 




et al., 2003b). Whether the increased NO release is a mere response to turbulent flow 
caused by mitral regurgitation or, further serves as a regulator in disease pathological 
process remains unclear.  
As mentioned previously, the VICs undergo phenotype alteration during the MMVD, 
transform from quiescent fibroblast-like qVICs to activated myofibroblast-like 
aVICs (Black et al., 2005; Disatian et al., 2008; Disatian et al., 2010; Han et al., 
2013; Han et al., 2008). In affected human and dog valve leaflets, the aVICs were 
found to play a key role in matrix remodelling by secreting excessive MMPs and 
TIMPs which indicates there is abnormal ECM catabolism (Aupperle et al., 2009b; 
Aupperle et al., 2009c; Disatian et al., 2008; Obayashi et al., 2011; Rabkin et al., 
2001). It has also been noticed the VICs are present in the endothelium denuded area 
(Black et al., 2005; Lester and Gotlieb, 1988). The wound repair ability of the VICs 
has been investigated in previous studies. The findings suggest VICs can respond to 
injury by cell migration, proliferation and de novo matrix protein synthesis (Durbin 
et al., 2005; Durbin and Gotlieb, 2002; Gotlieb et al., 2002; Lester et al., 1993; Lester 
et al., 1992; Tamura et al., 2000). 
The role of developmental signalling pathway in heart valve disease has caused great 
attention in recent studies, particularly the EndoMT related pathways (Bischoff and 
Aikawa, 2011; Dal-Bianco et al., 2009; Orton et al., 2012; Paranya et al., 2001; 
Paruchuri et al., 2006; Wylie-Sears et al., 2011). Taken the fact that in the embryonic 
stage the VICs are differentiated from a group of endothelial cells, it cannot be rule 
out that the adult VECs may possess VIC replenish capability. Previous studies have 
shown that the adult mitral VECs can undergo EndoMT in response to external 
mechanical stretch or TGF-β stimulation (Dal-Bianco et al., 2009; Wylie-Sears et al., 
2011). Whether the EndoMT process occurring in the MMVD or not requires further 
investigation. 
Inflammation in myxomatous valve disease is generally considered to be rare both in 
humans and dogs (Han et al., 2008; Rabkin et al., 2001; Stein et al., 1989). Sparsely 
distributed macrophages and T cells have been detected in both normal and diseased 




has been identified in canine MMVD (Oyama and Chittur, 2006). An increase in 
number of mast cells has been found in canine myxomatous mitral valves, however 
the role of these inflammatory evidence in the disease pathogenesis is unclear (Han 
et al., 2008).  
1.2.4 Histopathological Changes 
The histopathological classification of the disease is mainly based on the alteration of 
extracellular matrix components. Typical changes in the lesions include excessive 
expansion of the lamina spongiosa and distortion of fibrosa layer. In the early stage 
of the disease, accumulation of PGs leads to the expansion of the atrialis and 
spongiosa particularly in distal edge of the leaflets however the collagen fibers in the 
fibrosa are not affected. In moderate MMVD, moderately increased PGs are found in 
the spongiosa which causes the spongiosa to expand, the collagen bundles in the 
fibrosa degenerate mildly, while the proximal part of the valve remains normal. In 
marked MMVD, dramatically increased PGs are found in a further expanded 
spongiosa as well as fibrosa (Aupperle et al., 2009a; Kogure, 1980). Among all the 
ECM components, it seems that the altered quantity and distribution of PGs, GAGs 
and collagen in the disease process are the major events. Increased PG and GAG 
expression has been found in human and canine degenerated mitral valves (Gupta et 
al., 2009a; Han et al., 2010; Tamura et al., 1995). Specifically, expression of decorin, 
biglycan and versican increases in human myxomatous valves and hyaluronan 
metabolism is likely to be altered in the disease (Gupta et al., 2009a). Pronounced 
collagen bundle reduction and derangement are found in the fibrosa layer of affected 
canine mitral valve (Hadian et al., 2007). Moreover, increased immature collagen 
production is found in the lesion area (Hadian et al., 2010; Tamura et al., 1995). This 
may indicate that the newly produced immature collagen is not capable of normal 
collagen function which could be a reason for fibrosa distortion.  
It should be highlighted that the proteolytic enzymes contribute to the typical ECM 
degeneration seen in MMVD. Rabkin and colleagues have demonstrated that 
increased MMP-1, MMP-13, MMP-2, MMP-9 produced by VICs, as well as cysteine 




that these enzymes may be responsible for valve weakness and deformation (Rabkin 
et al., 2001). Similar excessive matrix catabolic activity has been identified in 
affected canine valves, in which increased MMP-1, MMP-3, MMP-13, MMP-14 and 
TIMP-2, TIMP-3 and TIMP-4 expression have been detected (Aupperle et al., 2009c; 
Disatian et al., 2008; Obayashi et al., 2011).  
1.2.5 Current Hypothesis of Disease Pathogenesis 
In the early days of canine mitral valve studies, Whitney proposed three possible 
causes of the disease: shear stress on the contacting area of the leaflets, disturbed 
blood pressure or pulmonary disease related hypoxia (Whitney, 1967). Forty years 
later, Gupta summarized work of other researchers to identify four possible 
pathogenesis hypotheses: failure in coping with mechanical shear stress, genetic 
abnormality, collagen and matrix dissolution and increased expression of 
proteoglycans (Gupta et al., 2009a). To date, the exact pathogenesis of canine 
MMVD remains unknown.  
The current favoured hypothesis is that the long term flow shear stress causes 
endothelial denuding, which then leads to changes in metabolic and enzymatic 
activity of VECs and VICs, resulting in ECM remodelling and further myxomatous 
pathological changes (Corcoran et al., 2004; Durbin and Gotlieb, 2002; Pedersen and 
Haggstrom, 2000; Prunotto et al., 2010; Stein et al., 1989). Usually, shear stress 
induced endothelium denudation is presumed to be an initiator of the MMVD, 
though the detail signalling mechanism of damaged endothelium to subjacent VICs is 
still unclear. In canine myxomatous mitral valves, increased endothelin receptors and 
NOS activity have been found to correlate with the disease severities (Mow and 
Pedersen, 1999; Olsen et al., 2003b). Induced NOS are found to be essential for 
mitral VIC migration in a wound repair cell culture model (Durbin and Gotlieb, 
2002). Therefore such molecules synthesized by the endothelial cells are possible 
mediators for sub-endothelial VIC activation in the MMVD disease process. In 
canine myxomatous valves, subjacent to endothelium loss areas, there is 
accumulation of activated myofibroblasts under transmission microscopy observation 




MMVD is associated with serotonin or 5-hydroxytryptamine (5-HT) and TGF-β 
signalling pathways (Orton et al., 2012; Oyama and Levy, 2010). The serotonin 
hypothesis is supported by the identification of up-regulated serotonin synthesis 
enzyme tryptophan hydroxylase 1 (TPH-1), increased TGF-β expression as well as 
the evidence of increased transcripts of serotonin Type 2 receptors in canine 
myxomatous mitral valves (Aupperle et al., 2008; Disatian et al., 2010; Oyama and 
Chittur, 2006). It is hypothesized that after the valves injured, the damaged 
endothelium attracted platelets in which the serotonin is largely stored; release of 
serotonin from the platelets also induces autocrine serotonin secretion; the 
extracellular serotonin binds to serotonin receptors on the VICs and further induces 
TGF-β signalling (Oyama and Levy, 2010). The members of TGF-β family are 
known to contribute to the VIC myofibroblast activation (Merryman et al., 2007; 
Walker et al., 2004) and can potentially lead to myxomatous pathological changes 
such as increased GAGs accumulation (Jian et al., 2002). 
Tensile strain induced local serotonin synthesis is alternative hypothesis for the VIC 
activation in the MMVD (Lacerda et al., 2012a; Lacerda et al., 2012b; Orton et al., 
2012; Richards et al., 2012). Hypertension or myxomatous changes of the mitral 
leaflets and chordae tendineae can alter the valve intrinsic mechanics (Dillon et al., 
2012; Han et al., 2010; Richards et al., 2012; Sacks et al., 2006; Singh et al., 1999). 
In response to the increased tissue stretch, the resident VICs synthesize serotonin and 
initiate TGF-β signalling pathway through extracellular-signal regulated kinase 
(ERK) phosphorylation to remodel the local matrix (Grewal et al., 1999; Orton et al., 
2012). This hypothesis was tested in ex vivo studies, in which 30% cyclic strain has 
been found to increase the expression of myxomatous disease related proteins in 
canine and ovine native mitral valves, through induction of autocrine serotonin 
(Lacerda et al., 2012a; Lacerda et al., 2012b).  
Though part of the pathogenesis loop of canine MMVD is understood, there is no 
definitive evidence that prove whether the disease initiated from shear stress 
damaged endothelium or from activation of sub-endothelial VICs (Han et al., 2013). 
This identifies a need to generate mitral valve models with endothelium injured or 




1.3 Tissue Engineering of Heart Valves 
1.3.1 Tissue Engineering Overview 
Tissue engineering has been defined as an application combining the principles and 
methods in engineering and life sciences, to develop biological substitutes for native 
organs (Langer and Vacanti, 1993). The early history of tissue engineering goes back 
to the 1960s when a type of artificial skin was developed for burn victims (Hall et al., 
1966). In the past two decades, tissue engineering has attracted great attention and 
has gradually become one of the most prevailing technologies in the area of 
regenerative medicine. By using either native or synthetic materials structural tissues 
and complex organs have been produced and optimized. Attempts have been made in 
generating many organs such as liver (Fiegel et al., 2008), pancreas (Opara et al., 
2010), skin (Metcalfe and Ferguson, 2007), brain (Cheng et al., 2013), bone (Marolt 
et al., 2012), heart (Ott et al., 2008), lung (Petersen et al., 2010), blood vessel (Chun 
et al., 2010), heart valves (Rabkin-Aikawa et al., 2005), bladder (Atala et al., 2006), 
muscle (Langelaan et al., 2010) and nerve tissue (Penna et al., 2011). Though the 
major purpose of tissue engineering is for producing therapeutic implants, other 
applications of tissue engineering include drug testing and establishment of in vitro 
physiological models. The latter approach can assist fundamental studies of tissue 
biology and physiology as well as improving understanding of pathogenesis of 
certain diseases (Butcher and Nerem, 2006; Gibbons et al., 2012; Rabkin-Aikawa et 
al., 2005).  
Typically, there are three fundamental elements involved in tissue engineering: cells, 
scaffolds and bioreactors. All these components work together aiming to best mimic 
the native tissue structure and function. These three elements, particularly in regard 







1.3.2 Heart Valve Tissue Engineering 
 Cell Source 1.3.2.1
Theoretically cell sources for tissue engineering can be allogenic, xenogenic or 
autologous cells (Rabkin-Aikawa et al., 2005). Because of the possibility of immune 
response or pathogen transmission risk, the allogenic and xenogenic cells are not 
ideal for constructs designed for transplantation purposes (Mendelson and Schoen, 
2006; Platt and Nagayasu, 1999; Rabkin-Aikawa et al., 2005). Such concerns do not 
exist in autologous cells, therefore they are superior for clinical applications 
(Cebotari et al., 2006; Jockenhoevel et al., 2001a; Metzner et al., 2010; Mol et al., 
2006). There are five types of autologous cells used in tissue engineering: (1) 
differentiated primary tissue cells; (2) tissue specific adult stem cells; (3) bone 
marrow stem cells; (4) bone marrow-derived, circulating stem cells including 
endothelial and smooth muscle cell precursors, and (5) pluripotent embryonic stem 
cells (Ballas et al., 2002; Bertipaglia et al., 2003; Rabkin-Aikawa et al., 2005; Walter 
et al., 2010). For engineering of cardiac valves, the tissue sources for cell isolation 
have included vessels, circulating blood, skin, adipose tissue, bone marrow, placenta, 
amniotic fluid, umbilical cord and primary heart valves (Black et al., 2005; Flanagan 
et al., 2007; Schmidt and Hoerstrup, 2006; Shinoka et al., 1996; Sodian et al., 2010; 
Sutherland et al., 2005; Weber et al., 2012). In theory, native valve cells especially 
valve stem cells probably would be the most ideal cell source. However, their 
availability is limited, the proliferative ability of adult valve cells may be poor and 
also the valve stem cells have not been fully characterized yet (Black et al., 2009; Liu 
et al., 2007). These factors limit the feasibility of using autologous valve cells to 
create a tissue engineered valve for clinical usage. In contrast, mesenchymal stem 
cells are thought to be the most attractive cell candidate for heart valve tissue 
engineering. They are easier to obtain than valve cells and are more likely to satisfy 
the requirements of differentiating into heterogeneous heart valve cell lineages and 
developing into functional native valve like structures (Rabkin-Aikawa et al., 2005; 
Sutherland et al., 2005; Weber et al., 2012). Additionally, adipose tissue derived 
stem cells have been proven to be a promising cell source. One study has shown that 
they possess more VIC like properties when compared to mesenchymal stem cells 





The role of a scaffold in engineered tissues is to act as a skeleton, which provides a 
platform for cells to attach and proliferate. It is crucial for bio-artificial tissue 
configuration (Black et al., 2009; Brody and Pandit, 2007; Sacks et al., 2009). The 
design criteria for a three dimensional (3D) scaffold is to ‘mimic natural ECM 
features sufficiently that cells function in the simulated environment as they would in 
vivo’ (Lee et al., 2008). An ideal scaffold should be bio-compatible, restorable and 
structure-wise it should favour cell attachment, proliferation, differentiation and 
migration, as well as ECM formation and remodelling (Brody and Pandit, 2007; 
Mendelson and Schoen, 2006; Rabkin-Aikawa et al., 2005; Sacks et al., 2009). 
Depending on material origins and properties, the scaffolds can be divided in two 
categories: synthetic scaffolds and natural scaffolds. Popular synthetic scaffolds for 
heart valve tissue engineering include polyglycolic acid (PGA), polylactic acid 
(PLA) and their polymers (Mendelson and Schoen, 2006; Rabkin-Aikawa et al., 
2005). The advantage of synthetic scaffolds is that their structures and mechanical 
properties can be well controlled. However, traditional synthetic scaffolds are not 
ideal for cell attachment and growth (Mendelson and Schoen, 2006). Other potential 
drawbacks of synthetic substrates are focal tissue inflammation or fibrosis, slow or 
incomplete scaffold degradation, and toxicity in the degradation process (Black et al., 
2009; Mendelson and Schoen, 2006). 
Natural scaffolds comprise ECM components such as de-cellularised connective 
tissues (Hopkins, 2005), collagen (Chen et al., 2012), GAGs (Flanagan et al., 2006b) 
and fibrin (Flanagan et al., 2007; Jockenhoevel et al., 2001b). Superior to synthetic 
scaffolds, the natural scaffolds are better substrates for cell attachment and growth 
therefore favour cellular and ECM remodelling in engineered tissue. Moreover, they 
have the advantage of maintaining natural signalling biomaterials and architecture of 
the native tissue.  
In the early tissue engineered heart valves, de-celluarised scaffolds were widely used 
(Kasimir et al., 2003; Mol et al., 2009; Simon et al., 2003; Vesely, 2005). Using 
various treatments, cellular components have been removed from donor valve 




scaffolds have a valve tissue matrix or a collagen based structure, which meets the 
requirement of mimicking the mechanical properties of native connective tissue 
(Hopkins, 2005; Kasimir et al., 2003; Metzner et al., 2010). However, this method 
has caused severe consequences in clinical application, such as immune-
incompatibility and tissue degeneration (Simon et al., 2003). Moreover, though many 
studies claimed that there was potential for cellular growth and remodelling on the 
re-populated acellular scaffold, clear evidence to support this has not been reported 
so far (Bouten et al., 2011). This has caused a major concern, as the cellular and 
ECM regeneration on the scaffolds is essential to maintain tissue structure for long-
term durability (Brody and Pandit, 2007; Sacks et al., 2009; Vesely, 2005).  
The second category of natural scaffolds is hydrogel systems based on native matrix 
components. They have become popular in heart valve tissue engineering recently, 
and are mostly based on collagen and fibrin. The general principle of this scaffold 
type involves mixing soluble ECM components with appropriate cells initially, and 
then a gel-like structure is produced through various polymerizations. The cells 
become entrapped within the hydrogel structure and interact with the surrounding 
matrix (Jockenhoevel et al., 2001b; Vesely, 2005; Ye et al., 2000). The merits of the 
hydrogel scaffolds include good bio-compatibility, no toxic degradation or 
inflammatory reactions and most attractively, they provide a supporting system for 
ECM synthesis and accumulation within the engineered structure (Pikaart, 2008; Ye 
et al., 2000). Fibrin is a good example. It is a natural structural protein which 
participates in the haemostatic process and is formed by fibrinogen reacting with 
thrombin in the presence of calcium ions. It has been described as ‘a potentially ideal 
cell delivery vehicle’ for tissue engineering (Black et al., 2009). By using a fibrin gel 
system, high cell seeding efficiency and uniform cell distribution can be achieved. 
Cell communication can be conducted in all directions of a 3D configuration (Lee et 
al., 2008). A tissue engineered fibrin based heart valve using autologous cells has 
been shown to exhibit excellent tissue remodelling and structure durability in vivo 
(Flanagan et al., 2009). The common drawback of hydrogel scaffolds is cell mediated 
contraction/shrinkage which is not preventable in static cultures in vitro. Dynamic 




based valve constructs (Flanagan et al., 2007). Apart from gel contraction, other 
concerns of hydrogel scaffolds are inadequate initial mechanical integrity and load 
bearing properties (Bouten et al., 2011; Brody and Pandit, 2007). A combination of 
synthetic and natural scaffold materials can improve on this limitation. A 
fibrin/textile co-scaffold tubular tissue engineered heart valve has been shown to be 
superior for cell distribution compared to mere fibrin scaffold, which can potentially 
provide adequate mechanical strength for valve conduit implantation in the aortic 
position (Weber et al., 2014).  
Recently, computational technology has been employed for scaffold design and 
remodelling. The details of this application will be discussed later. Another recent 
advance is development of instructive and responsive biomaterial scaffolds which 
allow specific interaction within the culture system and guide engineered tissue 
development (Boontheekul and Mooney, 2003; Bouten et al., 2011; Rabkin-Aikawa 
et al., 2005; Ulijn, 2006). 
 Bioreactor 1.3.2.3
The third important element in tissue engineering is the bioreactor. Usually a 
bioreactor refers to a dynamic conditioning device which serves as a means to 
generate a supporting culture environment to maintain tissue viability and to 
physically stimulate tissue growth in vitro (Barron et al., 2003; Gandaglia et al., 
2011; Lyons and Prandit, 2005; Wendt et al., 2009). The key functions for tissue 
engineering bioreactors used in research applications include (1) dynamic cell 
seeding within 3D culture matrices; (2) maintenance of the culture environment; and 
(3) physical stimuli to trigger tissue development (Barron et al., 2003; Freed and 
Vunjak-Novakovic, 2000; Wendt et al., 2009). Cell seeding with bioreactor system 
assistance allows well controlled and uniform cell distribution on the 3D constructs 
(Aleksieva et al., 2012; Lee et al., 2009; Lichtenberg et al., 2006; Sierad et al., 2010; 
Wendt et al., 2009). Dynamic cell seeding and conditioning have been applied to 
endothelialisation on a de-cellularised valve scaffold. Complete endothelium was 
achieved and the valve constructs possessed comparable mechanical tension to native 
ovine pulmonary valves (Lichtenberg et al., 2006). Another similar study utilising 




valve scaffolds also demonstrated successful endothelialisation on the valve 
constructs (Lee et al., 2009).  
Optimal biochemical culture condition is essential for artificial constructs healthy 
development in vitro. With the assistance of a bioreactor system, nutrient and gas 
supply as well as waste removal can be efficiently controlled. Moreover, the 
physiochemical parameters in the culture system (e.g. pH, concentration of O2 and 
CO2, temperature, humidity) can be monitored and optimised with bioreactors 
(Lyons and Prandit, 2004; Rabkin-Aikawa et al., 2005; Wendt et al., 2009; 
Ziegelmueller et al., 2010).  
Providing mechanical stimuli is another key application of bioreactors in tissue 
engineering. It has been well recognized that the mechanical stimuli can overcome 
the common mass transport limitation existing in static culture condition, enhance 
cell viability and proliferation and improve ECM synthesis and organization (Black 
et al., 2009; Flanagan et al., 2007; Sodian et al., 2000; Wendt et al., 2009; Weston 
and Yoganathan, 2001).  
Fundamentally the dynamic bioreactor applications aim to mimic physiological 
parameters in vivo (Hoerstrup et al., 2000b; Lyons and Prandit, 2004; Wendt et al., 
2009). The majority of the mechanical conditioning studies on  heart valves involves 
providing pulsatile flow stimuli (Aleksieva et al., 2012; Dumont et al., 2002; 
Flanagan et al., 2007; Hildebrand et al., 2004; Hoerstrup et al., 2000b; Ruel and 
Lachance, 2009; Sierad et al., 2010; Sun et al., 2011; Weston and Yoganathan, 
2001). A typical pulsatile flow bioreactor design contains a left heart replicator and 
this allows the native heart valves or valve constructs open and close in the system 
which mimic the valve motion that occurs in situ (Gheewala and Grande-Allen, 
2010; Goldstein and Black, 1999; Hildebrand et al., 2004; Hoerstrup et al., 2000a; 
Hoerstrup et al., 2000b). Enhanced cell adhesion and native valve tissue-like 
properties have been observed after pulsatile conditioning (Schenke-Layland et al., 
2003). Moreover increased pulsatile flow with low pressure conditions has been 
shown to enhance cell attachment and alignment, and affect ECM synthesis and 




Though dynamic flow conditioning has been proven to be beneficial to heart valve 
development in vitro, the detailed contribution of each individual mechanical 
stimulus has not been completely elucidated. Major modes of mechanical stimulation 
on native heart valve leaflets include flow shear stress, cyclic flexure and cyclic 
stretch/strain (Berry et al., 2010; Engelmayr Jr et al., 2005; Mol et al., 2005). Their 
effects on heart valve development have been evaluated respectively by different 
research groups.  
Flow shear stress plays a key role for engineered valve construct development ex 
vivo. A low shear stress environment has been recognized to facilitate initial valve 
construct development (Barron et al., 2003; Weston and Yoganathan, 2001). Shear 
stress effects on aortic valve leaflets have been estimated previously and it has been 
suggested the shear stress is essential for cell adhesion and synthesis (Weston et al., 
1999). In human aortic myofibroblast based tissue engineered construct, a laminar 
flow bioreactor providing shear stress for 14 days has been found to direct collagen 
fibril formation in the shear stress field and tissue mechanical stiffness has increased 
(Jockenhoevel et al., 2002). Endothelial cell activities are believed to associate with 
flow shear stress (Davies et al., 2005; Weston et al., 1999). Conditioned with steady 
laminar flow for up to 48 hours, porcine aortic VECs demonstrated differential 
responses to aortic endothelial cells regarding cell arrangement pattern and 
transcriptional profiles. Moreover, the VECs were found to have regulatory effects 
on VIC proliferation and synthetic activities under shear stress conditioning (Butcher 
and Nerem, 2006; Butcher et al., 2004; Butcher et al., 2006). Some researchers have 
suggested bioreactor systems can be applied to study shear stress related 
cardiovascular disease (Barron et al., 2003; Sun et al., 2011).   
The native heart valve is known to be subjected to cyclic circumferential stretch 
(Berry et al., 2010). The effect of cyclic strain/stretch on the heart valve leaflet has 
been extensively studied in vitro. Cyclic strain effect on aortic valve development 
has been assessed as an independent factor (Mol et al., 2003). Later on a diastolic 
pulsed stimulation (DPS) bioreactor was designed to replicate the diastolic phase of 
the cardiac cycle (Mol et al., 2005). In both studies, better tissue formation and 




samples. Another application of the DPS bioreactors is allowing estimation of valve 
compliance by analysing data from a computer based feedback loop (Vismara et al., 
2010). Other cyclic tension related studies showed increased VIC synthetic activities 
and moderate tissue tensile stiffness were observed under stretch conditions 
(Balachandran et al., 2009; Ku et al., 2006; Merryman et al., 2007; Syedain and 
Tranquillo, 2009). 
Similar to cyclic stretch studies, effect of cyclic flexure stimulus on tissue 
engineering heart valves has been evaluated independently (Engelmayr et al., 2003; 
Engelmayr Jr et al., 2005). Increased ECM production and tissue stiffness, as well as 
homogenous cell distribution were observed in the flex group (Engelmayr Jr et al., 
2005). The same researchers further developed a flexure-stretch-flow (FSF) system 
which combined all three key mechanical stimuli but allowed separate control of 
each factor (Engelmayr Jr et al., 2006; Engelmayr Jr et al., 2008). Higher collagen 
production rate and effective tissue stiffness were achieved in the combined 
conditioned constructs comparing to the static and single stimulus conditioned 
samples (Engelmayr Jr et al., 2006; Engelmayr Jr et al., 2008; Ramaswamy et al., 
2010). This mechanical combination is believed to be tremendously informative and 
closer to realistic mimicking of the native environment (Berry et al., 2010). It should 
be noted that optimal conditioning is not only dependent on dynamic stimuli, but a 
wide range of other factors such as cell source, scaffold materials and their 
interactions also need to be considered (Gandaglia et al., 2011; Ramaswamy et al., 
2010; Sacks et al., 2009). 
Innovative technologies such as computerization contribute to more advanced bio- 
reactor design. Computerization can allow the bioreactor to be customised and 
controlled by automation, thus allowing more optimal and standardised systems to be 
achieved (Engelmayr Jr et al., 2008; Lee et al., 2009; Vismara et al., 2010; Wendt et 
al., 2009). This will be useful in analysing and mimicking complex mechanical 
stimuli patterns on native tissues, and also help to improve understanding of the 





1.3.3 Current Progress of Heart Valve Tissue Engineering 
The early attempts of cardiac valve engineering go back to late 1980s when the de-
cellularised matrix approaches were patented (Brendel and Duhamel, 1989; Klement 
et al., 1988). However, it is likely that only after the first PGA fibre based pulmonary 
valve was created and implanted in a lamb model by Shinoka and others in 1995 that 
heart valve tissue engineering truly started (Shinoka et al., 1995). Compared to the 
conventional prosthetic heart valves, tissue engineered heart valves have certain 
advantages including possessing capability for tissue growth and remodelling, 
facilitating tissue development through dynamic conditioning, and overcoming some 
limitations existing in traditional valve prostheses (Black et al., 2009; Mendelson and 
Schoen, 2006; Rabkin-Aikawa et al., 2005).  
By using various cell sources, synthetic or native scaffolds, with or without dynamic 
conditions, tissue engineered heart valves have been produced and evaluated by 
research groups worldwide (Baraki et al., 2009; Flanagan et al., 2009; Jockenhoevel 
et al., 2001a; Shinoka et al., 1995; Steinhoff et al., 2000). From a clinical aspect, 
tissue strength as well as valve ECM content, metabolism and immune compatibility 
seem to be the major concerns in the bio-engineered valve development area (Mol et 
al., 2009; Rabkin-Aikawa et al., 2005; Sacks et al., 2009). The aim of heart valve 
tissue engineering has been described as follows ‘to create or regenerate a living 
valve that functions well hemodynamically, repairs on-going tissue damage and has 
long term durability and growth potential similar to those of the natural heart valves’ 
(Rabkin-Aikawa et al., 2005).  
Currently, three approaches have been used in heart valve tissue engineering based 
on different scaffold types: (1) de-cellularised tissue scaffold with cell pre-seeding in 
vitro or direct implantation; (2) bio-resorbable scaffolds with cell pre-seeding in vitro 
or direct implantation; (3) hydrogel based matrix scaffold with cell entrapment 
(Vesely, 2005).  
As has been discussed before, the acellular matrix based valves have been studied 
extensively, as the matrix network is considered a key feature for heart valve 




mechanical conformation (Sacks et al., 2009; Vesely, 2005). The results of acellular 
xenograft valves for human application, however, are controversial. Complete 
clinical failure has been reported by Simon (Simon et al., 2003). While in another 
study, a high success rate was shown using de-cellularised xenograft heart valves 
(Konertz et al., 2005). Currently, there are continuing attempts to optimize this 
approach, particularly focusing on complete cellular removal and reduction of 
immunogenic responses (Kasimir et al., 2003; Tudorache et al., 2007; Wong et al., 
2011).  
Compared with the acellular matrix approach, bio-resorbable scaffold based valves 
have better defined chemical and material properties and potentially cause less 
immunogenic responses (Mol et al., 2009). In situ studies on this type of valves are 
mainly carried out in animal models and the results seem to be promising (Kim et al., 
2001; Shinoka et al., 1996). To find an appropriate scaffold is the key challenge for 
this type of approach. The balance of scaffold resorption rate and ECM synthesis, as 
well as the scaffold catabolite biocompatibilities, are crucial factors for clinical 
applications (Mol et al., 2009; Sacks et al., 2009).  
The hydrogel approach is relatively novel compared to the above two approaches. It 
requires the greatest amount of design and engineering work and constructed valve 
leaflets are usually formed in customised moulds in vitro (Mol et al., 2009; Vesely, 
2005). Since autologous derivatives seem to be the most ideal cell and scaffold 
source for tissue engineering, this approach appears to be a promising direction for 
heart valve engineering. By using naturally derived collagen or fibrin scaffolds, 
tissue engineered heart valves have been successfully developed by a few groups 
both in vivo and in vitro (Chen et al., 2013; Chen et al., 2012; Flanagan et al., 2007; 
Flanagan et al., 2009; Robinson et al., 2008; Weber et al., 2014; Williams et al., 
2006). As was discussed earlier, the major drawback of hydrogel scaffold is the cell 
mediated contraction that, if used as prosthetics, could conceivably lead to valve 
regurgitation. It has been suggested a more robust bio-degradable supporting material 
would be necessary to overcome this issue and it could serve as a valve skeleton for 
cellular derived ECM to develop over a prolonged time (Flanagan et al., 2009;  




strength of the hydrogel system, which is another concern with these constructs 
(Bouten et al., 2011). 
Novel techniques such as computer assisted design (CAD) and/or computer assisted 
manufacturing (CAM) have been adapted to the tissue engineering field for more 
accurate structure analysis and model creation. By using computed tomography (CT) 
scanning systems, a native heart valve model can be obtained precisely and can be 
reproduced as a mould or scaffold for artificial valve fabrication (Duan et al., 2013; 
Schaefermeier et al., 2009; Sodian et al., 2010). Bio-printing or 3D printing 
technology has also been applied to heart valve tissue engineering very recently. It is 
suitable for creating layered organ structure with geometric and/or mechanical 
complexity (Duan et al., 2013). As natural heart valves exhibit unique layered ECM 
structure, a combination of CAD modelling and 3D printing can simulate this 
structure precisely and provide the opportunities of replicating customised heart 
valves on large industrial scale (Mironov et al., 2011). To date, bio-printing of heart 
valves is still at a preliminary stage. However, fabrication of a heterogeneous aortic 
valve conduit with CAD and 3D printing techniques has been proven to be feasible 
(Duan et al., 2013). It is believed that this might become the most dominant approach 
in the future of heart valve tissue engineering.  
To date, numerous exciting achievements have been made in the area of heart valve 
tissue engineering. To maximally optimise engineering materials and conditions, 
more advanced understanding of native valve biology is required. Heart valve 
engineering techniques could aid in this understanding of the native valve and valve 
response in disease.  
1.3.4 Tissue-Engineered Heart Valve as Research Models 
Though the main aim of heart valve tissue engineering has been the goal of 
developing valves for clinical implantation, generating a valve model as an in vitro 
research platform is also of great value. This is extremely useful for preclinical 
therapeutic tests or examination of tissue function. The classic example is the 3D 
tumor spheroid model in cancer research, in use since the 1970s (Sutherland 1971). 




this model but substantial biological information of tumor cells was also obtained 
(Mueller-Klieser, 1997; Nehls and Drenckhahn, 1995; Olive and Durand, 1994). 
There are several advantages of utilising 3D culture or tissue engineered models as in 
vitro research tools: (1) superior to traditional two dimensional (2D) culture, the cells 
in 3D cultures more resembles to in vivo situation in terms of cellular distribution, 
communication and ECM configuration (Mueller-Klieser, 1997); (2) compared with 
native tissues, engineered constructs can be produced as needed giving better 
availability; (3) the artificial constructs could replace animal models for preclinical 
therapeutic tests and could at least partially answer pathophysiological questions of 
certain disease conditions.  
In the tissue engineering heart valve field, though great efforts have been made in 
engineering technology, substantial fundamental questions regarding valve cell 
biology or valve construct ex-vivo development remain. As has been stated by 
Butcher and Nerem: ‘advanced understanding in valve cellular biology has not kept 
up with valve mechanical and scaffold studies’ (Butcher and Nerem, 2006). The need 
to obtain more information on heart valve biology is a clear driving force for using 
3D valve constructs as a research model rather than just clinical prosthetics. Valve 
cells especially VICs play a crucial role in almost all heart valve disease. Therefore, 
most of the in vitro model studies have been focused on VIC biological behaviour 
and functions. By utilising collagen gel scaffolds, it has been shown that human 
aortic VICs have the capacity of secreting metalloproteinase and are involved in 
ECM remodelling ex vivo (Dreger et al., 2006). Other studies confirmed the fact that 
VICs are distinct from other mesenchymal cell types. There are studies comparing 
VICs with vascular smooth muscle cells and pericardial fibroblasts. The VICs exhibit 
better ECM synthetic ability than smooth muscle cells (Butcher and Nerem, 2004). 
Moreover, VICs from different type of heart valves seem to have different force 
generation ability (Smith et al., 2007). All of these should be considered when 
selecting appropriate cell sources for specific heart valve tissue engineering.  
Heart valve endothelium has been suggested as having a role in valve disease 
pathogenesis, and the interaction between valve endothelium and sub-endothelial 




VICs in vitro co-culture model (Butcher and Nerem, 2006). It has been shown that 
without endothelium coverage, the VICs-collagen co-culture 3D construct expressed 
higher α-SMA compared to a VECs-VICs-collagen co-culture. When exposed to 
dynamic conditioning, VECs-VICs co-culture constructs have greater ECM synthesis 
comparing to VICs alone constructs. This indicates the valve endothelium is 
important for maintaining and regulating underlying VIC phenotypes, as well as 
functions. 
Other investigations in heart valve research utilising the 3D culture techniques aim to 
answer questions of heart valve developmental biology (Li et al., 2013) and to 
explore optimal engineering materials and mechanical conditions for heart valve 
regeneration (Colazzo et al., 2011; Grande-Allen and Liao, 2011).  
1.3.5 Toward Mitral Valve Tissue Engineering  
Compared to aortic and pulmonic valves conduits, fewer attempts have been made in 
mitral valve tissue engineering due to the complexity of the mitral valve apparatus 
(Black et al., 2009; Grande-Allen and Liao, 2011). Some studies have been done 
including a chordae tendinae structure generated by using collagen gel matrix with 
smooth muscle cells (Shi and Vesely, 2004). To date, making a tissue engineered 
mitral valve is far away from clinical applications. Current mitral valve tissue 
engineering is mainly to analyse and to collect fundamental information of the mitral 
valve tissue and cells, which will establish a solid base for future implantation 
orientated engineering. At the moment, the major research areas are: mitral valve 
cellular biology and mechanobiology (Flanagan et al., 2006a; Grande-Allen and 
Liao, 2011); heart valve embryonic developmental biology and signalling pathways 
(Butcher and Markwald, 2007; Chiu et al., 2010; Stock and Vacanti, 2001); and 
developing bioreactor culture systems for in vitro valve tissue culture (Gheewala and 
Grande-Allen, 2010; Lieber et al., 2010).  
Though cellular composition of mitral valves share common features with other heart 
valves, unique properties of mitral valve cells have been found in previous studies 
(Gotlieb et al., 2002; Grande-Allen and Liao, 2011; Liu and Gotlieb, 2008; 




differential responses to TGF-β (Liu and Gotlieb, 2008; Walker et al., 2004) and 
fibroblast growth factor-2 (FGF-2) (Gotlieb et al., 2002). Therefore, the research 
findings from semilunar valves should be taken with caution when applying them to 
the mitral valve tissue engineering field. One of the earliest studies assessing mitral 
valve cell function was carried out on a variety of valve tissue sources (Rabkin-
Aikawa et al., 2004b). This classic study compared VIC phenotype from normal 
adult, myxomatous and foetal mitral valves by using immunohistochemistry 
technique. The results showed that the majority of VICs in normal adult mitral valves 
are a quiescent phenotype, whereas in the developmental stage and myxomatous 
disease, the VICs are a more activated phenotype-expressing α-SMA and SMemb 
and proteomic enzyme MMP-13. This suggests that ECM remodelling in adult 
diseased mitral valves share similarities to the foetal valve development process. 
Moreover, in the same study, tissue engineered valves with in vitro dynamic 
conditioning are comparable to foetal valves regarding ECM distribution pattern. 
This indicates a developmental-like remodelling had occurred in engineered valves 
ex situ. The cell sources and scaffold materials in the tissue engineered valve 
constructs in this study were not derived from mitral valves (Rabkin-Aikawa et al., 
2004b; Rabkin et al., 2002), which might have had an impact on this result. In 
another study, the ability of mitral VECs and VICs to synthesise products has been 
assessed. Cardiovascular regulatory enzyme NOS has been found in 2D cultures of 
VECs and VICs respectively, and both cell types secreted basement membrane 
components and collagen Type III. However, Type I collagen was only detected in 
VIC culture (Flanagan et al., 2006a). This study confirmed VICs are the dominant 
synthetic cell type in mitral valves. In a later study done by the same group, a 3D 
collagen-GAG hydrogel mitral valve model has been generated. The collagen-GAG 
construct has demonstrated native valve-like morphology as well as enhanced ECM 
distribution and endothelialisation compared to mere collagen construct. This can be 
a potential model reference for future mitral valve tissue engineering (Flanagan et al., 
2006b). 
It has been known that VICs with diverse characteristics exist within the mitral 




properties were observed among VICs isolated from the anterior leaflet central 
region, posterior leaflet free edge and chordae tendineae. It has been suggested this 
phenomenon corresponds to localisation of physiological stress or altered 
haemodynamics in pathological conditions (Blevins et al., 2008).  
Current understanding of mitral valve leaflet and chordae mechanics has been 
reviewed by Grande-Allen and Liao (Grande-Allen and Liao, 2011). The mitral valve 
apparatus’s mechanical behaviour is best described as ‘heterogeneous’. For example, 
depending on differential underlying collagen fibre distribution, the stress-strain 
curves on the leaflets vary and also the tensile stiffness is distinct between valve 
leaflet clear zone and rough zone (Kunzelman and Cochran, 1992; Stephens et al., 
2009), and the chordae tendineae insertion region exhibits uneven tension 
distribution (Padala et al., 2010). The mechanical interaction between chordae 
tendineae and mitral valve leaflet certainly is one of the greatest challenges for mitral 
valve tissue engineering. 
Understanding of the developmental biology of the native valves is essential before 
functional tissue engineered mitral valves can be realized (Butcher and Markwald, 
2007). General information for mitral valve embryonic development has been 
reviewed in Section 1.1.2. However, valvulogenesis in vitro requires more advanced 
understanding of mechanical force effects and signalling pathways involved in valve 
development. One potential solution to allow examination of this topic is by 
comparing native embryo implant models with artificial embryo valve constructs to 
analyse common pathways (Butcher and Markwald, 2007). By using a collagen gel 
system and embryonic cardiac cushion tissue, avian mitral valve constructs have 
been developed and remodelled in vitro. The results indicate these 
explants/constructs assemble native embryonic AV valves and the development can 
be regulated by cardiac myocytes, TGF-β, bone morphogenetic protein-2 (BMP-2) 
and vascular endothelial growth factor A (VEGF-A) (Chiu et al., 2010; Goodwin et 
al., 2005). This valvulogenesis study utilising 3D culture techniques is particularly 




Mechanical and biochemical stimulation are important factors in heart valve 
physiological and pathophysiological conditions. Based on foetal cardiac valve 
development parameters, the following flow conditions have been suggested to result 
in reasonable initial development for the heart and vascular system: less than 5% 
radial strain, low oxygen level and a crescendo heart rate (Stock and Vacanti, 2001). 
Nevertheless, it has been questioned whether identical conditions should be used for 
all heart valves as they experience differential mechanical forces and surface shear 
stress patterns in cardiac cycles in vivo (Black et al., 2009). Therefore, bioreactor 
systems for specific mitral valve tissue engineering are needed. One preliminary 
study established a bioreactor suitable for entire mitral valve organ culture 
(Gheewala and Grande-Allen, 2010). This system reproduced physiological pressure 
and pulsatile flow and a similar mechanical environment to the native status was 
achieved (Gheewala and Grande-Allen, 2010). Another mitral valve ex vivo culture 
system was based on a splashing rotating bioreactor (Barzilla et al., 2010). This 
customised design provides perfusion and gentle mechanical stimuli which are 
essential to maintain mitral tissue ECM integrity. To investigate the role of tensile 
strain in myxomatous mitral valve disease, a cyclic strain bioreactor was designed 
and it has shown 30% of cyclic strain can induce myofibroblast activation, MMPs 
up-regulation and increased GAGs in both canine and ovine mitral valves (Lacerda et 
al., 2012a; Lacerda et al., 2012b). Moreover, local serotonin synthesis has been 
found to mediate these changes (Lacerda et al., 2012a). Apart from entire organ 
culture, bioreactor induced shear stress effects on mitral VIC synthesis and 
phenotypic alteration have also been investigated. Cyclic strain effect on GAG/PG 
synthesis from porcine mitral VICs has been assessed in a 3D collagen gel system. 
Mechanical stretch was found to up regulate total GAG production, and a stretch and 
relaxation process can reversibly regulate the GAG/PG metabolism in the valve 
constructs (Gupta et al., 2008a). Another collagen system based study demonstrated 
that 15% cyclic strain tended to regulate VICs from mild diseased myxomatous 
mitral valves toward a more quiescent phenotype (Waxman et al., 2012).  
As has been mentioned before, the unique heterogeneity of the mitral valve brings up 




However, the great need for mitral valve tissues in both clinical and research areas 
emphasises the need for mitral valve tissue engineering (Black et al., 2009). In the 
past decade, substantial  preparation studies have been carried out which gave rise to 
more clearer understanding of mitral valve physiological and biological properties 
both in vivo and ex vivo. Nevertheless, more unsolved questions remain and 
additional investigations on the key issues will be required to engineer a functional 
mitral valve (Grande-Allen and Liao, 2011).  
1.4 Aim, Scope and Hypothesis 
The aim of the current study is to use tissue engineering techniques to generate in 
vitro research models for an investigation of mitral valve biology and myxomatous 
disease pathogenesis.  
Primary canine mitral valve endothelial and interstitial cells were to be isolated and 
characterized in 2D culture, and archived as a cell source for tissue engineered mitral 
valve constructs.  
Three types of VECs-VICs 3D co-culture constructs were to be generated using a 
fibrin based hydrogel system in static culture as follows; Type 1-healthy VECs-
healthy VICs co-culture; Type 2-healthy VECs-diseased VICs co-culture; Type 3-
endothlium damage model based on healthy VECs-VICs co-culture. The following 
hypotheses were proposed: (1) 3D models will possess native valve-like features and 
can be used as a substitute for native valve tissue for research purposes; (2) 
Myxomatous disease related protein markers indicating VIC phenotypic activation 
(α-SMA and SMemb) and ECM catabolism (MMP-1 and MMP-3) will be increased 
in the Type 2 model compared to the Type 1 model; (3) In response to endothelium 
damage (Type 3 model), VICs will become activated in an attempt to repair the 
wound.  
To examine the hypothesis of shear stress causing endothelium damage and 
contributing to MMVD pathogenesis, a tissue engineered tubular mitral valve 
construct and a customised bioreactor system providing pulsatile flow would be 




(endothelial injury) would be generated using the dynamic conditioning system. It is 
hypothesized that (1) pulsatile flow dynamic conditioning will enhance tissue ECM 
synthesis and the shear flow conditioned construct morphology will be histologically 
more similar to a native mitral valve than static constructs; (2) endothelial injury of 
the pulsatile flow conditioned construct will result in a construct resembling a 
MMVD valve, showing up-regulation of a panel of disease related markers. 
Additionally, the expression of advanced glycation end products in MMVD were 
examined, with the intention of investigating the role of these products in MMVD 
pathogenesis utilising the 3D mitral valve constructs in future studies 
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Chapter 2: General Materials and Methods 
2.1 Tissue Materials 
Tissue samples were collected from The Hospital for Small Animals, the University 
of Edinburgh with full owner consent and sampling procedure conformed to 
institutional and national ethical guidelines. All dogs were euthanized for non-
cardiac reasons. Canine mitral valve tissue was mainly used in all studies in this 
project. During collection, mitral valve sample gross morphology was graded by at 
least two observers independently according to the Whitney grading system. In cell 
culture based studies, after euthanasia, all mitral valve samples were immediately 
isolated, rinsed and stored in sterile phosphate buffered saline (PBS) and kept on ice 
until transferred to a tissue culture laminar hood. For the immunoblotting or 
immunohistochemistry/immunofluorescence studies, at time of collection, mitral 
valve samples were either snap frozen on dry ice and stored at -80°C or fixed in 4% 
paraformaldehyde (VWR International, UK).  
Additionally, blood samples were collected for enzyme-linked immunosorbent assay 
(ELISA) analysis. Plasma was prepared by centrifuging the blood at 3,000 rpm, for 
15 min, and then the supernatant was divided into 50 l aliquots and stored at -80°C. 
Serum samples were selected from the existing blood sample archive in 
Cardiopulmonary Department of The Hospital For Small Animal, the University of 
Edinburgh, which were prepared by the technician of the clinical lab and were stored 
at -20°C.  
2.2 Protein Immunoblot (Western Blot) 
2.2.1 Protein Extraction 
 Tissue Protein Extraction 2.2.1.1
Fresh tissue samples were collected and snap frozen on dry ice, then stored at -80C 
before protein extraction. Urea lysis buffer (7 M urea (Fisher Scientific, UK)/0.1 M 
dithiothreitol (DTT) (Melford Laboratories)/0.05% Triton X-100 (Sigma-Aldrich, 
USA)/25 mM NaCl (Fisher Scientific, UK)/20 mM HEPES-KOH (Fisher Scientific, 
UK) pH 7.6) was used for extracting soluble proteins and additional Sodium dodecyl 
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sulfate (SDS) (BDH Laboratory Supplies) extraction buffer (0.15 M NaCl/50 mM 
Tris (Fisher Scientific, UK) pH 8.0/0.1 mM Na2EDTA (Sigma-Aldrich, USA)/10% 
SDS) was used for extracting less soluble proteins. For protein extraction, Lysing 
Matrix Tubes (6913, MP-Biomedicals, Germany) with 250 l urea lysis extraction 
buffer added were placed for 5 min on ice. Buffer was removed from the tube and 
replaced with 250 l fresh buffer. Fifty micrograms tissue samples were thawed and 
finely cut the tissue into approximate 1mm
3
 in size with a sterile scalpel (Swann 
Morton, UK). The tissue was added to the lysate tube containing buffer and 
homogenized for 40 s using Thermo Savant FastPrep FP120 Homogenizer (Thermo 
Electron Inc, USA) at a speed of 4.0 m/s and then centrifuged at 13,000 g for 2 min 
at 4°C. Supernatant was collected into 1 ml eppendorf tubes and centrifuged again at 
13,000 g for 15 min at 4°C. Supernatant was collected from the second 
centrifugation and kept on ice. A volume of 250 l SDS extraction buffer (contained 
1% β-mercaptothanol (Sigma-Aldrich, USA)) was added to the tube containing 
second centrifugation sediments, mixed well and the mixture transferred to the 
original lysate tubes. The homogenization step was repeated as above and then 
centrifuged at 13,000 g for 2 min at 4°C. The supernatant was collected into 1 ml 
eppendorf tubes and centrifuged again at 13,000 g for 15 min at 4°C. The protein 
supernatant was collected and combined with the protein supernatant extracted by 
urea lysis buffer, divided into small aliquots and stored at -80 °C.  
 Cell Protein Extraction 2.2.1.2
Primary cultured cells were harvested at 80-90% confluence (the cell harvest 
protocol is described in details in Section 2.4.3) and re-suspended in 1 ml chilled 
PBS. They were then centrifuged at 300 g, at 4°C for 3 min. The supernatant was 
removed and cell pellets snap frozen on dry ice. Cell pellets were stored at -80°C. 
For cell lysis 2-3 volumes of urea lysis buffer was added to the frozen cell pellets and 
mixed well until the solution became homogenous. They were then incubated on ice 
for 30 min, before centrifugation at 13,000 g for 10 min at 4°C. The lysate 
supernatant was collected and transferred to a new eppendorf tube, before snap 
freezing on dry ice and storing at -70°C. 
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2.2.2 Protein Sample Quantification and Preparation 
For total protein quantification, a Bradford assay was carried out on each sample. 
Standard protein solutions were prepared with 10 mg/ml Bovine Serum Albumin 
(BSA) stock solution (A-7638, Sigma) to 0.125 mg/ml, 0.25 mg/ml, 0.5 mg/ml, 1 
mg/ml, 2 mg/ml and 4 mg/ml BSA. Protein samples were thawed out on ice and 
diluted 1 in 10 with ddH2O (for sample with low protein concentration, neat sample 
was used). Either 1 l of standard solution or sample solution were added to a well in 
a clear 96-well plate and then 200 l 1 x Bradford reagent (Bio-Rad, UK) was added 
and mixed well avoiding bubbles. Both standard assays and protein samples were 
triplicated. The absorbance reading at optical density (OD) 595 nm was measured by 
Victor3 V1420 Multilabel Plate Counter (Perkin Elmer, USA). A BSA standard 
curve was made by plotting each standard assay concentration and OD 595 nm 
absorbance reading respectively. The equation for the curve was calculated in 
Microsoft Office Excel software (Microsoft Corporation, USA). The formula was 
applied to protein samples and undiluted sample protein concentration calculated. 
Samples were prepared to a concentration of usually 1 g/l with 4 x SDS sample 
buffer (4% SDS/200 mM Tris (pH 7)/20% Glycerol (Fisher Scientific, UK)/10 mM 
EDTA/50 l/ml 1% bromophenol blue (Sigma, UK)/0.2 M DTT), stored at -20°C. 
2.2.3 Gel Electrophoresis  
Proteins were resolved on the basis of their molecular weight by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Different percentage 
acrylamide gels were prepared according to the size of the protein of interest. For 
proteins less than 150 KDa, 10% resolving gel was used; for protein size between 
150-225 KDa, 6% resolving gel was used. The polyacrylamide gels were prepared 
and assembled using Bio-Rad Protean II mini-gel system (Bio-Rad, UK). Spacer 
plates and cover glass plates was cleaned by wiping with 70% ethanol (Fisher 
Scientific, UK) and assembled in a casting frame. It was ensured that the plates were 
level before clipping back the side hinges. The plates and casting frame were then 
secured into a clear casting stand. The space between the plates was tested with water 
to ensure there was no leakage. The resolving gel for protein band separation 
contained ddH2O, 30% acrylamide (National Diagnostics, UK), 1.5 M Tris (pH 8.8), 
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10% SDS, 10% ammonium persulfate (AP) (Sigma, UK) and 
tetramethylethylenediamine (TEMED) (Sigma, UK). Just before gel pouring 0.1% 
AP and 0.08% TEMED were added as they initiated polymerization. The resolving 
gel was prepared as described in Table 2.1. 
 
 
Table 2.1 Solutions for SDS-PAGE resolving gel preparation 
Solution component  Component volumes (ml) per gel mold 
volume of  
5 ml 10 ml 15 ml 20 ml 25 ml 30 ml 
6%       
  ddH2O 2.6 5.3 7.9 10.6 13.2 15.9 
  30% acrylamide 1.0 2.0 3.0 4.0 5.0 6.0 
1.5 M Tris (pH 8.8) 1.3 2.5 3.8 5.0 6.3 7.5 
  10% SDS 0.05 0.1 0.15 0.2 0.25 0.3 
  10% AP 0.05 0.1 0.15 0.2 0.25 0.3 
  TEMED 0.004 0.008 0.012 0.016 0.02 0.024 
       
10%       
  ddH2O 1.9 4.0 5.9 7.9 9.9 11.9 
  30% acrylamide 1.7 3.3 5.0 6.7 8.3 10.0 
1.5 M Tris (pH 8.8) 1.3 2.5 3.8 5.0 6.3 7.5 
  10% SDS 0.05 0.1 0.15 0.2 0.25 0.3 
  10% AP 0.05 0.1 0.15 0.2 0.25 0.3 
  TEMED 0.002 0.004 0.006 0.008 0.01 0.012 
       
15%       
  ddH2O 1.1 2.3 3.4 4.6 5.7 6.9 
  30% acrylamide  2.5 5.0 7.5 10.0 12.5 15.0 
1.5 M Tris (pH 8.8) 1.3 2.5 3.8 5.0 6.3 7.5 
  10% SDS 0.05 0.1 0.15 0.2 0.25 0.3 
  10% AP 0.05 0.1 0.15 0.2 0.25 0.3 
  TEMED 0.002 0.004 0.006 0.008 0.01 0.012 
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Approximately 3 ml of resolving gel solution was added to the space (0.75 mm 
spacer) between the plates to make the gel level sit just below the green band of the 
casting frame. Isopropanol (Fisher Scientific, UK) was added on top of the resolving 
gel to remove air bubbles, and the gel was left to set at room temperature for 20-30 
min. Then the isopropanol was removed and 5% stacking gel prepared as described 
in Table 2.2: 
 
Table 2.2 Solutions for SDS-PAGE stacking gel preparation 
Solution component  Component volumes (ml) per gel mold volume of  
1 ml 2 ml 3 ml 4 ml 5 ml 6 ml 
  ddH2O 0.68 1.4 2.1 2.7 3.4 4.1 
  30% acrylamide 0.17 0.33 0.5 0.67 0.83 1.0 
1.0 M Tris (pH 6.8) 0.13 0.25 0.38 0.5 0.63 0.75 
  10% SDS 0.01 0.02 0.03 0.04 0.05 0.06 
  10% AP 0.01 0.0. 0.03 0.04 0.05 0.06 
  TEMED 0.001 0.002 0.003 0.004 0.005 0.006 
       
 
The stacking gel solution was added on top of the resolving gel to the top of the 
plates. A 10- or 15-well loading comb was inserted and the gel left to set at room 
temperature for 20-30 min. Once set the gel was removed from the casting stand and 
frame, the combs removed and wells washed gently with water to rinse off remaining 
gel in the wells. The gels were placed in the running module and immersed in SDS-
PAGE Running Buffer (192 mM glycine, 25 mM Tris, 0.1% (w/v) SDS) prior to 
protein sample loading. The samples were thawed and heated at 95
o
C for 3 min to 
denature the proteins prior to loading. From 5-30 g of protein samples were loaded 
into wells in the stacking gel dependent on experiment. Commercial pre-stained 
protein markers (Bio-Rad and GE Healthcare, UK) were used to gauge size of the 
protein bands. The tank lid was secured and subjected to electrophoresis at 180 volts 
for 45-60 min. Proteins of interest separated in the resolving gel.  
 




The resolved protein sample in the gel was transferred to Protran
®
Nitrocellulose 
Transfer Membrane (Whatman GmbH, Germany) by electroblotting. In detail, one 
litre 1 x transfer buffer (192 mM glycine (Sigma), 25 mM Tris, 20% (v/v) methanol 
(Fisher Scientific, UK)) was prepared. The transfer system was prepared, 
components included one cassette, two blotting paper, two sponges, one 
nitrocellulose membrane and the gel. A shallow dish was half filled with the transfer 
buffer to soak the blotting paper and sponges. The cassette was placed in the dish 
with black side down. The transfer components were assembled as follows: One 
sponge → one piece of blotting paper → the gel → the nitrocellulose membrane → 
one piece of blotting paper → the sponge. Bubbles were removed after placing each 
layer. The gel was separated from the glass plates by inserting a green wedge in the 
glass space. The stacking gel part was gently chopped off and the resolving gel lifted 
from the plate and placed on the blotting paper. After assembling, the cassette was 
closed. The cassette was inserted into a black and red transfer holder ensuring that 
the black side of the cassette was facing the black side of the holder. An ice block 
was placed in the transferring tank. The tank was filled with 1 x transfer buffer. 
Electroblotting was carried out at 300 mA for 1 h or alternatively run overnight at 30 
mA without an ice block. The protein marker was checked to see if it had been 
transferred to the blot as an indicator for successful electroblotting.   
2.2.5 Immunoblotting 
The nitrocellulose membrane was removed from the transfer cassette and washed 
with 1 x PBS-0.1% Tween 20 (Scientific Laboratory Supplies, UK). Ponceau S 
(kindly provided by Dr Karen Tan) stain was applied to the membrane to check equal 
protein loading. The membrane was washed with PBS-0.1%Tween 20 and blocked in 
5% milk/PBS-0.1%Tween 20 for 1 h at room temperature. The primary antibody was 
diluted with 5% semi-skimmed milk (Sigma-Aldrich, USA)/PBS-0.1%Tween 20 and 
membranes probed with the primary antibody for 1 h at room temperature or 
overnight at 4
o
C. The membrane was washed with PBS-0.1%Tween 20 for 3 x 5 min 
and then incubated for 1 h at room temperature with a secondary horseradish 
peroxidase (HRP) conjugated antibody diluted in 5% milk/PBS-0.1% Tween20. The 
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Western Blot Detection Reagent (RPN2290, GE Healthcare, UK) was applied to 
drained blot on a clear glass plate, left for 1-2 min, excessed reagent was removed 
and blot covered with cling film and placed in a film cassette. Radiographic film (GE 
Healthcare) was loaded into the cassette in a dark room and developed for 30 s-20 
min depending on signal strength of different proteins of interest based on trial and 
errors. Protein bands were visualised by developing films in a SRX-101A 
radiographic processor (Konica Minolta, UK). After development, the molecular 
weight size of target protein was checked by comparing with the standard protein 
markers on the blot.   
2.3 Enzyme-Linked Immunosorbent Assay (ELISA) 
For ELISA study, the protocols provided in the commercial kit were followed. 
Details of the protocols are described in Section 6. Once all reactions had been 
completed, OD value of each well was measured at 450 nm using a Victor3 V1420 
Multilabel Plate Counter. Standard curves were obtained using MasterPlex® EX 
2010-Multiplex Expression Data Analysis Software (Hitachi Solutions America, 
USA).  
2.4 Cell Culture 
2.4.1 Canine Mitral Valve Endothelial Cell and Interstitial Cell 
Isolation 
Canine mitral valves were dissected immediately post mortem by using sterile 
surgical instruments. Blood was rinsed from the valve surface with cold sterile pH 
7.4 PBS, the valves was kept in 50 ml conical tubes (Greiner Bio-One, UK) with 20 
ml sterile PBS on ice. In a tissue culture hood, excess annular, visible myocardium 
on the leaflets and chordae tendineae were carefully dissected from the valve leaflets 
to avoid cell contamination. Usually both anterior and posterior leaflets were 
collected; in some experiments only anterior leaflets were used due to other 
experiment needs. The valve leaflets were rinsed with sterile PBS or culture medium 
(details described in Section 2.4.2), then placed in a 35 mm sterile petri dish with 3-5 
ml (depending on the size of the leaflets) pre-warmed 600 Units/ml collagenase II 
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(17101-015, Invitrogen, UK) solution. Tissue was incubated at 37C and 5% CO2 for 
10 min. Mitral valve endothelial cell (VEC) population was obtained by gently 
rotating a dry sterile swab over the surface of the leaflet (approximate 5 times for 
each side) and then dabbing the swab in the collagenase solution to release cells from 
the swab. The collagenase solution was aspirated and the cells pelleted in a 
Heraeus
®
Labofuge 400 centrifuge (Thermo Scientific, UK) at 1,000 rpm for 5 min at 
room temperature. The supernatant was removed and cells washed in 5 ml culture 
medium. The cell solution was centrifuged again at 1,000 rpm for 5 min and the cells 
re-suspended in 10 ml of culture medium. The cells were seeded on 2% gelatin 
(Sigma, USA) pre-coated cell culture flasks/plates (Thermo Scientific, UK) and the 
cells cultured at 37C and 5% CO2 for at least 2 days before the first medium change.  
Mitral valve interstitial cell (VIC) population was isolated either by using an explant 
or collagenase digestion technique. The explant technique was used in earlier 
experiments and was replaced by the collagenase digestion in later experiments. For 
the explant technique, after VEC isolation, the rest of the valve tissue was finely 
minced into small pieces (around 2 x 2 mm) with sterile scalpels and the pieces were 
immediately transferred to T80 culture flasks. A couple of minutes allowed for the 
pieces to adhere to the flasks, and then 10 ml culture medium was gently added to 
each flask. The explants were incubated under standard tissue culture conditions. 
Once the VICs substantially migrated from the tissue (6-8 days), the valve explants 
were removed and discarded.  
The explants technique was only used in the earlier VICs isolation experiments, due 
to the concerns that the VICs that migrate from the explants might not represent the 
entire VIC population; a collagenase digestion technique was used instead for further 
experiments. All VICs used in Section 4-5 were isolated by collagenase digestion. 
For collagenase digestion, after VEC isolation the valve tissue was placed in a 15 ml 
conical tube with 10 ml collagenase II solution (600 Units/ml), the tissue was 
digested  for 18 h at 37C and 5% CO2. Then the degraded tissue was mixed with a 
serological pipette until cells and collagenase solution became homogenized. The 
cell suspension was centrifuged and cells washed using the same protocol which was 
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described above for harvesting VECs. The VICs were re-suspended in 10 ml culture 
medium, seeded on 1 x T80 culture flasks and incubated at 37C and 5% CO2. VIC 
primary cultures were normally left for 2 days before changing medium, and usually 
reached confluence within 2-4 days under light microscopy observation. 
2.4.2 Culture Medium 
Advanced DMEM/F-12 medium (26134, Life Technologies) with supplement (10% 
foetal bovine serum (FBS) (Life Technologies, UK), 1% penicillin G and 
streptomycin (100 U/ml-100 µg/ml) (Invitrogen, UK) and 1% L-glutamine (2 
mmol/L) (Gibco, UK) was used for both VECs and VICs culture.  
In endothelial culture condition optimization experiments, canine endothelial basal 
medium kit (Cn211K-500, Cell Application Inc., USA) was also used for VECs 
culture. Commercial medium supplement in the kit contains antibiotics, FBS, 
hydrocortisone, fibroblast growth factor-2 (FGF-2) and epidermal growth factor 
(EGF). 
2.4.3 Cell Harvest and Sub-culture 
Once the cells reached confluence the medium was removed and sterile PBS was 
added into the flasks to wash the cells. PBS was removed and the cells were 
incubated at 37C and 5% CO2 with 0.05% 1 x Trypsin/EDTA (253000, Life 
Technologies, UK) or 1 x TrypLE Express (12604, Life Technologies, UK) (volume: 
one well of six well plate or T25 flask-1 ml, T80 flask-3 ml, T175 flask-5 ml) for 5-
30 min to dissociate the cells. After trypsinization/TrypLE Express dissociation, the 
cell suspension was diluted with 3-10 ml (depending on the culture vessel) culture 
medium and centrifuged at 1,500 rpm for 5 min. If cell counting was being 
performed, the medium was removed, cells were re-suspended in 1-5 ml (depending 
on the cell number, which was estimated by observing cell pellets) medium then 
counted; if cell counting was not required, the cells were re-suspended in medium 
(one well of 6 well plate-3 ml; T25-5 ml; T80-10 ml; T175-30 ml) and seeded on the 
culture flasks/plates.  
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2.4.4 Cell Counting 
A haemocytometer was used for cell counting. 10 µl cell suspension was mixed with 
10 µl Trypan Blue (Sigma-Aldrich, UK) and was added into each side of the 
counting chamber. Live cells were counted (no Trypan Blue staining) in the two 
central big squares of the haemocytometer. One cell in one single big square 
represents 10
4 
cells. Therefore Cell Number/ml suspension = Cell Counting Number 




Freezing medium (70% culture medium, 20% FBS, 10% dimethylsulphoxide 
(DMSO) (Invitrogen, UK)) was prepared into 5 ml aliquots, stored at -20 °C until 
used. The cells were counted as described previously and re-suspended in freezing 
medium at approximately 1.5 x 10
6
 cells per ml for VICs; 2 x 10
6
 cells per ml for 
VECs and cell suspensions transferred to pre-labelled cryogenic tubes (Wheaton, 
USA). The tubes were placed in a cryopreservation canister (Thermo Scientific, UK) 
which contained isopropyl alcohol in the base, the coolant allowing a cooling rate of 
1°C/min when transferred to a -80°C freezer. For long term storage, tubes were 
transferred to a -150°C freezer or stored in liquid nitrogen. 
2.4.6 Reviving Cells from Cryopreservation 
The cell culture vial was retrieved from the freezer and immediately transferred to a 
water bath at 37°C and cells thawed without allowing the water to penetrate the cell 
tube. When the vial contents thawed (generally 1-2 min), the contents were 
transferred to a 15 ml centrifuge tube in the laminar hood and 5 ml pre-warmed 
medium slowly added to the cell suspension. The cells were centrifuged at 3,000 rpm 
for 5 min to remove the freezing medium components, especially DMSO. The 
supernatant was aspirated, and cells re-suspended in a volume of culture media 
appropriate for the flask or culture plate, and cultured at 37C with 5% CO2. 
2.4.7 Cell Morphology Observation 
Cell morphology was observed by using a light microscope during culture period. 
Representative cell images were captured by using a camera connected Zeiss 
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Axiover 40 microscope (Carl Zeiss, Germany) at different magnifications: x 50, x 
100 and x 200.   
2.5 Polymerase Chain Reaction (PCR) 
2.5.1 Primer Design and Preparation 
Canine nucleotide sequences of the selected markers were found either in National 
Centre for Biotechnology Information (NCBI) Gene Bank (USA) or Ensembl 
Genome Browser Website (UK). Based on the published genome sequences, the 
primers pairs were designed by utilizing Primer 3 Input software (Version 4.0) and 
intron spanning pairs were selected. The specificity of the chosen primers was 
checked by using NCBI BLAST online program. All primers were ordered through 
MWG Eurofins Operon online service (Eurofins MWG Operon, Germany) and 
diluted to 50 pmol/µl, then aliquoted and stored at -20°C.  
2.5.2 Cell Ribonucleic Acid (RNA) Extraction  
Canine mitral valve cells were trypsinized, counted, re-suspended in cold PBS and 
centrifuged for 10 min at 300 g, 4°C. Removed the supernatant and snap froze the 
cell pellets. Frozen cell pellets were stored at -80°C until ribonucleic acid (RNA) 
extraction. Less than 5 x 10
6
 cells were pelleted and washed in 1 ml cold PBS. The 
cell suspension was centrifuged at 300 g for 10 min at 4°C. Supernatant was 
removed and cells snap frozen on dry ice. Samples were stored at -80°C until RNA 
extraction was performed. Cell total RNA was isolated by utilising RNeasy Mini Kit 
(74106, Qiagen, UK), following the manufacture’s instruction. Cells were disrupted 
by mixing with 350 µl Buffer RLT (provided in the kit), the lysate transferred 
directly into a QIAshredder spin column (79656, Qiagen, UK), and centrifuged for 2 
min at full speed. Then 350 µl 70% ethanol was added to the homogenized lysate, 
mixed well and the solution transferred to an RNeasy spin column (provided in the 
kit) and centrifuged for 15 s at ≥ 10,000 rpm. The flow-through was discarded. 
Buffer RW1 (provided in the kit) 700 μl was added to the RNeasy spin column and 
centrifuged for 15 s at ≥ 10,000 rpm to wash the spin column membrane. Flow 
through was discarded. 500 μl Buffer RPE (provided in the kit) was added to the 
RNeasy spin column, and centrifuged for 2 min at ≥ 10,000 rpm. The RNeasy spin 
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column was placed in a new 2 ml collection tube and centrifuged at full speed for 1 
min. RNeasy spin column was placed in a new 1.5 ml collection tube. 50 μl RNase-
free water (129112, Qiagen, UK) was added directly to the spin column membrane 
and centrifuged for 1 min at  ≥ 10,000 rpm) to elute the RNA.  
The RNA was subsequently cleaned up using RNase-Free DNase Set (79254, 
Qiagen, UK) using the following protocol: mixed ≤ 87.5 μl RNA solution, 10 μl 
Buffer RDD and 2.5 μl DNase I stock solution (provided in the kit) in a micro 
centrifuge tube, and made up the final volume to 100 μl with RNase-free water, the 
allowed to react for 10 min at room temperature. Afterwards, 350 μl Buffer RLT and 
250 μl 100% ethanol was added to the diluted RNA, mixed well and the sample 
transferred to an RNeasy Mini spin column. The column was centrifuged for 15 s at 
≥ 10,000 rpm and flow-through discarded. 500 μl Buffer RPE was added to the 
RNeasy spin column and centrifuged for 15 s at ≥ 10,000 rpm and flow-through was 
discarded. Another 500 μl Buffer RPE was added to the RNeasy spin column and 
centrifuged for 2 min at ≥ 10,000 rpm and flow-through was discarded. To ensure 
that no excessive RPE buffer was remained, the RNeasy spin column was placed in a 
new 2 ml collection tube and centrifuged at full speed for 1 min. Then the RNeasy 
spin column was placed in a new 1.5 ml collection tube, 40 μl RNase-free water 
added directly to the spin column membrane, centrifuged for 1 min at ≥ 10,000 rpm 
to elute the RNA. The total RNA extracted was quantified and quality evaluated by 
reading absorbance ratio 260 nm: 280 nm and 260 nm: 230 nm on Nanodrop
TM
 
machine (Thermo Scientific, USA).  
2.5.3 Complementary Deoxyribonucleic Acid (cDNA) 
Synthesis 
Before reverse transcription (RT), the RNA was diluted to the desired concentration 
using Nuclease Free water (129114, Qiagen, UK) and was denatured at 65℃ for 5 
min, and stored on ice. Complementary Deoxyribonucleic acid (cDNA) was 
synthesized using Omniscript Reverse Transcription Kit (205111, Qiagen, UK). The 
solutions and their volumes used in the reaction system are described in Table 2.3. 
The solutions were added to a 200 μl PCR tube in the following order: Nuclease Free 
water, 10 x Reverse Transcription Buffer, 5 mM dNTP, 0.1 M DTT, random primers, 
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RNA template, RNase Inhibitor and Ominiscript Reverse Transcriptase. The mixture 
was incubated for 60 min at 40℃, cooled down on ice, and then stored at -20℃.  
 
Table 2.3 Reverse transcription PCR system 
Components µl 
10 x Reverse Transcription Buffer     2 
Deoxyribonucleotide triphosphate (dNTP) Mix (5 mM) 2 
DTT (0.1 M) 2 
Random primers 2 
RNase Inhibitor (10 units/µl) 0.25 
Ominiscript  Reverse Transcriptase 1 
Nuclease Free water 8.75 
RNA Template 2 (500 ng) 
 
 
Total Volume                                        20 
 
2.5.4 Polymerase Chain Reaction (PCR) Amplification  
Undiluted or 1 in 20 diluted cDNA template was used in the experiment. Polymerase 
chain reaction (PCR) was performed using Go taq PCR Core System I (M7650, 
Promega, USA). The solutions and their volumes used in the reaction system are 
described in Table 2.4. The solutions were added to a 100 μl PCR tube in the 
following order: Nuclease Free water, 5 x colourless Go taq Buffer, 10 mM dNTP, 
MgCl2, primers, cDNA template and Go taq DNA polymerase. After experimental 
trials, optimal reaction conditions were developed. The PCR results presenting in this 
thesis were all amplified under the optimized conditions which are described as 
follows: the reaction started from initial denaturation at 95℃ for 5 min, followed by 
30 cycles of 95℃ for 1 min, 58℃ for 1 min, 72℃ for 1 min and final extension at 
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72℃ for 10 min. For short term storage, PCR products were kept at 4℃; long term, 
samples were stored at -20℃.  
Table 2.4  PCR system 
Component  µl 
Nuclease Free Water  31.75 
dNTP (10 mM) 1 
MgCl2 4 
5 x colorless Go taq Buffer 10 
Primer(forward) 0.5 (25 pmol) 
Primer(reverse) 0.5 (25 pmol) 
Go taq DNA polymerase 0.25 
cDNA template 2 
                   Total volume                                                            50
  
 
2.5.5 Agarose Gel Electrophoresis Analysis 
Two percentage agarose (Sigma-Aldrich, USA) gel was used for PCR products 
analysis. Agarose gel powder was dissolved in 1 x Tris acetate EDTA (TAE) buffer 
(Invitrogen, UK). Gel Red (Biotium, USA) was added at a ratio of 1 in 10,000 
(volume). The gel was dissolved by microwaving, poured into a gel casting frame, 
comb inserted and left for 40-60 min to set. The comb was removed, gel with casting 
frame placed in a gel tank, and 1 x TAE buffer added to cover the gel. Before 
loading, PCR products were mixed with 6 x Blue/Orange Loading Dye (Promega, 
UK). A100 base pair (bp) DNA ladder (Promega, UK) was loaded as a size control. 
Samples were run in the gel at 60 volts for 1-1.5 h to allow DNA band separation. 
Molecular Imager Gel Doc system (Bio-Rad, UK) was used to visualize the results 
after electrophoresis. 
2.6 Immunocytochemistry 
After dissociation, cells were counted and adjusted to 0.5 x 10
5
/ml for both VECs 
and VICs. Cell pellets were re-suspended in culture medium. 200 l (i.e. 1 x 10
4
 
Chapter 2-General Materials and Methods 
72 
 
cells) cell suspension was added into each well of culture glass slides (BD, USA) 
(slides for VECs were pre coated with 2% gelatin). Cells were incubated on the 
slides at 37C, 5% CO2 for 24-48 h until the cells attached to the bottom of the slide. 
Culture medium was removed from chamber slide wells and cells washed with 1 x 
PBS several times. Cells were then fixed in acetone for 10 min at -20C. Fixation 
was followed by two washes with 1 x PBS, 5 min each time. Subsequently slides 
were incubated with blocking buffer (10% goat serum (Invitrogen, UK)/0.1% Tween 
20/PBS) for 1 h at room temperature to eliminate unspecific protein binding to 
antibodies. Primary antibodies were diluted with buffer (0.1% goat serum/0.1% 
Tween 20/PBS) to desired concentrations and prepared in a volume of 100 l for 
each sample. The primary antibody was added to each sample well and slides placed 
in a humid chamber and incubated overnight at 4C. The slides were washed twice 
with 1 x PBS, 5 min each time. A volume of 100 l fluorescent secondary antibodies 
were applied to the slides and slides incubated for 1 h at room temperature in a dark 
humid chamber. The wells were removed and slides placed in a staining jar and 
washed with 1 x PBS for three times, 5 min each. Slides were mounted using the 
VECTASHIELD Mounting Medium with 4', 6-diamidino-2-phenylindole (DAPI) 
(H-1200, vector, UK). Nail polish was used to seal the edge of the slide. The slides 
were left to dry in a dark humid chamber before observation by a LEITZ DMRB 
fluorescent microscope (Leica, UK).  
Images were captured by using Leica Firecam imaging software (Leica, UK). 
Antibody staining and DAPI staining images of the same sampled field were merged 
by Adobe Photoshop CS6 software (Adobe System Incorporated, USA). After 
observing, the slides were stored at 4C for short term and at -20C for long term. 
2.7 Acetylated Low Density Lipoprotein Labelling 
Acetylated low density lipoprotein conjugated with fluorescence dye1, 1'-dioctadecyl 
-3, 3, 3', 3'-tetramethyl-indocarbocyanine perchlorate (DiI-Ac-LDL) was used as an 
endothelial cell marker. Cells were seeded on a chamber slide at the concentration of 
1 x 10
4
 cells per well for at least 36 h. Chamber slides for VEC cultures were pre-
coated with 2% gelatin. DiI-Ac-LDL (BT902, Biomedical Technologies, UK) 
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reagent was diluted to 5 g/ml with cell culture medium and was added to a cell 
chamber in a 200 l volume. The following steps were carried out avoiding light 
exposure. After 4 h incubation at 37C, 5% CO2, cells were washed several times 
with sterile 1 x PBS and slides observed immediately under a LEITZ DMRB 
fluorescent microscope. Images were captured by using Leica Firecam imaging 
software (Leica, UK). For long term storage of the slides, cells were fixed in 3% 
paraformaldehyde/1 x PBS solution for 20 min, rinsed with distilled water for 5 s, the 
liquid drained and inverted coverslip on a drop of 90% Glycerol and 10% PBS on the 
slide. The edge of the slides were sealed with paper tape and stored them at 20°C in 
dark environment. 
For live construct endothelium labelling, the protocol is similar to above. Constructs 
were rinsed several times with sterile 1 x PBS and remained in culture well (static 
construct) or transferred to a culture plate (tubular construct). Diluted DiI-Ac-LDL 
reagent was added to each construct well in a volume of 0.5-1 ml (enough to cover 
the tissue). The treated constructs were kept away from alight in the following steps. 
After 4 h incubation at 37°C and 5% CO2, constructs were rinsed 3 x 5 times with 1 
x sterile PBS. The constructs were transferred to an inverted glass chamber slide and 
maintained in warm PBS immediately followed by observation with a LSM710 
confocal microscope (Carl zeiss, Germany) and the images were processed by using 
ZEN software (Carl zeiss, Germany). 
2.8 Flow Cytometry  
Cells were harvested, washed and adjusted to 1 x 10
6
 for each sample in 50 µl cold 
washing buffer (0.1% NaN3/1% FBS/PBS). The experimental protocol was based on 
a BD company flow cytometry protocol. Antibody was diluted with washing buffer.  
Then 50 µl of antibody and 50 µl cell suspension were added to a 1.5 ml eppendorf 
tube and gently mixed well before incubation for 1 h at 4C in a dark environment. 
Cells were washed twice with 200 µl cold washing buffer and centrifuged at 300 g 
for 5 min after each wash. The cell samples were re-suspended in 0.5 ml ice cold 
washing buffer and cells pellets transferred to polystyrene round-bottom tubes with 
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cell strainer caps (BD, Bioscience, UK), kept on ice and light exposure avoided until 
analysed by BD FACsAria
TM
 IIIu Cell Sorter (BD Biosciences, UK).  
2.9 Fluorescence Activated Cell Sorting (FACS) 
Cells were harvested, washed and adjusted to a concentration of 1 x 10
7
 cells per 500 
µl cold washing buffer (1% FBS/PBS). Antibody was diluted 1:50 with cold washing 
buffer in a total volume of 500 µl. Diluted antibody was added to the conical tube 
containing 1 x 10
7
 cells, following mixing the solution was incubated for 1 h at 4°C 
in the dark. For the unstained control, 500 µl cold washing buffer was added instead 
of the primary antibody.  
Following incubation, cells were washed with 2 x 200 µl ice cold washing buffer, 
centrifuged at 300 g for 5 min at 4C and re-suspended in 2 ml advanced DMEM/F-
12 medium supplemented with 1% L-glutamine and 1% antibiotics. For unstained 
cells, cells were re suspended in 0.5 ml medium (to above). Samples were kept in the 
dark and immediately analyzed and sorted by BD FACsAria
TM
 IIIu Cell Sorter. After 
sorting, both positive and negative cell populations were collected for culture and 
kept in 1 ml cell culture medium respectively. The collected cells were subsequently 
centrifuged, re-suspended in 10 ml culture medium, seeded on T80 flasks and 
cultured at 37C, 5% CO2. 
2.10 Mitral Valve Construct Tissue Engineering 
2.10.1 Fibrinogen Preparation 
Fibrinogen powder from bovine plasma (F8630, Sigma) was stored at -20°C. Before 
use, the fibrinogen powder was allowed to warm up by being kept at room 
temperature for 20 min. Bovine fibrinogen (50-70 mg) was gently sprinkled onto 3 
ml distilled water or pH 7.4 Tris buffered saline (TBS) in one well of a six well 
tissue culture plate (Thermo Scientific, UK). The culture plate lid was left off for 
several minutes to avoid the surface fibrinogen powder sticking on the lid due to 
static electricity. The lid was placed on the plate and the plate left at room 
temperature for at least 4 h or at 37°C for 3-4 h to dissolve the fibrinogen. An 
appropriate length (3.3 ml volume/cm) of dialysis membrane Spextra/Pro®1 (1956.1, 
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Carlroth, Germany) was prepared. The dialysis tube was soaked in 0.05% NaN3 
(S8032, Sigma), then rinsed/soaked with a large amount of distilled water 
immediately before use. Once the fibrinogen solution was ready, it was transferred 
into the prepared dialysis tube, and the two ends of the tube secured with dialysis 
tubing closures (Z371009-10EA, Sigma). The dialysis tube was placed in 4 L pH 7.4 
TBS solution on a stir plate and the fibrinogen solution purified at room temperature 
overnight. On the following day, the dialyzed fibrinogen solution was filtered 
through a 5.0 µm syringe filter (Sartorius Stedim, UK) and sterilized by passing it 
through a 0.22 µm syringe filter (Sartorius Stedim, UK) in a laminar hood. The 
solution was kept under sterile condition from this point on. Measurement of the 
fibrinogen solution concentration was based on its 280 nm absorbance using a 
Nanodrop
TM
 analyser. To get a reliable absorbance value (between 0.5-1), normally 
it required 1 in 20 dilution of the neat fibrinogen solution. The concentration of 
original fibrinogen was determined using the following formula: Concentration 
[mg/ml] = (A280/1.55)*dilution factor. For fibrinogen stock, the solution was made 
into 1 ml aliquots, labelled with the date and concentration and stored at -80°C. 
2.10.2 Fibrin Based Mitral Valve Constructs in Static 
Culture 
Four solutions were used for the preparation of fibrinogen gels: TBS, 50 mM CaCl2 
(BDH, UK) in TBS (pH 7.4), 40 IU/ml bovine thrombin (T4648, Sigma, UK) and 
fibrinogen. All the solutions were prepared under sterile conditions. TBS and 50 mM 
CaCl2 were kept at 4°C. Bovine thrombin (40 IU/ml) solution aliquots were stored at 
-20°C. Either freshly prepared fibrinogen solution or -80°C fibrinogen stock aliquots 
were used in experiments. Dissociated canine VICs were counted and re-suspended 
in warm TBS. The final concentration of the VICs in TBS was approximate 5.7 x 10
6
 
per ml. A 24 well plate was prepared and the following solutions added to each well 
in order: 37.5 µl 40 IU/ml bovine thrombin, 37.5 µl 50 mM CaCl2, 175 µl TBS cell 
pellet (1 x 10
6
 cells/gel) and 250 µl fibrinogen (10 mg/ml). The control fibrin gel was 
made at this stage using the same protocol but using TBS solution instead of VICs-
TBS suspension. The gels were placed in the tissue culture incubator for 40-60 min 
to polymerise. Dissociated VECs were re-suspended in customised bioreactor 
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medium (advanced DEME/F-12 medium/0.003% ascorbic acid (857653, 
Sigma)/10% FBS/1% penicillin G and streptomycin (100 U/ml-100 µg/ml)/1% L- 
glutamine (2 mmol/L)/0.0001% tranexamic acid (857653, Sigma, UK)) at the 
concentration of 1.8 x 10
4




). The recipe of the bioreactor 
medium was kindly provided by Dr Thomas Flanagan from the University College 
Dublin, Ireland. Once the gels were completely polymerized, 1 ml bioreactor 
medium-VECs suspension was seeded on the top of each fibrin/VICs construct. 
Constructs were cultured at 37C, 5% CO2 for 2 weeks. Culture medium was 
changed every day. 
2.10.3 Fibrin Based Mitral Valve Tubular Constructs 
Similar to the static constructs all the fibrinogen gel ingredients i.e. pH 7.4 TBS, 50 
Mm CaCl2 in TBS and 40 IU/ml bovine thrombin and fibrinogen were prepared. 
Additionally, the following components were autoclaved in advance: one customized 
mould, one medium reservoir and connectors (provided by collaborators in Aachen, 
Germany), corn oil (Sigma, UK), Tygon
®
 SI 3350 silicone tubes (SC0584A, IDEX, 
Germany) and PharmMed
®
-BPPT tubes (MF0013, IDEX, Germany). One MCP 
process pump (ISM915/ISM734B, IDEX, Germany) was assembled and thoroughly 
sprayed with 70% ethanol before placing it in the tissue culture hood. Using a six 
well tissue culture plate, fibrinogen solution (Solution 1) was added in one well and 
50 mM CaCl2 in pH 7.4 TBS and 40 IU/ml bovine thrombin (Solution 2) were added 
in a separate well on the same plate. The inner side of the mould and inner cylinder 
was painted with sterile corn oil, and the mould assembled. The VICs were 
harvested, cells counted and re-suspended in warm TBS. The concentration of the 
VICs in TBS was approximately 5.7 x 10
6
 per ml. The VICs-TBS solution was well 
mixed with CaCl2 and thrombin. Two 5 ml syringes were used to take out 3.5 ml of 
Solution 1 and Solution 2 respectively, bubbles were carefully removed from the 
syringes, and the volume adjusted to 3 ml for both solutions. The syringes were 
attached to a customised syringe applicator and 2.6 ml of each solution injected into 
the mould at a constant rate. 
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The construct was left standing in the tissue culture incubator for 45-50 min to 
polymerise according to visual observation. VECs were harvested and re-suspended 
in bioreactor medium to get a concentration at 1.8 x 10
4
/ml.   
The inner cylinder of the construct was carefully removed and the VEC suspension 
added to the construct lumen. A T80 flask gas filter cap was connected to the open 
end of the mould. The cap neck was secured with parafilm (Pechiney Plastic 
Packaging, USA). In the first and second experiment, four and eight vertical 
directions were marked on the cap and the device placed in tissue culture incubator 
respectively. The device was rotated by 90
o
 every 15 min for 2 h and 45
o
 every 15 
min for 4 h respectively. An illustration of the seeding devise is shown in Figure 5.2. 
After seeding, the remaining VEC suspension was removed and the construct gently 
rinsed once with the bioreactor medium. The construct was carefully separated from 
the mould and a 2 ml syringe (BD, USA) with plug, inserted into the construct lumen 
to provide support.  
Before the construct was placed in the medium reservoir, the supporting syringe plug 
was removed to allow the construct stand in the reservoir. Medium was added and 
reservoir connected to the MCP process pump. The pump was turned on and bubbles 
removed in the connecting tubes. Lastly, flow rate was set at 30 rpm.   
The whole device was transferred to the tissue culture incubator. Constructs were 
cultured for 7 days before harvesting.  
2.11 Histological Staining and Immunohistochemistry 
2.11.1 Native Mitral Valve Tissue Section Preparation 
Canine mitral valve tissue was harvested post mortem and washed with PBS. After 
scoring with Whitney grading system, the valve leaflet was fixed in 4% 
paraformaldehyde overnight and transferred to 70% ethanol on the next day for 
storage. Fixed tissues were dehydrated and embedded in paraffin blocks. Sections 
were cut into 5 m thickness and mounted on coated glass slides. Unstained slides 
were stored at room temperature.  
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2.11.2 Tissue Engineered Mitral Valve Constructs Section 
Preparation 
Fresh fibrin based mitral valve constructs were collected and rinsed with 1 x PBS 
several times before fixing in Methacarn fixative (60% methanol/30% chloroform 
(Fisher Scientific, UK)/10% acetic acid (VWR International, UK)) for 4 h at room 
temperature or overnight at 4°C. Samples were stored in 30% ethanol at 4°C before 
further processing. Samples were dehydrated in serial ethanol solutions and 
embedded in paraffin blocks. Sections were cut into 5 m thickness and mounted on 
coated glass slides. Unstained slides were stored at room temperature. 
2.11.3 Hematoxylin and Eosin (H&E) Staining 
Paraffinized tissue sections were de-waxed through three changes of xylene then 
three changes of ethanol, 2 min each. Sections were rinsed with running water for 2 
min, then Harris Haematoxylin stain applied to the sections for 18 min, then rinsed 
twice with running water for 1 min each. Sections were placed in acid alcohol for 10 
s, then washed with running water for 2 min. Sections were stained with Scott’s tap 
water substitute for 2 min, rinsed with running water for 2 min, stained with Eosin 
for 30 s and then rinsed with running water for 4 min. Sections on the slides were 
dehydrated through three changes of absolute ethanol and three changes of xylene, 
mounted with glass cover slips in DePex mounting medium. Slides were dried out in 
the fume hood at room temperature. Slides were observed under a LEITZ DMRB 
microscope and the images were captured by using Leica Firecam imaging software. 
2.11.4 Russel-Movat Pentachrome Staining 
Russell-Movat Pentachrome Stain kit (KTRMP, American MasterTech) was used for 
detecting and differentiating connective tissue components. Staining process 
followed product instruction and all solutions were prepared within the kit except 
xylene and ethanols. In detail, slides were de-paraffinised using xylene for 10 min 
and sections hydrated through 100%, 95%, 90%, 70% ethanol and distilled water for 
5 min each. Slides were stained with freshly prepared Verhoeff’s Elastic Stain (2.5% 
alcoholic hematoxylin/25% ethanol/2.5% ferric Chloride/25% universal Iodine) for 
15 min. Slides were rinsed in warm running tap water for 5 min, followed by distilled 
water. Sections were differentiated under light microscope in 2% ferric chloride until 
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elastic fibers were sharply defined. Slides were rinsed in distilled water and stained 
with 5% sodium thiosulphate for 1 min. Slides were washed in running tap water for 
5 min and then immersed in 3% glacial acetic acid for 3 min. Slides were placed 
directly in 1% alcian blue solution for 15 to 30 min and then rinsed thoroughly in 
warm running tap water for 1 min, followed by distilled water. Slides were placed in 
crocein scarlet-acid fuchsin for 2 min, followed by rinsing with 3 changes of distilled 
water. Slides were dipped 5 times in 1% glacial acetic acid then stained in 2 changes 
of 5% phosphotungstic acid for 2-5 min each. Sections were checked under the 
microscope and reaction stopped when connective tissue was clear but without de-
staining elastic fibres. Slides were dipped 5 times in 1% glacial acetic acid. After 
dehydrating tissue sections through 3 changes of fresh absolute alcohol, slides were 
placed in alcoholic safferon solution for 15 min to stain collagen. Slides were 
dehydrated through 3 changes of fresh absolute alcohol and 3 changes of fresh 
xylene, mounted with glass cover slips in DePex mountant and dried in the fume 
hood at room temperature. Slides were observed under a LEITZ DMRB microscope 
and the images were captured by using Leica Firecam imaging software. 
2.11.5 Native Mitral Valve Tissue Immunohistochemistry 
Tissue sections were de-waxed in xylene (Fisher Scientific, UK) for 10 min and re-
hydrated through a series of graded ethanols and ddH2O for 5 min each. If antigen 
retrieval was required (positive control shows negative signal), sections were 
incubated with 40 g/ml Proteinase K (19131, QIAGEN, UK) in 20 mM Tris-HCl 
(pH 8.0). Slides were then incubated in 0.3% H2O2 (Sigma, UK) in methanol to 
block endogenous peroxide for 30 min at room temperature. Slides were washed with 
tap water for 2 min. Sections on one slide were separated using an ImmEdge
TM
 pen 
(H-4000, Vector Laboratories Inc., UK) to isolate sections. Sections were blocked 
with 10% normal horse serum (provided in the kit)/PBS for 20 min, primary 
antibody was applied to sections and incubated for 30 min at room temperature or 
4°C overnight. For the negative control sections, primary antibody was omitted.  
Slides were washed with 1 x PBS (pH 7.5) for 3 x 3 min on a rocker. R.T.U. 
VECTASTAIN Elite ABC Kit (Universal) (PK7200, Vector Laboratories, UK) was 
used for immunohistochemistry staining. Sections were incubated with a                                                                                                                                                                                                                                                                                                                            
Chapter 2-General Materials and Methods 
80 
 
secondary antibody (provided in the kit) for 30 min at room temperature, followed by 
30 min incubation with VECTASTAIN Elite ABC reagent (provided in the kit) and 
developed with NovaRed
TM
 Substrate kit (SK-4800, Vector Laboratories, UK) for 5-
10 min until desired staining intensity appeared. Sections were rinsed in ddH2O for 2 
x 3 min on a rocker. Slides were counter-stained with Mayer’s haematoxylin (Sigma) 
for 3 min and washed under the tap for 30 s and then counter-stained in pH 8.0 
Scott’s Tap Water (0.35% sodium hydrogen carbonate/2% magnesium sulphate 
(VWR International, UK)) for 30 s. Slides were placed in distilled water, 70% , 90%, 
95% graded ethanol solutions for 2 min each, 100% clear ethanol for 5 min and clear 
xylene for 10 min before mounting glass cover slips with DePex mounting medium 
(VWR International, UK).  
Slides were left to dry in the fume hood overnight at room temperature and staining 
was observed under Slides were observed under a LEITZ DMRB microscope and the 
images were captured by using Leica Firecam imaging software. 
2.11.6 Immunofluorescence 
Native mitral valve sections or tissue engineered construct sections were prepared as 
has been described in Sections 2.11.1 and 2.11.2. The sections were de-paraffinised 
in xylene for 10 min and rehydrated through serial ethanol: 100%, 95%, 90% and 
70% and 1 x PBS for 5 min each. For native mitral valve samples, additional antigen 
retrieval step was required, which  was carried out by incubating the sections in pH 
9.0 Tris-EDTA buffer (10 mM Tris Base/1 mM EDTA/0.05% Tween 20) in a 
microwave at high power setting or in a 95C water bath for 30 min. When sections 
were cooled down they were rinsed with distilled water. Individual sections were 
delineated on slides with ImmEdgeTM wax pen. Blocked Non-specific protein sites 
were blocked with 10% goat serum in 0.5% PBS-Tween for 30 min at room 
temperature. In some experiments, Image-iT TM FX Signal Enhancer (I36933, 
Invitrogen) was used to improve nonspecific protein blocking prior to common 
blocking step, by incubating the slides for 30 min with the reagent and then rinsing 
off with 1 x PBS. After blocking, the primary antibody was diluted with diluting 
buffer (same recipe as blocking buffer) to desired concentration and the sections 
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probed with primary antibody in a humid chamber at room temperature for 1 h or 
overnight at 4°C. For negative control samples, the primary antibody was omitted. 
Primary antibody incubation was followed by 3 x 5 min wash with 1 x PBS on 
rocker. The fluorescent secondary antibody was prepared with diluting buffer and 
sections incubated in a dark humid chamber at room temperature for 1 h. After 
probing, excess secondary antibody was rinsed off with 1 x PBS on rocker for 3-5 
times x 5 min. Slides were mounted using the VECTASHIELD Mounting Medium 
with DAPI. Nail polish was used to seal the edges of the slides. The slides were left 
to dry in a dark humid chamber before observation by a LEITZ DMRB fluorescent 
microscope. Images were captured by using Leica Firecam imaging software. 
Antibody staining and DAPI staining images of the same sampled field were merged 
by Adobe Photoshop CS6 software. After observing, the slides were stored at 4C for 
short term and at -20C for long term. 
2.12 Electron Microscopy 
2.12.1 Scanning Electron Microscopy (SEM) Sample 
Preparation 
Construct samples were collected from the culture plates and briefly washed in 
culture medium or sterile PBS, followed by 2 x 5 min wash in 0.1 M sodium 
cacodylate (C0250, Sigma, UK)/HCl buffer (pH 7.2). Samples were fixed in 2% 
glutaraldehyde (23114.02, AMS Biotechnology, UK)/2% paraformaldehyde in 0.1 M 
sodium cacodylate buffer (pH 7.2) at room temperature for 1 h. Samples were then 
rinsed for 2 x 5 min in 0.1 M sodium cacodylate/HCl buffer (pH 7.2) and stored in 
airtight containers in 0.1 M sodium cacodylate/HCl buffer (pH 7.2) at 4C before 
future processing.  
2.12.2 Transmission Electron Microscopy (TEM) Sample 
Preparation 
Construct samples were collected from the culture plates and briefly washed in 
culture medium or sterile PBS, followed by 2 x 5 min wash in 0.1 M sodium 
cacodylate/HCl buffer (pH 7.2). Samples were fixed in 2% glutaraldehyde/2% 
paraformaldehyde in 0.1 M sodium cacodylate buffer (pH 7.2) at room temperature 
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for 20-24 h. Samples were then rinsed for 2 x 5 min in 0.1 M sodium cacodylate/ 
HCl buffer (pH 7.2) and stored in airtight containers in 0.1 M sodium cacodylate/HCl 
buffer (pH 7.2) at 4C before future processing. 
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Chapter 3: Canine Mitral Valve Cells Isolation 
and Characterization 
Abstract 
Mitral valve cells especially VECs and VICs are believed to play a crucial role in 
valve physiology and pathophysiology. It is hypothesized that by using previous 
reported methods for porcine aortic valve cell separation, canine mitral VECs and 
VICs can be isolated and cultured in vitro. Moreover the two populations can be 
differentiated by specific markers.  
Canine mitral valves were harvested immediately post mortem. Mitral VECs and 
VICs were isolated by collagenase digestion sequentially. Primary mitral VECs and 
VICs were expanded and characterized utilising a variety of techniques. Moreover, 
preliminary experiments were carried out to optimise the purity of VEC cultures.  
VECs and VICs were successfully isolated from canine mitral valves and cultured in 
vitro. Relatively pure cultures were obtained for both populations. In general, cells in 
VEC and VIC cultures exhibited differential morphology and growth patterns. 
Endothelial markers were expressed in VEC cultures alone only. Expressions of 
mesenchymal, activated mesenchymal and myofibroblast marker were detected in 
both cultures at transcriptional level. These findings were consistent at protein level 
except myofibroblast marker alpha-smooth muscle actin expression was absent in 
majority of examined VEC cultures. In order to obtain a higher purity of VECs, the 
current results indicated that additional cell sorting followed by endothelial basal 
medium culture proved the most promising. 
In this study, both canine mitral VECs and VICs were isolated, sub-cultured and 
characterized in vitro. It provides new insights to the fundamental understanding of 
canine mitral valve cell biology which will help in interpreting the pathogenesis of 
canine MMVD.  
 




Cellular components play a key role in heart valve biology and mechanical functions. 
They are actively involved in valve tissue development (Armstrong and Bischoff, 
2004; Person et al., 2005), maintenance of physiological function (Mulholland and 
Gotlieb, 1997; Tao et al., 2012; Taylor et al., 2003) and also in the valve remodelling 
process under pathophysiological conditions (Durbin and Gotlieb, 2002; Lester et al., 
1992; Lester and Gotlieb, 1988). Knowledge of cellular biology is essential for 
understanding of the heart valves in both healthy and diseased conditions, especially 
for investigating disease pathogeneses such as myxomatous mitral valve disease 
(Bischoff and Aikawa, 2011; Black et al., 2005; Han et al., 2013; Han et al., 2010; 
Han et al., 2008; Prunotto et al., 2010; Salhiyyah et al., 2011).  
Recent research on heart valve cells has mainly focused on valve endothelial cell 
(VEC) and valve interstitial cell (VIC). The VECs form a monolayer lining both the 
atrial and ventricular side of the valve leaflets. They possess common endothelial 
features such as sensing environmental alteration of the blood tissue interface and 
response to haemodynamic shear stress and cytokine stimulation (Balachandran et 
al., 2011; Butcher et al., 2004; Chalajour et al., 2004; Leask et al., 2003; Paranya et 
al., 2001). VECs have been characterized by having close cell to cell contacts and 
expressing endothelial markers such as CD31 (Gould and Butcher, 2010; Paruchuri 
et al., 2006; Wylie-Sears et al., 2011) and DiI-Ac-LDL (Cuy et al., 2003; Gould and 
Butcher, 2010). Additionally, the VECs also have unique features which differentiate 
them from endothelial cells of other organs. For example, in response to laminar flow 
conditioning the aortic VECs show perpendicular arrangement to flow direction 
rather than the parallel pattern that is observed in aorta endothelial cells, and also 
have differences in transcriptional profiles (Butcher et al., 2004; Butcher et al., 
2006). Compared to semilunar valves, there is little information on mitral VEC 
biology. However, the mitral valve endothelium has been shown to be an important 
factor involved in pathological conditions such as myxomatous mitral valve disease 
(Moesgaard et al., 2012; Mow and Pedersen, 1999), functional mitral regurgitation 
(Dal-Bianco et al., 2009) and pulmonary hypertension due to mitral stenosis (Snopek 
et al., 2000). In both human mitral valve prolapse and canine myxomatous mitral 
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valve disease, there is evidence of the endothelial cell damage (Corcoran et al., 2004; 
Han et al., 2013; Stein et al., 1989) and abnormal endothelial related synthesis 
activity (Mow and Pedersen, 1999; Olsen et al., 2003b). Endothelium dysfunction 
seems to be associated with sub-endothelial VIC activation in myxomatous mitral 
valve disease and physiological remodelling process which emphasizes the 
importance of VECs in maintaining normal mitral valve function (Black et al., 2005; 
Han et al., 2013; Lester et al., 1993; Rabkin et al., 2001). Regional pleomorphism has 
been found in mitral VECs indicating cells ability to adapt to different environments 
(Corcoran et al., 2004; Sarphie, 1980; Sarphie and Allen, 1978). The plasticity of 
mitral VECs has been further confirmed in a recent study by Wylie-Sears et al., 2011 
where osteogenic and chondrogenic features were induced in mitral VECs through 
endothelial mesenchymal transition (EndoMT) process (Wylie-Sears et al., 2011).  
The VICs are the major cell type in all four heart valves. In the embryonic stage, they 
derive from the a subset of foetal VECs that are activated by myocardial signalling, 
migrate to the cardiac jelly and transform into mesenchymal cells through EndoMT 
process (Armstrong and Bischoff, 2004; Markwald et al., 1977; Oosthoek et al., 
1998; Patten et al., 1948; Person et al., 2005). Mature interstitial cells are localized in 
the sub-endothelium and disperse through valve ECM layers. It has been proven that 
the VICs are responsible for valve ECM production and remodelling (Flanagan et al., 
2006a; Gupta et al., 2009b; Rabkin-Aikawa et al., 2004b), valve tension (Smith et al., 
2007), wound repair (Durbin et al., 2005; Durbin and Gotlieb, 2002; Gotlieb et al., 
2002; Lester and Gotlieb, 1988) and are actively involved in pathological conditions 
such as mitral valve prolapse (Prunotto et al., 2010) and myxomatous mitral valve 
disease (Rabkin et al., 2001). The VICs have been found to be heterogeneous 
(Blevins et al., 2006; Lester et al., 1988; Taylor et al., 2000; Zacks et al., 1991) and 
their composition of sub-phenotypes is dynamic in response to trauma (Durbin and 
Gotlieb, 2002; Tamura et al., 2000), myxomatous valve disease (Disatian et al., 
2008; Han et al., 2013; Han et al., 2008) and environment alteration (Rabkin-Aikawa 
et al., 2004b; Rabkin et al., 2002). In normal adult heart valves, most VICs are 
described as a quiescent phenotype, which are characterized by expressing vimentin 
but not alpha smooth muscle actin (α-SMA) (Han et al., 2008; Rabkin-Aikawa et al., 
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2004b). In disease or remodelling processes, there is phenotypic alteration with 
increased activated myofibroblast-like VIC (aVIC) presumed to be actively involved 
in the repairing process (Black et al., 2005; Disatian et al., 2008; Han et al., 2008; 
Lester et al., 1993; Rabkin et al., 2001). The aVICs are positive for activated 
mesenchymal marker embryonic form non-smooth muscle myosin heavy chain 
(SMemb) (Disatian et al., 2008; Disatian et al., 2010; Rabkin et al., 2001), 
myofibroblast marker α-SMA (Blevins et al., 2006; Disatian et al., 2008; Han et al., 
2008; Stephens et al., 2011) and smooth muscle cell marker transgelin (SM22) (Della 
Rocca et al., 2000; Wiester and Giachelli, 2003). Similar to mitral VECs, VICs from 
mitral valves have also been found to have distinct features from other VICs. As 
mention in Section 1.3.5, mitral VICs demonstrated a differential response to 
transforming growth factor beta (TGF-β) compared to aortic VICs: exogenous TGF-
β promotes proliferation of mitral VICs but inhibit proliferation and apoptosis in 
aortic VICs (Liu and Gotlieb, 2008; Walker et al., 2004). Moreover human mitral 
VICs and aortic VICs were found to have differences in transcriptional profiles and 
in cell proliferation and the mitral VICs are more susceptible to calcification in vitro 
(Sun et al., 2013). This addresses the needs of developing specific VIC study systems 
derived from mitral valves for mitral valve related research. 
Cell culture techniques provide opportunities to investigate valve cellular biology in 
vitro. Enzymatic digestion techniques have been reported to isolate VECs and VICs 
(Cheung et al., 2008; Gould and Butcher, 2010; Simon et al., 1993). Although 
general success has been achieved with these techniques, contamination with other 
cell types or cell differentiation are particular confounding factors in VEC cultures 
(Bischoff and Aikawa, 2011; Cheung et al., 2008). Additional cell sorting techniques 
can improve these issues to obtain higher endothelial cell purity (Cheung et al., 2008; 
Hoerstrup et al., 1998).  
A number of studies have been done cultivating and characterizing mitral VECs and 
VICs in vitro (Blevins et al., 2006; Blevins et al., 2008; Flanagan et al., 2006a; Liu 
and Gotlieb, 2008; Simon et al., 1993; Stephens et al., 2011; Stephens et al., 2010b; 
Sun et al., 2013; Xu et al., 2012), but only a few are reported in veterinary field 
(Heaney et al., 2009; Waxman et al., 2012). The aim of this study was to isolate and 
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culture canine mitral VECs and VICs using a previously reported protocol and 
moreover characterize canine mitral VECs and VICs by using a variety of techniques 
in vitro. It was hypothesized that: (1) canine mitral VECs and VICs can be 
successfully isolated and cultured in vitro using current methods; (2) in phenotypic 
characterization, mitral VECs exhibit common endothelial cell features and express 
mesenchymal marker vimentin; while VICs are negative for the endothelial markers 
but express vimentin and a panel of selected activated VIC markers; (3) fluorescent 
activated cell sorting can separate VECs from other contaminating cell types; and 
endothelial specific medium is superior in maintaining VEC endothelial properties 
than standard culture medium. 
3.2 Materials and Methods 
3.2.1 Isolation and Culture of Canine Mitral Valve Cells  
Cells were isolated from 26 canine mitral valves in total. Mitral VECs were isolated 
by collagenase digestion from healthy valves only (n=14). Mitral VICs were 
harvested using an explant technique in the first 6 dogs (2 healthy mitral valves and 4 
MMVD valves). All remainder of the VICs were isolated by collagen digestion (12 
healthy mitral valves and 8 MMVD valves). Due to time limitation, later cell 
characterization was only carried out in cell cultures isolated by enzymatic digestion 
but not in explant derived cells. The characterized mitral VEC and VIC cultures were 
collected from 1.5-5 year old MV healthy dogs, which were potential cell source for 
later construct engineering. A summary of the 1.5-5 year old MV healthy dog 
information is shown in Table 3.1. Details of the cell isolation protocol have been 
described in Section 2.4.1.  
Details of cell culture medium, sub-culture and cryopreservation were described in 
Section 2.4.2-2.4.5. In this project, VECs were expanded up to passage 3 while VICs 
were cultured up to passage 8.  
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Table 3.1  Details of dogs from which healthy mitral valve cells were collected using 
collagenase digestions.  
Age (Year) 3.2  + 1.2 
 




Breed Large breed n=4 
 
Small/middle breed n=8 
 
 
3.2.2 Canine Mitral VEC and VIC Characterization  
 Morphology Observation 3.2.2.1
Cell morphology was observed by using a light microscope during culture period for 
cell morphology and confluence assessment. Representative cell images were 
captured by a Zeiss Axiover 40 microscope at different magnifications: x 50, x 100 
and x 200.  
 Cell Characterization at Gene Transcriptional Level  3.2.2.2
Isolated VECs and VICs were characterized by using RT-PCR. Canine nucleotide 
sequences of target makers were found in either NCBI Gene Bank or Ensembl 
website. Primers were designed, ordered and prepared as has been described in 
Section 2.5.1. The following markers were selected to characterize the VECs and 
VICs: CD31 and von Willebrand factor (vWF) (endothelial specific); α-SMA, 
SMemb and SM22 (aVIC markers) and vimentin (a marker for mesenchymal origin 
cells) (Flanagan et al., 2006a; Heaney et al., 2009). Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as an internal control gene in PCR amplification. 
The vWF-1, α-SMA and GAPDH primers were kindly provided by Dr. Hannah 
Hodgkiss-Geere and vWF-3 primers were from a previous publication (Fulton et al., 
2000). All other primer pairs were original in design. Primer details are listed in 
Table 3.2. 
Total RNA extraction, cDNA synthesis, PCR reaction system and agarose gel 
electrophoresis was carried out following the protocols described in Section 2.5.2-
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2.5.5. In each RT-PCR reaction, RNA template from cultured cells were amplified 
with GAPDH primers and served as a negative control. The PCR results were 
accepted only if the negative controls were completely clean for target transcripts. 
When comparing marker expression in differential cell lines, transcript band intensity 
was quantified by using Image J software and the genes of interest were normalized 
to GAPDH. Ratio of Target gene band intensity to GAPDH band intensity was 
illustrated in histograms. 
 Immunocytochemistry and Acetylated LDL Labelling  3.2.2.3
The immunocytochemistry protocol for VEC and VIC characterization was detailed 
in Section 2.6. The antibodies used are listed in Table 3.3. DiI-Ac-LDL labelling for 
detecting endothelial cells was carried out using the protocol in Section 2.7. After 
staining, the slides were observed with a Leica DMRB fluorescence microscope 
using the red fluorescence channel (excitation wavelength of 568 nm) or green 
fluorescence channel (excitation wavelength of 488 nm) for target antibody staining. 
DiI-Ac-LDL was assessed at 568 nm (excitation wavelength of DiI dye = 554 nm). 
Cell nuclei stained with DAPI was observed using the blue fluorescence channel. 
Positive staining was defined as fluorescence signals detected above background 
threshold (unstained negative control). 
Images were captured by using Leica Firecam imaging software. The antibody 
staining and DAPI staining images were converted into grayscale with Image J 
software. Colour antibody staining and DAPI staining images of the same sampled 
field were merged by Adobe Photoshop CS6 software. The immunocytochemistry 
data in this thesis is presented as a DAPI staining in grayscale, an antibody staining 
in grayscale and an antibody-DAPI merged image. For DiI-Ac-LDL assay, bright 
field images were taken from the same sampled area demonstrating cell distribution. 
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Table 3.2  Primer sequences used in PCR analysis for cell characterization.  
Gene Primer Sequence (5’-3’) Product size 
CD31 (F) AATCCCAAATTCCACGTCAG          
(R) GAATGGAGCACCACAGGTTT 
346bp 
vWF-1 (F) CTGGGAGAAGAGAGTCACGG                     
(R) GTGGATGGAGTACACGGCTT 
235bp 
vWF-2 (F) GGCTGTACCTGGATGAGAGG                     
(R) GACAGGACAGGCTCCTTTTG 
228bp 
vWF-3 (F) AATATAGGGCCCCGGCTCACTCAA              
(R)  ACATCCCCGGGCCTCTTCTCATTC 
512bp 
SM22 (F) AAGAACGGCGTGATTCTGAG                      
(R) CGGTAGTGCCCATCATTCTT 
269bp 
α-SMA (F) GGGGATGGGACAAAAGGACA                    
(R) GCCACGTAGCAGAGCTTCTCCTTGA 
525bp 
SMemb (F) AGAAGCGAGCTGGAAAACTG                     
(R) TCTTGCTCTGTCCGATTCTG 
252bp 
Vimentin (F) GGAGCAGCAGAACAAGATCC                      
(R) AGACGTGCCAAAGAAGCATT 
282bp 




F, forward primer; R, reverse primer. 
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Table 3.3  Antibodies for VEC and VIC immunocytochemistry characterization 
Primary antibody Cat No. and company WC 
Anti-CD31 (RP) Ab28364, Abcam, UK 1:200 
Anti-SMemb Ab24761, Abcam, UK 1:400 
Anti-vimentin (MM) V6389, Sigma, USA 1:1600 
Anti-α-SMA A2547, Sigma, USA 1:400 
Secondary antibody Cat No. and company WC 
Goat Anti rabbit IgG (H+L) Alexa 
Fluor568 
A11011, Invitrogen, UK 1:500 
Goat Anti mouse IgG (H+L) Alexa 
Fluor488 
A10667, Invitrogen, UK 1:500 
 
RP, rabbit polyclonal; MM, mouse monoclonal; WC, working concentration.  
 
 
3.2.3 Optimization of Canine Mitral VEC Culture 
 Endothelial Purity Evaluation by CD146 Flow cytometry 3.2.3.1
To check purity of the VECs, two endothelial markers CD31 and CD146 also called 
melanoma cell adhesion molecule (MCAM) were evaluated in VEC cultures by flow 
cytometry. As described in Section 2.8, cells were harvested, washed and adjusted to 
1 x 10
6
 concentration for each sample in 50 µl cold washing buffer (0.1% NaN3/1% 
FBS/PBS). Mouse monoclonal [WM-59] to CD31 with fluorescein isothiocyanate 
(FITC) conjugated (ab13466, Abcam) or mouse monoclonal [P1H12] CD146 (FITC) 
antibody (ab78451, Abcam) was diluted (1:2.5 for CD31; 1:25 for CD146) with 
washing buffer in a volume of 50 µl. 50 µl of antibody and 50 µl cell suspension 
were added to a 1.5 ml eppendorf tube and gently mixed before incubation for 1 h at 
4C in dark. For the unstained control, 50 µl cold washing buffer was added instead 
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of CD146 antibody. Cells were washed twice with 200 µl cold washing buffer and 
centrifuged at 300 g for 5 min after each wash. The cell samples were re-suspended 
in 0.5 ml ice cold washing buffer and cells pellets transferred to polystyrene round-
bottom tubes with cell strainer caps, kept on ice and protected from light exposure. 
Samples were analysed by BD FACsAria
TM
 IIIu Cell Sorter to obtain data and 
histograms. The cell gating strategy was done by arbitrarily circling obvious live 
cells and separating them from cellular fragments and dead cells.  
 CD146 Based FACs for Purifying Canine VECs  3.2.3.2
The detailed sorting protocol has been described in Section 2.9. The same CD146 
antibody and cell sorter used in flow cytometry was used in FACs. After sorting, 
CD146 positive and negative cell populations were collected in 1 ml cell culture 
medium and the purity was checked with the same cytometer. Histograms of 
fluorescence intensities were obtained. The collected cells were subsequently 
centrifuged, re-suspended in 10 ml culture medium, plated on T80 flasks and 
cultured at 37C, 5% CO2. Cell morphologies were observed during culture with 
Zeiss Axiover 40 microscope for cell shape and confluence assessment, 
representative images were captured. A series of characterization were done, and the 
details will be discussed in Section 3.3.3. 
 Comparison of Two Culture Media in Culturing Canine VECs 3.2.3.3
Two experiments were undertaken to compare canine endothelial basal medium 
(EBM) with standard culture medium i.e. advanced DMEM/F-12 medium with 
supplements (AF12). In the first experiment, primary VECs (passage 0) were 
cultured with standard culture medium. After one passage, the standard culture 
medium was replaced with canine EBM. In the second experiment, canine EBM was 
used to culture primary VECs (passage 0) right after cell isolation. Standard medium 
cultured VECs from the same dogs were compared as controls in both studies. 
Cell morphologies and biomarker expressions for the two experimental protocols 
were compared. 
 




3.3.1 Canine Mitral VEC Characteristics  
On morphological observation with light microscopy, endothelial progenitor cells 
usually started to appear randomly in canine mitral VEC culture flasks in 1-2 days 
post primary isolation. They presented typical cobblestone morphology and formed 
clusters (Figure 3.1A). In later stage of the primary culture, cells started to proliferate 
extensively and usually reached confluence within 6-8 days in one T80 flask (Figure 
3.1B). In confluent cultures, most cells exhibited growth contact inhibition and 
formed a monolayer. However, heterogeneous cell morphologies were observed in 
the culture; cobblestone morphology cells were dominant but elongated and spindle 
shape cells were also present (Figure 3.2). As passage times increased, cuboid cells 
decreased and the spindle shapes cells gradually became dominant in the culture 













Figure 3.1. Primary isolated canine mitral VECs morphology. A. At the early stage 
(1-2 day culture), single colony clusters randomly appeared in the culture. B. Once 
the cells reached confluence, the majority exhibited cobblestone morphology and 
were growth-contact inhibited. Scale bar = 100 μm. 









  Figure 3.2. Cells in primary VEC culture exhibited varying morphologies. Though 
the majority of cells were cuboidal (white arrow), elongated spindle shape cells 
(yellow arrow) and polymorphic cells (blue arrow) with multiple cytoplasmic 
extensions were also observed. Scale bar = 200 μm. 
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Results of canine mitral VEC phenotypic characterization are summarized in Table 
3.4. Endothelial marker CD31, mesenchymal marker vimentin and activated 
mesenchymal marker SMemb were detected in VECs at gene level. Moreover, 
myofibroblast marker α-SMA and smooth muscle cell marker SM22 were also found 
in VECs by RT-PCR (Figure 3.3). Endothelial marker vWF primers were designed to 
characterize the VECs at gene level, however, no obvious positive expression was 
observed in canine VECs whereas the target products were expressed by other cell 
lines having endothelial nature, such as a human umbilical vascular endothelial cell 
line and a canine haemangiosarcoma cell line (Thamm et al., 2006; Fosmire et al., 




Figure 3.3. RT-PCR characterization on primary canine mitral VECs. Total RNA of 
cultured cells were used in the amplification. Endothelial marker CD31 and activated 
VIC markers i.e. α-SMA, SMemb and SM22 were detected in VEC cultures at 
transcriptional level. Vimentin and GAPDH were used as internal controls. 
 





Figure 3.4. The vWF gene expression was not evident in primary canine mitral VECs. 
Three vWF primer pairs were used to detect the target gene expression. In contrast to 
the limited expressions in primary canine mitral VECs (VE),  the vWF1 gene (235bp), 
vWF2 gene (228bp) and vWF3 gene (512bp) were clearly expressed by the two 
positive control cell lines-human umbilical vascular endothelial cell line (HU) and a 
canine haemangiosarcoma cell line (HS). 
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On fluorescence/immunofluorescence, cells in VEC cultures exhibited endothelial 
features by expressing two endothelial markers: DiI-Ac-LDL (Figure 3.5) and CD31 
(Figure 3.6). Vimentin and SMemb protein expressions were detected in cytoplasm 
of all cells in VEC cultures (Figure 3.6). The majorities of cells did not express α-
SMA protein in the VEC cultures (Figure 3.6), except in one VEC culture limited α-
SMA protein expression was detected in some cells (data not shown).  
  
Figure 3.5. DiI-Ac-LDL labelled canine mitral VECs. A. The acetylated low density 
protein (red in A) was up taken by cells in VEC culture through endocytosis 
pathway. B. A bright field image provided the cells distribution information. Scale 
bar = 100 μm. 
 
 




















Figure 3.6. Immunofluorescent characterization on canine mitral VEC cultures. 
Cells expressed CD31 (red in C), vimentin (green in G) and SMemb (red in K), but 
was generally negative for α-SMA (O). DAPI stained cell nuclei (blue). DAPI 
channel (A, E, I, M), target protein channel (B, F, J, N) and merged images (C, G, 
K, O) were showed respectively for each marker. Same cell lines served as negative 
controls on which primary antibodies were omitted (D, H, L). Cells from a VIC 
culture expressed α-SMA which served as a positive control (P). Scale bar = 50 μm. 
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3.3.2 Canine Mitral VIC Characteristics 
Canine mitral VICs typically had elongated cell process, though polymorphic and 
cuboidal cells were also present. By using the explant technique, substantial cell 
outgrowth from the tissue was usually observed within 7 days, with the explants then 
being removed and the cells were not harvested until they reached 80% confluence. 
By using collagenase digestion, in early primary VIC culture, cell growth was in a 
random distributed pattern. When at confluence, the cells tended to form a vortex 
pattern with multiple layers and did not show growth contact inhibition (Figure 3.7). 





Figure 3.7. Primary isolated canine VIC morphology. A. The mitral VIC 
appearance under light microscopy before confluence, and B. At confluence. Cells 
in VIC cultures exhibited fibroblast-like morphology, cells tended to arranged in a 
‘hill and valley’ pattern in confluent cultures.  Scale bar = 200 μm. 
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Results of mitral VIC phenotypic characterizations are summarized in Table 3.4. On 
RT-PCR, cells in VIC cultures were negative for the endothelial marker CD31, but 
positive for aVIC marker α-SMA, SM22, SMemb and mesenchymal marker 
vimentin (Figure 3.8). The absence of endothelial features in VICs has been 
supported by findings in acetylated low density lipoprotein metabolic analysis and 
immunofluorescence where the VICs were negative for endothelial markers DiI-Ac-
LDL (Figure 3.9) and CD31 (Figure 3.10), but expressed vimentin, SMemb and α-










Figure 3.8. RT-PCR characterization on primary canine mitral VICs. They were 
negative for CD31, but positive for α-SMA, SMemb, SM22 and vimentin. As a 
positive control, cDNA template derived from cells in a VEC culture was used to 
amplify CD31 transcripts in the same experiment (data not shown).  
 







Figure 3.9. DiI-Ac-LDL expression was absent in the primary canine mitral VIC 
culture. Cells in VIC cultures did not up take DiI-Ac-LDL and had a background 
level staining (red in A). Cells from VEC cultures were assessed in the same 
experiment and served as a DiI-Ac-LDL positive control (red in C). Bright field 
images of corresponding VICs and VECs in the experiments are shown in B and D 
respectively. Scale bar = 200 μm.  
  








Figure 3.10. Immunofluorescence characterization on canine mitral VIC cultures. 
Cells were negative for endothelial marker CD31 (C), but positive for vimentin 
(green in G), SMemb (red in K) and α-SMA (green in O). DAPI (blue) stained 
nuclei. DAPI channel (A, E, I, M), target protein channel (B, F, J, N) and merged 
images (C, G, K, O) were showed respectively for each marker. Cells from a VEC 
culture were used in the same experiment and served as a positive control for CD31 
primary antibody (D), while sample from same VIC cell lines without primary 
antibody incubation served as negative controls respectively (H, L, P). Scale bar= 
50 μm.  
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Table 3.4 Result summary of mitral VEC and VIC culture characterization 
 
 PCR characterization 
 
 Endothelial Activated VIC Mesenchymal 
CD31 SMemb α-SMA SM22 vimentin 
VEC + (n=4) + (n=4) + (n=4) + (n=3) + (n=4) 
VIC – (n=4) + (n=3) + (n=4) + (n=3) + (n=4) 
Immunocytochemistry and acetylated LDL labelling 
 
 Endothelial Activated VIC Mesenchymal 
DiI-Ac-LDL CD31 SMemb α-SMA vimentin 
VEC + (n=5) + (n=4) + (n=3) + (n=1); 
– (n=3) 
+ (n=4) 
VIC – (n=4) – (n=4) + (n=3) + (n=3) + (n=4) 
 
The ‘n’ indicates the number of dog mitral valves used to derive the cell lines. 
 
3.3.3 Optimization of Canine Mitral VECs in vitro Culture  
 Purity Evaluation of Canine Mitral VECs by Endothelial Marker 3.3.3.1
Based Flow Cytometry 
As described, heterogeneous cells were observed in the primary VEC cultures. VIC 
contamination in primary isolated VECs seem to be an issue thus additional cell 
sorting was undertaken (Cheung et al., 2008; Hoerstrup et al., 1998). After isolation 
and sub-culture, the purity of VECs was assessed by using endothelial cell surface 
marker based flow cytometry. Both CD31 and CD146 antibodies were tried in 
preliminary experiments. The CD31 antibody labelled 0.6%-2.6% (mean percentage 
of replicate samples) positive cells in the VEC cultures. This result did not fit the 
morphological observation according to which a much higher number of VECs were 
expected, suggesting this antibody didn’t identify canine VECs efficiently. 
Therefore, the CD31 antibody for flow cytometry was not selected in later 
experiments. While for antibody CD146, in VEC culture at passage 1, 77.4% cells 
(mean percentage of replicate samples) were identified as positive (Figure 3.11), 
which suggested the majority of the cells in VEC culture exhibited the endothelial 
cell marker. The experiment has also been done in VICs using the same protocol and 
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in contrast, 3.6% (mean percentage of replicate samples) cells were found to possess 






Figure 3.11. Representative results of CD146 flow cytometry on primary canine 
mitral VECs. The majority of cells in VEC culture (79.5%) showed affinity to 
endothelial marker CD146. The horizontal axis indicates FITC tagged CD146 
fluorescence intensity; the vertical axis indicates cell count in each sample. Cells 
incubated with antibody diluting buffer instead of CD146 antibody served as an 
unstained control and cells incubated with IgG1 antibody served as an isotope 
control. 












Figure 3.12. Representative results of CD146 flow cytometry on primary canine 
mitral VICs. Under the same experimental conditions to VEC CD146 flow 
cytometry, a small number of CD146 positive cells (3.9%) were found in VICs, the 
majority of cells were unstained. The horizontal axis indicates FITC tagged CD146 
fluorescence intensity; the vertical axis indicates cell number in each sample. Cells 
incubated with antibody diluting buffer instead of CD146 antibody served as an 
unstained control. 
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 CD146 Positive VEC Separation  3.3.3.2
Since the primary isolated VECs would be used for 3D tissue construction in the 
later stage of this project, it was considered ideal to have pure VECs population. 
Therefore cell sorting by FACs was carried out to separate VECs from contaminating 
cell types. It was hypothesized that the purified VEC population would have typical 
endothelial appearance in morphology and reduced activated VIC marker expression 
than unsorted cells.  
As previous flow cytometry results suggested CD146 to be a promising marker for 
differentiating VECs and VICs, the sorting experiments were based on the same 
antibody. Cells positive for CD146 were identified and separated from the remaining 
cell populations. Isolated cell purities were checked right after sorting (Figure 3.13). 
Both CD146 positive (CD146+) and CD146 negative (CD146-) populations were 
collected and subsequently plated in cell culture flasks using the same culture 
conditions prior to sorting. Cell morphologies were observed during the culture 
(Figure 3.14). In the early days after the separation, CD146+ and CD146- cell 
populations exhibit apparently different morphologies. CD146 positive cells showed 
close growth contact with each other and possessed typical endothelial morphology; 
while the CD146 negative cells had elongated cell bodies and formed networks with 
their long extensions, which were similar to cells in VIC culture. The two 
populations were further characterized by using DiI-Ac-LDL. DiI-Ac-LDL labelled 
cells were found in both populations, though CD146+ population appeared to have 
more positive cells than CD146- population (Figure 3.14). 
  




Figure 3.13. Primary canine mitral VEC cultures were separated by CD146 FACs. 
The cell gating strategy was illustrated in A: Blue dots indicate CD146+ cells and 
green dots represent CD146- cells. The red dots represent cells having fluorescence 
intensities in between of these two populations, which were not collected in the 
sorting procedure. Cell purities were checked immediately after sorting, CD146+ 
population (B) and CD146- (C) population have apparent differential fluorescent 
magnitudes, which suggest the sorting technique was effective. The horizontal axis 
indicates FITC tagged CD146 fluorescence intensity; the vertical axis indicates cell 
number in each sample. SSC, side scatter intensity value, indicating the complexity 
of the cell inner structure; FSC, forward scatter intensity value, reflecting the cell 
size.  





  Figure 3.14. Primary canine mitral VEC morphologies at Day 3 post CD146 FACs 
sorting. Apparent differential morphologies were observed in CD146+ (B, D, F) 
and CD146- cell cultures (C, E, G). DiI-Ac-LDL staining was evaluated and both 
populations had cells uptake it. However, more intense red fluorescence was 
observed in CD146+ VEC culture (D) then CD146- culture (E). Light field images 
of cells in CD146+ and CD146- culture were shown in (F) and (G) respectively. 
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Furthermore, CD146+ VECs have been evaluated for activated VIC marker 
expression by RT-PCR (Figure 3.16). Previous data suggested that, cells in VEC 
culture and VIC culture expressed similar levels of SM22 (Figure 3.15). In contrast 
to VECs without FACs, CD146+ VECs have much lower SM22 expression than the 
VICs (Figure 3.16 B and C). Moreover, the α-SMA expression was minimal in 
CD146+ VECs (Figure 3.16 B and C). These results indirectly indicate the activated 
VIC characteristics in CD146+ VECs were reduced compared to unsorted VECs. 
However, myofibroblast morphology was observed in the CD146+ VECs confluent 
culture (Figure 3.16A).  
To summarise, CD146 FACs sorting was efficient to separate a more pure 
endothelial population from primary VEC culture. However, the isolated CD146+ 
population still acquired activated VIC features, though maker expression levels 




















Figure 3.15. RT-PCR marker comparisons between primary canine mitral VECs 
and VICs. The transcripts were amplified in the same RT-PCR reaction and 
analysed on the same agarose gel. The VECs and VICs expressed similar levels of 
SM22 and vimentin; the VICs expressed higher levels of α-SMA and SMemb than 
VECs and did not express endothelial marker CD31. 





Figure 3.16. Reduced activated VIC marker expressions in CD146+ VEC culture. 
Myofibroblast-like morphology (yellow arrow in A) was present in CD146+ VEC 
confluent culture, notice that cells tend to form a vortex pattern. Compared to VICs, 
SM22 was much less in CD146+ VECs at transcriptional level (B and C) and α-
SMA expression was minimal in CD146+ VECs.  
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 Comparison of Canine Endothelial Basal Culture Medium and 3.3.3.3
Standard Culture Medium in Canine Primary VEC Culture 
The primary VECs are well known as being less stable in long term culture. There 
are two reasons resulting in this: VIC contamination in VEC culture and/or the VECs 
undergo differentiation in vitro (Bischoff and Aikawa, 2011; Cheung et al., 2008; 
Hoerstrup et al., 1998). In Section 3.3.3.2, FACs was tried to purify the VECs, 
however, the purified VECs only maintained typical endothelial cell morphology for 
a short period (within one Passage) then cells altered to mesenchymal phenotype in 
confluent culture. This phenotypic transformation has been considered to be similar 
to the foetal EndoMT process (Bischoff and Aikawa, 2011; Butcher and Markwald, 
2007; Butcher and Nerem, 2007; Person et al., 2005). This complex transition 
process involves multiple signalling pathways and can be modulated by a number of 
biochemical factors such as endothelial growth factors and TGF-β (Armstrong and 
Bischoff, 2004). To maintain endothelial properties, VECs in vitro culture usually 
require specific culture medium containing growth factors favouring endothelial 
proliferation (Ci et al., 2013; Paranya et al., 2001; Wylie-Sears et al., 2011). In this 
study, a commercial canine endothelial culture medium (EBM) was compared with 
standard culture medium i.e. Advanced DMEM/F-12 medium with supplements 
(AF12) to culture canine VECs. It has been hypothesized that canine EBM would 
maintain the endothelial phenotype better than the standard medium.   
Two experiments were done comparing canine EBM with standard culture medium. 
In the first experiment, primary VECs (passage 0) were cultured with AF12 medium. 
After one passage, the AF12 medium was replaced with canine EBM. In the second 
experiment, canine EBM was used to culture primary VECs (passage 0) right after 
cell isolation. Standard medium cultured VECs from the same dogs served as 
controls in both studies. 
In medium replacement experiment, VECs (passage 1) were cultured in canine EBM 
or AF12 for 24 h. Cell morphologies were evaluated at passage 1 and passage 2 
(Figure 3.17). At passage 1, EBM medium replacement seemed to drive VECs to a 
differentiation state, as cells with thin long cellular extensions were widely seen in 
the culture, though overall cell morphologies were similar to VECs cultured in 
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standard medium. At passage 2, differential VEC morphologies and arrangement 
patterns were observed in EBM and in AF12. Cells in EBM culture were smaller in 
size comparing to VECs in AF12, and substantial spindle shape cells were observed 




Figure 3.17. Cell morphologies in primary canine mitral VEC sub-cultures in EBM 
and in AF12 medium. In early culture time of the medium replacement, cells in 
EBM (A) had similar morphologies to cells cultured in standard AF12 medium (B), 
though the former cells exhibited long extensions. In later confluent cultures, cell 
sizes were decreased in the EBM culture (C) comparing with cells in AF12 culture 
(D) and spindle shape cells forming whirling pattern were noticed in the culture (C). 
Scale bar =100 μm. 
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Canine VECs (passage 2) in EBM and in AF12 were characterized by expression of 
endothelial markers DiI-Ac-LDL (Figure 3.18) and CD31 (Figure 3.19). Both 
cultures were positive for the endothelial markers, and VECs in EBM have higher 
fluorescence intensity than cells in AF12. At transcriptional level, α-SMA expression 
diminished in EBM cultures, which indicated a dramatic decrease of the 
myofibroblast feature in EBM cultured VECs (Figure 3.20).  
To summarise, replacing standard culture medium with specific endothelial medium 
to culture canine VECs seemed to maintain a more endothelial phenotype for the 
cells in culture.  
 
  
Figure 3.18. DiI-Ac-LDL labelled EBM and AF12 cultured VECs. VECs in EBM 
(A) appear to have more intense red fluorescence than cells in AF12 (B). Bright 
field cell images of the DiI-Ac-LDL labelled VECs in EBM and in AF12 are shown 
in C and D respectively. Scale bar = 100 μm.  






















Figure 3.19. Endothelial marker CD31 expression in EBM cultured and in AF12 
cultured primary VECs. Higher CD31 expression was observed in EBM VEC 
cultures (red in A) than in AF12 VEC cultures (red in B). Secondary antibody alone 
served as negative controls (C for VECs in EBM, D for VECs in AF12). DAPI 
(blue) stained nuclei. Scale bar = 100 μm 
Figure 3.20. RT-PCR characterization on EBM cultured and AF12 cultured primary 
VECs. Higher CD31 expression but much reduced α-SMA expression was detected 
in EBM cultured VECs comparing with AF12 cultured VECs on RT-PCR. The 
expression of SMemb was not apparently different between the two cultures. 
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Since the results of using commercial canine EBM for VECs sub-culture suggested 
that EBM is superior in maintaining endothelial properties comparing with AF12 
medium, it was hypothesized that using canine EBM to culture primarily isolated 
VECs (passage 0) could stabilize their endothelial features immediately after the in 
vitro isolation.  
Primary isolated VECs from the same individual mitral valve leaflet (n=5) were 
cultured in both EBM and AF12 medium respectively. Cell morphologies were 
observed during the cultures. All primary VEC cultures in EBM experienced same 
fate: from initial endothelial progenitor colonies to altered morphologies in later 
culture. At Day 3, endothelial progenitor cell colonies were observed in both EBM 
and AF12 culture, with no apparent differences between the two. At Day 6, VECs in 
AF12 medium reached approximate 80% confluence with the majority of cells 
exhibiting a cobblestone morphology, spindle shape cells also existed in the culture 
which was consistent with previous findings. Whilst in the EBM medium, typical 
endothelial colonies diminished in the culture by Day 6. Cells remaining in the 
culture were spindle shape with very elongated cell process and less robust according 
to visual observation under light microscope. No obvious cell growth was observed 
in the EBM culture between Day 6 to Day 10. At Day 11, cells in EBM started to 
proliferate; heterogeneous morphologies of cells were observed in the culture. At 
Day 13, three types of cell growth patterns were observed in a 70%-80% confluent 
EBM VEC culture (Figure 3.21). They are a sparse distribution of cells with long 
extensions; confluent arrangements formed by spindle shape cells and another type 
of confluent colony containing both spindle shape and cobblestone morphology cells.  
The EBM cultured primary VECs were evaluated by RT-PCR techniques (Figure 
3.22). Compared to standard medium cultured VECs and VICs, VECs in EBM 
expressed higher level of CD31 and lower level of α-SMA, which was consistent 
with the medium replacement results.  
In conclusion, using canine EBM to culture primary isolated VECs resulted in an 
unexpected morphology alteration process, which indicated differential phenotypes 
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were existing in the cultures. Enhanced endothelial marker expression and reduced 





Figure 3.21. Primary isolated VECs cultured in EBM morphologies altered in the 
early culture days. A. On Day 6, cells with long extensions were observed in 
primary VEC EBM culture, where typical endothelial cobblestone colonies 
disappeared. On Day 13, morphological heterogeneities were observed in the same 
culture. There were three patterns: B. Sparse distribution of cells with long 
extensions; C. Confluent fibroblast-like colony formed by spindle shape cells and 
D. another type of confluent colony containing both spindle shape and cobblestone 
morphology cells. Scale bar = 50 μm. 
















Figure 3.22. Primary isolated VECs consistently cultured in EBM characterized by 
RT-PCR. Cells (passage 2) demonstrated higher expression of CD31 and decreased 
expression of α-SMA than VECs cultured in AF12 medium.  




3.4.1 Primary Canine Mitral VEC Exhibit Endothelial 
Properties and Differentiation Potentials in Vitro 
Primary canine mitral VECs possessed common endothelial properties such as 
expressing endothelial specific cell surface molecule CD31 and uptake of acetylated 
low density protein through endocytosis. CD31 is a 130 kilodalton (kDa) cell 
adhesion molecule which is involved in inflammation and vascular structure 
development (Ilan and Madri, 2003; Woodfin et al., 2007). It has been well accepted 
as one of the classic markers to characterize endothelial cells (Ferrer et al., 1995; 
Gould and Butcher, 2010). DiI-Ac-LDL has been found to be specifically taken up 
by macrophages and endothelial cells through scavenger pathway which is not 
present in other cell types and it has been used to identify endothelial cells for more 
than two decades (Cuy et al., 2003; Voyta et al., 1984). Therefore a combination of 
these two markers confirms endothelial identity of the cells in VEC culture in aspects 
of both surface molecule synthesis and unique metabolic function.   
In initial studies, vWF was tried as a marker to identify endothelial cells. 
Unexpectedly, this common endothelial marker was not obviously expressed in our 
VEC cultures. Three pairs of vWF primers were used for RT-PCR amplification 
along with annealing temperature optimization. All the primer pairs were 
successfully amplified in both human umbilical endothelial cell line and canine 
haemangiosarcoma cell line (tumor in endothelial nature) (Thamm et al., 2006; 
Fosmire et al., 2004), which indicate that the absence of vWF in VECs was unlikely 
due to technical issues. This could be a result of tissue specific heterogeneous 
expression of vWF, as has been previously observed in endothelium from different 
anatomic sites (Pusztaszeri et al., 2006). Interestingly, in one previous report vWF 
expression in porcine mitral VECs at transcriptional level was also weak (Flanagan 
et al., 2006a). To enhance the vWF expression signal in VEC cultures, possibly using 
stimulating cytokines such as tumor necrosis factor alpha (TNF-α) could boost the 
vWF synthesis in the culture (Bernardo et al., 2004).  
Consistent with marker characterization, the majority of cells in VEC culture exhibit 
typical cobblestone morphology in early culture (< 3 passages). However cellular 
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pleomorphism was seen. This non-cobblestone phenotype of cells in the VEC culture 
might arise from three sources: endothelial cells with differential morphology, other 
cell type contamination or endothelial cell differentiation.  
Previous reports have showed the presence of different endothelial cell morphologies 
in native mitral valves (Corcoran et al., 2004; Sarphie and Allen, 1978). Endothelial 
cells on the ventricular side of canine mitral valve leaflet seem to be larger, with 
more prominent nuclei and in a more orderly arrangement than the atrial side 
(Corcoran et al., 2004; Sarphie and Allen, 1978). Consistently, the side specific 
heterogeneity has also been observed in aortic VECs (Simmons et al., 2005).   
Apart from the above possibility, it is more likely the use of an enzymatic digestion 
technique released sub-endothelial cells (i.e. VICs) from the valve leaflet during 
VECs isolation. This technical issue has been discussed in studies isolating VECs 
from semilunar valves (Cheung 2008; Butcher 2004). Additional cell sorting or 
single cell clonal expansion might be a possible solution (Cheung 2008; Hoerstrup 
1998; Parayan 2001; Gould 2011).  
Lastly, the possible identity of these spindle shaped cells might be transformed VECs 
which undergone EndoMT in vitro, as occurs in embryonic development. The 
possibility of EndoMT potential in adult valve cells has been examined in recent 
studies (Bischoff and Aikawa, 2011; Mahler et al., 2013; Paranya et al., 2001; 
Paruchuri et al., 2006). It has been proposed to be one of the key remodelling 
mechanisms in heart valve disease, where a subset of adult VECs possess foetal cell 
characteristics such as differentiation potential, and can replenish the VIC population 
when needed, for example during disease or remodelling process (Bischoff and 
Aikawa, 2011; Liu et al., 2007; Paruchuri et al., 2006). Hallmarks of EndoMT 
include induction of mesenchymal marker expression and decreased endothelial 
marker properties (Bischoff and Aikawa, 2011). In this study, myofibroblast marker 
expression was present in VEC cultures at the transcriptional level, but as stated 
above VIC contamination might contribute. A more convincing finding of EndoMT 
is SMemb expression in VECs at both gene and protein levels. Extensive expression 
of SMemb in cells from VEC culture on immunofluorescence would suggest VIC 
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contamination was not responsible for all SMemb expression. SMemb is a 200 kDa 
non-muscle type myosin heavy chain which was first reported in embryonic vascular 
structures (Aikawa et al., 1993; Kuro-o et al., 1991). This protein has been 
considered as an activated mesenchymal marker and has been found expressed 
highly in foetal VECs, but minimally in normal adult VECs in semilunar valves 
(Aikawa et al., 2006). Moreover, it has been shown the SMemb is expressed by the 
majority of VICs in MMVD, but absent in normal human mitral valves (Rabkin et 
al., 2001). Similarly, SMemb phenotype VIC transformation has also been observed 
in canine MMVD (Disatian et al., 2010). These studies suggest SMemb is involved 
in VIC activation during the disease remodelling process. To our knowledge, this is 
the first study showing apparent SMemb expression in adult VECs. This suggests 
VECs from adult canine mitral valves are activated in vitro and possibly still possess 
developmental EndoMT potential, which is consistent with the VEC progenitor cell 
hypothesis (Bischoff and Aikawa, 2011).  
For further confirmation, it will be necessary to counterstain endothelial markers 
with mesenchymal markers on VEC populations to detect whether there is co-
expression of these proteins in individual cells. A more straightforward method of 
confirming the EndoMT hypothesis will be evaluating a series of markers involved 
in the EndoMT process. 
3.4.2 Primary Canine Mitral VIC Characteristics in Vitro 
In this study, canine mitral VICs were isolated by using both explant culture and 
collagen digestion techniques. Cells were successfully cultured on standard tissue 
culture vessels without additional coating substrates. In a previous report, coating 
substrate such as collagen has been necessary for primary canine mitral VIC growth 
from explants (Heaney et al., 2009). The collagenase digestion method was used to 
isolate primary VICs, after several explant cultures were undertaken, as it was 
believed a digestion of the entire leaflet tissue would be less selective and so results 
in obtaining a complete set of VIC sub-phenotypes.  
Regarding cell morphology, distinct from VECs, primary mitral VICs typically 
exhibited fibroblast-like morphology, which is consistent with previous reports 
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(Gould and Butcher, 2010; Heaney et al., 2009). Heterogeneous populations (based 
on morphology) were also observed in the VIC cultures. Apart from morphological 
differences, it was noticed that cells in VIC cultures showed different responses to 
enzymatic dissociation, with a number of cells in the culture showing stronger 
adhesion properties to culture substrate compared to others (data not shown). The 
same phenomenon has been observed previously. It has been shown that 
trypsinization sensitive mitral VICs expressed low levels of α-SMA (15-35%) 
whereas the more adhesive VICs expressed α-SMA highly (>98%) (Blevins et al., 
2006). A similar study also managed to obtain mitral VIC sub-populations by 
utilising their differential adhesion properties to fibronectin (Stephens et al., 2010b). 
Factors such as anatomic region and age are associated with mitral VIC phenotypic 
and synthetic differences in culture, which might be linked with incidence of 
myxomatous mitral valve disease in vivo (Blevins et al., 2008; Stephens et al., 2011).  
The heterogeneity of native VICs has been reviewed by Liu et al. in 2007, where at 
least 5 sub-phenotypes are reported to exist in native VICs (Liu et al., 2007). 
Moreover, the relative density of these sub-populations is proposed to respond 
dynamically to stimulation and environment alterations (Liu et al., 2007). The 
complex mechanism under-pinning this heterogeneity is not known.  
To date, there is no definitive marker panel for differentiating each VIC sup-
phenotype. In this study, the identity of VICs was determined by their lack of 
endothelial properties, but being positive for vimentin (Heaney 2009). Endothelial 
markers were absent in all VIC cultures examined. The expressions of activated VIC 
markers SMemb, SM22 and α-SMA were detected in VIC cultures at the 
transcriptional level. SMemb protein was found to be expressed by all cells in VIC 
culture, while α-SMA expression varied between different cultures on 
immunofluorescence. The α-SMA positive cells were generally estimated on visual 
examination at less than 10% in VIC cultures. This figure is much less than 
previously reported (Taylor et al., 2003). Culture conditions such as cell density and 
substrate types have been reported to be associated with α-SMA expression (Engler 
et al., 2006; Stephens et al., 2011; Xu et al., 2012).  
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Mitral aVIC function and properties have been studied both in vivo and in vitro. Most 
in situ studies have focused on the roles of aVICs in myxomatous mitral valve 
disease (Black et al., 2005; Disatian et al., 2008; Han et al., 2013; Han et al., 2008; 
Rabkin et al., 2001). The number of aVICs are reported increased in disease 
remodelling (Disatian et al., 2008; Han et al., 2008) or repair processes (Durbin and 
Gotlieb, 2002; Tamura et al., 2000), and they are possibly associated with cell 
migration (Black et al., 2005), increased ECM synthesis (Aupperle et al., 2009a; 
Gupta et al., 2009a; Han et al., 2010) and degradation activity (Aupperle et al., 
2009b; Disatian et al., 2008; Rabkin et al., 2001). 
In vitro studies on mitral VICs mainly refer to the activated phenotype (aVIC) (note: 
caution has to be exercised in equating cultured VIC phenotypic characteristics with 
native valve VICs, but for the purpose of this discussion the VICs appear to be 
activated). The ECM synthetic ability of VICs has been evaluated (Flanagan et al., 
2006a; Gupta et al., 2008b), as well as wound repairing capacity (Durbin et al., 2005; 
Fayet et al., 2007; Lester et al., 1993). Similar to aortic VICs, the mitral VICs have 
been found to be ‘mechanosensitive’-with differential α-SMA expression and 
collagen synthesis activity in response to different culture substrates and conditions 
(Stephens et al., 2011), which might better explain VICs-valve matrix interaction in 
vivo. Recent studies have also identified other mitral VIC properties, such as 
osteogenic, chondrogenic and adipogenic potentials, and a higher predisposition to 
calcification comparing to aortic VICs (Sun et al., 2013; Wylie-Sears et al., 2011). In 
the current study, due to time constraints, only cell phenotypic markers have been 
evaluated in cultured mitral VICs, without further function investigation of activated 
VICs. 
In future studies, it would be worth obtaining accurate percentages of activated VICs 
in the culture by additional techniques such as flow cytometry and separating aVICs 
from the main VIC culture population, to investigate biological functions targeting 
this specific VIC sub-population.  
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3.4.3 Evaluation and Improvement of Primary Canine Mitral 
VEC Purity  
The marker CD146 has been used to identify canine circulating endothelial cells 
previously (Wills 2009). In this study, CD146 expression was evaluated in passage 1 
VEC cultures by flow cytometry and over 75% of cells were positive. This suggests 
that the majority of cells in proposed VEC cultures were actually endothelial. There 
was no well-characterized canine VEC cell line available to serve as a positive 
control; however there was marked differential CD146 expression in primary 
isolated VECs and VICs (less than 4% CD146 positive cells) under the same 
experimental conditions. The results of VEC flow cytometry is consistent with the 
morphological observation (judging by estimating the typical endothelial cobblestone 
appearance cell numbers in the VEC cultures). Therefore this suggests CD146 would 
be reasonable efficient in detecting endothelial cells in primary VEC culture, and be 
a potential marker for VEC purification. As this experiment was only undertaken in 
samples from one dog further work is required to confirm this finding.  
It should be noted that around 4% of cells were positive for CD146 in VIC culture. In 
the other characterization protocols, VICs were negative for all endothelial markers, 
suggesting the identity of these CD146 positive VICs was not endothelial. 
Furthermore, caution should be exercised in using CD146 as a lone endothelial 
marker, not least as it can be present in other cell types such as vascular smooth 
muscle cells (Ren et al., 2002).  
Mouse monoclonal [WM-59] CD31 antibody (ab13466) was also used for the VEC 
flow cytometry. However, this antibody seemed to fail to label canine mitral VECs 
possibly due to species differences of the antigen epitope. Another rabbit polyclonal 
CD31 antibody (ab28364) successfully labelled canine mitral VECs on 
immunocytochemistry which proved the presence of CD31 protein on the canine 
VECs. However, as polyclonal antibodies can bind to multiple antigen epitopes 
which might intensify the fluorescence quantification, they are not ideal for flow 
cytometry. Therefore, the rabbit polyclonal CD31 antibody was not applied to 
current flow cytometry study. A limitation of the sorting experimental design is a 
common endothelial cell surface marker was used to identify VECs. It is likely that 
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other endothelial cell types such as circulating endothelial cells might also exist in 
the VEC cultures. Therefore, to ensure a pure VEC population, it would be necessary 
to use additional cell markers to differentiate VECs from other types of endothelial 
cells (Gould and Butcher, 2010).   
Cell sorting techniques have been commonly used in optimizing primary isolated 
endothelial cells (Cheung et al., 2008; Hoerstrup et al., 1998). Magnetic sorting has 
been tried to separate pulmonary VECs from contaminating cell types (Cheung et al., 
2008). Based on evaluation of CD31 expression, VEC purity increased to 96 + 3%. 
However, it has been shown that the interstitial cells re-appeared in the culture once 
they reach confluence (Cheung et al., 2008). This is similar to the observation in the 
current study. Although the sorting technique seemed to be efficient to separate 
endothelial cells from the VEC culture, mesenchymal cell morphology re-occurred in 
a later confluent CD146+ VEC culture. 
An alternative method for getting high purity VECs would be single clonal 
expansion followed by specific endothelial medium culture (Cheung et al., 2008). 
However, this method results in selected VEC clones which might not be 
representative for the entire population. Also cell doubling number of the clones is 
very limited in each expansion, and extensive expansion may affect cell quality 
(Gould and Butcher, 2010).  
Specific endothelial culture medium or adding additional endothelial growth factors 
should be helpful in maintaining endothelial properties and preventing the 
development of mesenchymal properties (Armstrong and Bischoff, 2004). With that 
in mind, a commercial canine endothelial basal culture medium (EBM) was used in 
this study and compared with standard culture medium (AF12). Endothelial colony 
forming cells in VEC culture occurred in both EBM and AF12 medium at the early 
stages of culture. However, cells appeared undergone an unexpected differentiation, 
particularly in the EBM VEC cultures. Moreover, when cells in EBM reached 
confluence, their morphologies were not limited to typical endothelial type, but 
showed morphological heterogeneity. The exact mechanism of this phenomenon was 
not investigated. It should be noted that other cell types rather than VECs could also 
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survived in endothelial basal medium (Cheung et al., 2008; Gould and Butcher, 
2010). A further concern is the commercial canine EBM used in this study is for 
culturing aortic endothelial cells, but not specific for mitral VECs. As has been 
reported previously the vascular endothelium and valve endothelium possess 
differential inflammatory and mechanical responsive characteristics (Butcher et al., 
2004; Butcher et al., 2006), it is possible that the mitral VECs could respond to the 
culture medium in a manner distinct from vascular endothelial cells. Customising 
media in the laboratory would be another solution for mitral VECs culture. Despite 
the above mentioned transformation process in EBM culture, characterization results 
suggested EBM is superior to AF12 in maintaining endothelial characteristics, as 
higher expressions of endothelial markers and dramatically decreased α-SMA 
expression were observed in the EBM culture compared to AF12 culture.  
In summary, cell sorting can separate VECs from a mixed population culture but 
standard culture media cannot maintain the endothelial properties in long term 
culture. Specific endothelial basal medium can preserve endothelial properties and 
down regulate mesenchymal marker expressions, but cannot eliminate contaminated 
cell types in the culture. To obtain the purest VEC population, a combination of cell 
sorting followed by specific endothelial medium culture should give better results. In 
this study, due to sample number and time limitation, this purification approach was 
not undertaken.  
To guarantee a relatively pure VEC population (for endothelial lining of tissue 
engineered constructs), the VECs used in later experiments were not passaged more 
than three times and over-confluent cultures were avoided to reduce the chance of 
EndoMT differentiation (Gould and Butcher, 2010).  
3.5 Conclusion 
Primary canine mitral VECs and VICs were successfully isolated, cultured and 
characterized in vitro. Relatively pure cell populations were obtained. Endothelial 
markers differentiated VECs from VICs and mesenchymal features existed in both 
cultures. Additional cell sorting and specific culture medium can contribute to 
endothelial cell purity in VEC cultures. This study provides fundamental information 
Chapter 3-Canine Mitral Valve Cells Isolation and Characterization 
127 
 
for canine mitral valve cellular biology, which will benefit mitral valve disease 
research and valve constructs in tissue engineering. 
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Chapter 4: Fibrin Based Canine Mitral Valve 3D 
Constructs in Static Culture 
Abstract 
It is uncertain if canine myxomatous mitral valve disease (MMVD) is initiated by 
long term shear stress damage to the valve endothelium or from abnormalities of 
valve interstitial cells (VICs). Examining these questions is problematic in vivo. In 
this study, an alternative approach was taken and tissue-engineered fibrin based 
canine mitral valve constructs were developed which can be used as an in vitro 
platform to study the pathogenesis of MMVD.  
Canine mitral valves were collected post mortem and categorized into two groups: 
healthy (Whitney grade 0/4) and diseased (Whitney grade 1/4-2/4). Dogs in 1.5-5 
years age range were used in current study. Mitral valve endothelial cells (VECs) and 
VICs were cultured and characterized as described in Section 3 prior to three 
dimensional (3D) culture (VECs passage 2-3; VICs passage 4-7). Three types of 
models were generated by using fibrin based 3D culture techniques. Samples were 
maintained in static culture for 14-20 days and analysed by using light microscopy, 
immunofluorescence microscopy, Western blot and electron microscopy techniques.  
Histological examination demonstrated partial native tissue-like morphology of the 
3D constructs. Relatively comparable expression of cellular and ECM associated 
markers was detected between artificial constructs and native valves. Comparing 
healthy VIC constructs (Type 1) with diseased VIC based models (Type 2), no 
apparent difference was detected in expression of the VIC activation markers (α-
SMA and SMemb) and matrix catabolic enzymes (MMP-1 and MMP-3). The partial 
ultrastructure analysis using transmission electron microscopy revealed cells in the 
construct with variable morphologies. Atypical endothelial cells or cell 
loss/degradation were observed in the proposed endothelium surface, and the VICs 
typically were either in active or degraded state. 
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In endothelium damaged model (Type 3), without changing mechanical tension, up-
regulated VIC activation (SMemb up-regulation) was observed after damaging; 
while in Type 3 with decreased external mechanical tension, generally the VIC 
phenotype appeared to be more quiescent based on marker expression (decreased 
SMemb and α-SMA expression) and showing some signs of degradation or 
decreased proliferation (vimentin down-regulation). However, some cellular 
activities were observed at the wound sites which may indicate an undergoing repair 
process. Additionally, distinct association patterns of SMemb and α-SMA to some of 
the ECM proteins suggested aVIC heterogeneity. These findings were further 
supported by ultrastructure analysis using TEM, where differences in cell activity 
were observed within a “smooth muscle” cell phenotype population. 
In conclusion, canine fibrin-based 3D mitral valve constructs have been successfully 
developed using cells from both normal and diseased dogs, and appear to be 
promising models for valve research. Results suggest that current static cultured 
constructs express MMVD markers irrespective of using healthy or diseased VICs. 
Simple mechanical stimulation was found to regulate VIC activity in the 3D models. 
Endothelial damage resulting in VIC phenotypic activation (a change typically 
observed in MMVD), and decreased mechanical tension appeared to be a negative 
regulator of this effect. Moreover, there appears to be heterogeneity in the aVIC 
population.  




Myxomatous mitral valve disease (MMVD) is the most common cardiac disease in 
dogs and also accounts the leading cause for human mitral valve prolapse (Buchanan, 
1977; Connell et al., 2012; Olsen et al., 2010). It has been proven this disease is 
strongly associated with age (Beardow and Buchanan, 1993; Davies et al., 1978; 
Whitney, 1974). Affected leaflets have been described as thickened, distorted and 
less transparent when compared to normal valves, and with myxomatous nodule 
lesions occur on the valve surface progressing from distal free edge to more proximal 
region (Buchanan, 1977; Han et al., 2010; Kogure, 1980; Whitney, 1967).  
Underlying microstructural alterations on the affected leaflets mainly comprise valve 
resident cell changes and extracellular matrix (ECM) remodelling. In the case of 
cells, the most dramatic features are valve endothelium denudation and valve 
interstitial cell phenotypic transformation (Barth et al., 2005; Black et al., 2005; 
Corcoran et al., 2004; Disatian et al., 2008; Disatian et al., 2010; Han et al., 2008; 
Mow and Pedersen, 1999; Prunotto et al., 2010; Rabkin-Aikawa et al., 2004b; Stein 
et al., 1989). Typical ECM changes in myxomatous valves include collagen 
abnormalities (Aupperle et al., 2009a; Cole et al., 1984; Hadian et al., 2010; Tamura 
et al., 1995) and increased proteoglycan (PG) and glycosaminoglycan (GAG) 
accumulation (Gupta et al., 2009a; Han et al., 2010; Tamura et al., 1995). Resident 
cellular change and ECM alterations lead to abnormal mechanical properties in 
diseased valves (Butcher and Nerem, 2007; Richards et al., 2012; Schoen, 2008), and 
adversely affect valve physiological functions in vivo.  
To date, the pathogenesis of MMVD is not completely understood. Studies on two 
highly susceptible dog breeds the Cavalier King Charles Spaniel (CKCS) and 
Dachshund suggest polygenetic inheritance may play a role in canine MMVD 
development (Olsen et al., 1999; Olsen et al., 2003a; Swenson et al., 1996). Another 
study on CKCS identified two potential loci associated with MMVD development 
(Madsen et al., 2011), but this was not confirmed in a later study (French et al., 
2012). Recent study of CKCSs suggests the inheritance component of the disease is 
mainly affecting the age of onset but not pathological changes (Lu. et al., in press). In 
Chapter 4-Fibrin Based Canine Mitral Valve 3D Constructs in Static Culture 
131 
 
humans, mitral valve prolapse has been found to associate with some general 
connective tissue disorder such as Marfan syndrome and Ehlers-Danlos syndrome 
(Grau et al., 2007; Jaffe et al., 1981; Ng et al., 2004; Schoen, 2005). Considering 
majority of MMVD cases develop through a chronic degenerative process, genetic 
factors certainly would not be the only contributor. A current hypothesis for 
myxomatous degeneration is that the lesion is a result of valve leaflet responsive 
adaption to long-term shear stress damaging on valve endothelium which triggers 
sub-endothelial VIC activation and ECM remodelling (Corcoran et al., 2004; Durbin 
and Gotlieb, 2002; Pedersen and Haggstrom, 2000; Prunotto et al., 2010; Stein et al., 
1989). However, so far there is no definitive evidence that can clarify whether this 
disease is initiated from damaged endothelium or from abnormal valve interstitial 
cells (Corcoran et al., 2004; Han et al., 2013). It has been shown that VIC 
abnormalities exist in MMVD in respect to cell phenotypic alteration (Black et al., 
2005; Disatian et al., 2008; Disatian et al., 2010; Han et al., 2013; Han et al., 2008; 
Rabkin-Aikawa et al., 2004b) and excessive ECM remodelling (Aupperle et al., 
2009c; Disatian et al., 2008; Obayashi et al., 2011; Rabkin et al., 2001). VICs in 
diseased mitral valve transform from a quiescent fibroblast phenotype into an 
activated myofibroblast-like phenotype (Black et al., 2005; Disatian et al., 2008; 
Disatian et al., 2010; Han et al., 2013; Han et al., 2008; Prunotto et al., 2010; Rabkin-
Aikawa et al., 2004b). The latter phenotype is usually characterized by expressing 
the myofibroblast marker alpha smooth muscle actin (α-SMA) and/or an embryonic 
form of non-muscle myosin heavy chain (SMemb) (Disatian et al., 2008; Disatian et 
al., 2010; Han et al., 2008; Lester et al., 1992; Rabkin-Aikawa et al., 2004b; Rabkin 
et al., 2001). Activated VICs have been found to have a number of properties and 
functions including contractile and force generation (Filip et al., 1986; Mulholland 
and Gotlieb, 1997; Smith et al., 2007; Stephens et al., 2010a) ECM related synthesis 
(Disatian 2008; Disatian 2010; Rabkin 2001) as well as migration and proliferation 
potential in early stage valve injury (Durbin et al., 2005; Durbin and Gotlieb, 2002; 
Gotlieb et al., 2002; Lester et al., 1993; Lester et al., 1992; Lester and Gotlieb, 1988; 
Tamura et al., 2000). Matrix metalloproteinases (MMPs) and their tissue inhibitors 
(TIMPs) secreted by aVICs are major enzymes involved in valve matrix remodelling 
which play a crucial role in valve ECM dynamics (Aupperle et al., 2009b; Aupperle 
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et al., 2009c; Disatian et al., 2008; Dreger et al., 2002; Obayashi et al., 2011; Rabkin 
et al., 2001).  
In contrast to increased understanding of the role of VICs in MMVD, the mechanism 
of how VECs might contribute to the disease is still uncertain. Since endothelium 
loss is a commonly seen in MMVD, an endothelial damage model has been 
previously generated and investigated utilising mitral valve organ culture (Lester and 
Gotlieb, 1988). With endothelium denuding, activated VICs were found to migrate 
and proliferate in response to the injury (Lester and Gotlieb, 1988). Later studies 
showed that mitral VICs possess wound repair ability in response to injury by 
migration, proliferation and secreting ECM components at wound sites (Durbin et 
al., 2005; Durbin and Gotlieb, 2002; Gotlieb et al., 2002; Lester et al., 1993; Lester et 
al., 1992; Lester and Gotlieb, 1988; Tamura et al., 2000). Since then there have been 
no further studies reported using injury mitral valve models. 
Tissue engineering is a novel technology in regenerative medicine field, which 
provides opportunities for developing artificial organs in vitro. Apart from clinical 
orientated development, 3D culture constructs have also been utilised as research 
models particularly for improving understanding of cell biological behaviour and 
functions (Butcher and Nerem, 2004, 2006; Dreger et al., 2006; Gibbons et al., 2012; 
Griffith and Swartz, 2006; Gupta et al., 2008a; Gupta et al., 2008b).  
In the present study, primary canine mitral valve cells used to develop a fibrin based 
3D valve construct as a research platform to investigate pathogenesis of MMVD. 
Generally three types of models were generated: healthy VECs-VICs co-culture 
(Type 1), healthy VECs-diseased VICs co-culture (Type 2) and an endothelium 
damage model (Type 3). It was hypothesized that (1) Type 1 models possess some 
features of normal mitral valve, and can be used as a substitute for native tissue in in 
vitro studies; (2) phenotypically, VICs in Type 2 models would be more active, and 
there would be greater ECM remodelling activity in Type 2 constructs compared to 
Type 1; and (3) after damaging construct endothelium, VIC activation and migration 
would occur to repair the wound in Type 3 models.  
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4.2 Materials and Methods 
4.2.1 Cell Source  
Canine mitral VECs and VICs were isolated and cultured as described in Section 
3.2.1. VEC cultures derived from healthy mitral valves (n=3, ‘n’ indicates the 
number of dog mitral valves) were used. While VIC cultures (n=3 respectively) were 
derived from both healthy and diseased mitral valves (Whitney Grade 1/4-2/4) for 
construct fabrication. Since age is strongly associated with MMVD disease 
progression (Davies et al., 1978; Whitney, 1974) and VIC heterogeneity (Stephens et 
al., 2011), cells were collected from 1.5-5 year old dogs for all cultures to reduce the 
influence of age. One elderly adult dog was included in the diseased VIC group, this 
was due to limited sample availability. Because of the same limitation and to control 
for the variation effect of using individual dogs, pooled cell cultures were used in the 
later experiment. Identical numbers of cells, at same passage, were derived from each 
individual culture (n=3-4 for each cell type) and all contributed to each cell pool.  
All cells were assessed for the expression of vimentin and CD31, prior to 3D culture, 
using immunocytochemistry, which was described in Section 3.2.2.3. VEC identity 
was confirmed by expressing vimentin and CD31, while VICs were defined as 
positive for vimentin but negative for CD31 (Heaney et al., 2009). VECs at passage 
2-3 and VICs at passage 4-7 were used for 3D construct fabrication. 
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4.2.2 Fibrin Based Canine Mitral Valve Models Fabrication 
 Fibrin/VECs-VICs Co-culture Hydrogel System 4.2.2.1
Fibrin based canine mitral valve constructs in static culture were produced as 
described in Section 2.10.1 and 2.10.2. The schematic image below briefly 
demonstrates the fabrication process (Figure 4.1). Fibrin/VICs constructs were 
generated by mixing VICs suspension (1 million cells per gel) with fibrinogen, 
thrombin and CaCl2 solution. Once the solid hydrogel formed, VECs suspension (1, 
000 cells/cm
2
) was seeded on the upper surface of the Fibrin/VICs gels. The co-
culture constructs were maintained in standard tissue culture conditions for 14 days 
before manipulation or analysis. 





Figure 4.1. Fabrication of fibrin/VECs-VICs 3D co-culture constructs in static 
culture.  
Chapter 4-Fibrin Based Canine Mitral Valve 3D Constructs in Static Culture 
135 
 
Table 4.1 Types of fibrin based canine mitral valve 3D construct in static culture 
Construct Name  Description 
Type 1 Healthy VECs-healthy VICs 3D co-culture on fibrin matrix, 
cultivate for 14 days in standard tissue culture system (static 
culture). 
Type 2 Healthy VECs-diseased VICs 3D co-culture on fibrin matrix, 
cultivate for 14 days in static culture. 
Type 3-A Healthy VECs-healthy VICs 3D co-culture on fibrin matrix, 
cultivate for 14 days in static culture. On Day 14, damage the 
proposed construct endothelium and maintain the construct 
in static culture for up to 6 days. The constructs attach to 
culture plate during the entire culture period. 
Control-A Sham control for Type 3-A. 
Type 3-F Healthy VECs-healthy VICs 3D co-culture on fibrin matrix, 
cultivate for 14 days in static culture. On Day 14, damage the 
proposed construct endothelium and detach the construct 
from culture plate to float them, and maintain the construct 
in static culture for up to 6 days. 
Control-F Sham control for Type 3-F. 
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 Experimental Design Comparing Healthy and Diseased Mitral 4.2.2.2
Valve Constructs  
Four separate Type 1 and Type 2 experiments were carried out using cells derived 
from different dogs. Six constructs of each type were fabricated and cultured in one 
24 well plate in each experiment. The sample plate arrangement is illustrated in 
Figure 4.2. Fibrin gels without added cells served as cell free controls. Constructs 
were harvested after 14 days culture. Two samples of each type were collected and 
prepared for full panel analysis (illustrated in Figure 4.2). Each construct was divided 
into four parts each of which was processed as follows: methacarn fixation (histology 
and immunofluorescence), snap frozen and protein extraction (Western blot), and 
glutaraldehyde/paraformaldehyde fixation (electron microscopy). Detail of protocols 
for methacarn fixation, protein extraction and EM sample pre-fixation are described 
in Section 2.11.2, Section 2.2.1, Section 2.12.1 and Section 2.12.2. Remaining 
construct samples of each type were pooled and snap frozen as tissue protein stock 







Figure 4.2. Typical culture plate design and analysis plan for Type 1 and Type 2 
constructs comparison study. His/IF, histology and immunofluorescence; WB, 
Western blot; SEM, scanning electron microscopy; TEM, transmission electron 
microscopy. 
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 Experimental Design and Wounding Procedure for Endothelium 4.2.2.3
Damaged Mitral Valve Constructs 
4.2.2.3.1 Construct Endothelium Damage 
Three separate endothelium wounding experiments were carried out using cells 
derived from different cultures. Fibrin based healthy VECs-VICs co-culture 
constructs were made and maintained in static culture for 14 days on one 24 well 
culture plate. On Day 14, the culture medium was removed and the constructs were 
rinsed with sterile PBS. The constructs were divided into two groups: intact control 
and wounded (Type 3). Constructs in the wounded group were manually damaged on 
their upper surface (presumed endothelium) using the flat end of surgical forceps. 
Several linear wounds (scratch) were made all through construct endothelium 
surface. The constructs were rinsed with sterile PBS to remove detached cells before 
adding fresh culture medium. Both wounded and control constructs were maintained 
in static culture for 0-6 days. Based on differential manipulation techniques, the Type 
3 constructs were further divided into ‘adherent’ and ‘floating’ groups. 
4.2.2.3.2 Adherent Type 3 Construct and Analysis 
Constructs remained attached to the culture plate in the first construct endothelium 
damage experiment (T3-1). To be differentiated from later Type 3 models, the 
wounded constructs in T3-1 were designated as adherent Type 3 (Type 3-A). The 
adherent constructs with intact endothelium served as controls (Control-A). 
Experimental design of T3-1 is shown in Figure 4.3. One construct pair was collected 




Figure 4.3. Culture plate design of endothelium damage experiment-adherent 
constructs. Ten healthy constructs were fabricated and divided into two groups. One 
pair of constructs was collected at each time point (identified in red squares).  
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Samples were prepared for histology and immunofluorescence study using methods 
described in Section 2.11.2.  
4.2.2.3.3 Floating Type 3 Constructs and Analysis 
Generation of floating constructs was not planned as part of the original study 
design. However, occasionally construct detachment occurred during wounding in 
the second (T3-2) and third (T3-3) Type 3 experiments. To eliminate potential effects 
of adherence affecting mechanical tension across the constructs, all constructs 
including controls were detached from the culture plate using a sterile forceps and 
lab spatula in T3-2 and T3-3. The endothelium damaged constructs are so called 
floating Type 3 (Type 3-F). Floated constructs with intact endothelium served as 
controls (Control-F). 
Following on from results from T3-1 experiments, the harvesting time points in later 
experiments were reduced to three (Day 0, Day 2 and Day 6) as this was most likely 
to allow identification of the most evident changes as well as to increase 
repeatability. Sample arrangement and collection plan are shown in Figure 4.4. Two 
pairs of samples were harvested at each time point. Samples were prepared for 
histology, immunofluorescence and Western blot using methods described in Section 





Figure 4.4. Culture plate design for endothelium damage experiment-floating 
constructs. Twelve healthy constructs were fabricated and divided into two groups. 
Two sample pairs were collected at each time point (circled in red squares).  
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4.2.3 Constructs Analysis 
 Histology and Immunofluorescence  4.2.3.1
Type 1 and Type 2 construct histological features were assessed by hematoxylin and 
eosin (H&E) staining and Russel-Movat Pentachrome staining. Detailed staining 
protocols are described in Section 2.11.3 and 2.11.4. 
On Day 14 fibrin/VECs-VICs co-culture constructs were assessed for endothelium 
layer formation using DiI-Ac-LDL labelling and the protocol is described in Section 
2.7. Stack images were processed by using Zen imaging software and maximum 
intensity image was presented. 
On immunofluorescence, Type 1, Type 2 and Type 3-F constructs were assessed for 
activated VIC phenotype and ECM related markers. Healthy canine mitral valve 
tissue was also assessed for the same marker panel to have a comparison with the 
Type 1 construct. Type 3-A constructs were only assessed for activated VIC 
phenotypes. Staining protocol details are described in Section 2.11.6. Antibody 
information and working concentrations are listed in Table 4.2. Secondary 
fluorescence-labelled antibodies and working concentrations are the same as used for 
immunocytochemistry in Table 3.3. Fluorescent image capture and processing was as 
described in Section 3.2.2.3, and images were captured at x 100 and x 200 
magnification.  
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Table 4.2  Primary antibody source and dilution used for fibrin based constructs 
analysis using immunofluorescence and Western blot.  
Primary antibody 
 
Cat No. and company           WC 
  IF             WB 
Anti-vimentin (MM) V6389, Sigma, USA 1:1600 1: 2000 
Anti-SMemb (RP) Ab24761, Abcam, UK 1:1000 1 in 1000 
Anti-α-SMA (MM) A2547, Sigma, USA 1:200 1 in 1000 
Anti-Collagen I and III 
(RP) 
Ab24137, Abcam, UK 1:10       / 
Anti-MMP-1 (RP) Ab38929, Abcam, UK 1:200 1 in 5000 
Anti-MMP-3 (RP) Ab53015, Abcam, UK 1:100 1 in 500 
Anti-GAPDH (MM) CB1001, Calbiochem, 
Finland 
    / 1 in 1000 
 
MM, mouse monoclonal; RP, rabbit polyclonal; WC, working concentration; IF, 
immunofluorescence; WB, Western blot. 
 Western Blot 4.2.3.2
Type 1, Type 2 and Type 3-F constructs were analyzed by using immunoblotting 
(Western blot) to semi-quantify cell activation and matrix metalloproteinase (MMP) 
synthesis. Samples derived from four (Type 1 and Type 2) or two (Type 3-F) 
separate experiments were analyzed. 50mg construct tissue was used for protein 
extraction. Related experimental protocols for protein extraction and Western blot 
are described in Section 2.2. Primary and secondary antibody details for Western blot 
are listed in Table 4.2 and 4.3 respectively. 
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As sample number of Type 3-F construct was limited, triplicated protein sample 
loading was carried out in each Western blot experiment to eliminate loading error. 
The mean value of triplicate sample data is used in the semi-quantification analysis.  
Table 4.3 Secondary antibody source and dilution used for construct Western blot 
Secondary antibody Cat No. and company WC 
Polyclonal Rabbit Anti-Mouse 
Immunoglobulins/HRP 
P0260, Dako, Denmark 1 in 1000 
Polyclonal Swine Anti-Rabbit 
Immunoglobulins/HRP 
P0217, Dako, Denmark 1 in 3000 
 
WC, working concentration  
 Western Blot Data Semi-Quantification and Statistical Analysis  4.2.3.3
Protein bands on radiographic film were scanned by using an office photocopier and 
the protein band intensity was quantified using ImageJ software.  
For the comparison of Type 1 and Type 2 models, data was initially semi-quantified 
by normalizing protein band intensity of interest to internal control GAPDH 
intensity, then normalised further by calculating the mean value of Type 2/Type 1 
ratio for each marker. Statistical analysis was carried out on Type 1 and Type 2 
Western blot semi-quantitative data. One way analysis of variance (ANOVA) test 
was performed to determine the difference between two groups of data. Statistical 
significance was considered at p< 0.05. The results are presented as mean ± standard 
deviation.  
For Type 3-F model, data was initially semi-quantified by normalizing protein band 
intensity of interest to internal control GAPDH intensity, followed by further 
normalization to Day 0 control. Sample data directly normalized to Day 0 control 
without semi-quantified with GAPDH is also shown.  
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 Transmission Electron Microscopy (TEM) 4.2.3.4
Construct samples were prepared for electron microscopy analysis using the 
protocols stated in Section 2.12. Due to time constrains, only transmission electron 
microscopy (TEM) analysis has been carried out in examples of the 3D constructs. 
One sample of the following construct types were used for TEM analysis: Type 1, 
Type 2, Type 3-F Day 0, Control-F Day 0, Type 3-F Day 6 and Control-F Day 6. The 
prefixed TEM samples were sent to the Electron Microscopy Service in School of 
Biological Sciences in the University of Edinburgh, where they were further 
processed and embedded in resin blocks. A toluidine blue staining was applied and 
areas of interest were selected in a view of light microscopy images. The sample 
blocks and selected toluidine blue staining images were sent to Dr. Alexander Black 
in National University of Ireland, Galway for TEM analysis. Dr. Alexander Black 
kindly contributed to all TEM image processing and interpretation, and the TEM 
results in this chapter is based on a summary report provided by Dr. Alexander 
Black.   
4.3 Results 
4.3.1 Cell Identity Authentication Prior to 3D Culture 
Prior to 3D culture experiment, cell identities were assessed. All individual VEC 
cultures (n=3) were positive for both vimentin (Figure 4.5) and the endothelial 
marker CD31 (Figure 4.6), while both healthy and disease VIC cultures (n=3 
respectively) were positive for vimentin, but negative for CD31.  
Pooled cells were checked with same marker panel and they demonstrated similar 
marker expression pattern for each individual culture: i.e. on immunofluorescence 
pooled VECs are CD31+/vimentin+; pooled VICs are CD31-/vimentin+ (Figure 4.7 
& Figure 4.8). No apparent differences in cell morphology or abnormal cell death 
were observed in the pooled cells during culture compared to individual cultures. 




  Figure 4.5. Vimentin expression in canine mitral valve cell cultures used for 3D 
construct fabrication. Vimentin (green) was expressed by VECs (A-C), healthy 
VICs (HVICs) (E-G) and diseased VICs (DVICs) (I-K). Same cell lines served as 
negative controls in which vimentin primary antibody was omitted (D, H, L). DAPI 
(blue) counterstained cell nuclei. Scale bar = 50 µm. 










Figure 4.6. CD31 expression in canine mitral valve cell cultures used for 3D 
construct fabrication. CD31 (red) was expressed by VECs (A-C) but not HVICs (E-
G) or DVICs (I-K) in 2D culture. Same VEC cell line served as a negative control 
on which CD31 primary antibody was omitted (D); cells from a VEC culture 
expressed CD31 served as a positive control for HVICs and DVICs (H and L 
respectively). DAPI (blue) counterstained cell nuclei. Scale bar = 50 µm. 






Figure 4.7. Vimentin expression in canine mitral valve cell culture pools used for 
3D construct fabrication. Vimentin (green) was expressed by pooled VECs 
(PVECs) (A-C), pools of healthy VICs (PHVICs) (E-G) and diseased VICs 
(PDVICs) (I-K). Same cell lines served as negative controls on which vimentin 
primary antibody was omitted (D, H, L). DAPI (blue) counterstained cell nuclei.  
Scale bar = 50 µm. 













Figure 4.8. CD31 expression in canine mitral valve cell culture pools used for 3D 
construct fabrication. CD31 (red) was expressed by PVECs (A-C) but not PHVICs 
(E-G) or PDVICs (I-K). Same PVEC cell line served as a negative control on which 
CD31 primary antibody was omitted (D); cells from a VEC culture expressed CD31 
served as a positive control for PHVICs and PDVICs (H and L respectively). DAPI 
(blue) counterstained cell nuclei. Scale bar = 50 µm. 
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4.3.2 General Features of Fibrin Based Canine Mitral Valve 
Constructs in Static Culture 
After 14 days static culture, fibrin based VECs-VICs co-culture mitral valve 
constructs shrunk in size and exhibited tissue-like morphology, which were less 
transparent than cell-free fibrin control constructs (Figure 4.9A).  
H&E staining showed cells were distributed all through construct thickness, with an 
even distribution in the construct stroma and a dense cell/matrix layer toward the 
surface (presumed endothelial layer) (Figure 4.9B). Russel-Movat Pentachrome 
staining showed there was de novo valve ECM synthesis in the constructs (n=4) 
(Figure 4.9C). Collagen fibres were detected mainly in the construct stroma, while 
GAGs production was localized in the loose matrix layer in the immediate sub-
endothelial area.  
Live constructs without endothelium damage were treated with DiI-Ac-LDL on Day 
14 and patchy positive expression was observed on the construct medium contact 
surface only (n=4) (Figure 4.9D). This is the proposed endothelial layer.  






Figure 4.9. Gross morphology of fibrin based canine mitral valve constructs. A. the 
VECs-VICs co-culture construct (dash arrow) shrunk in size after 14 days culture 
compared to the cell free control (solid arrow); B. H&E staining shows construct 
histology, with arrow indicating ‘endothelial’ surface; C. ECM expression in 3D 
construct using Movat Pentachrome staining; collagen fibers in stroma (yellow), 
GAGs in sub-endothelial area (blue to green); D. proposed construct endothelium 
labelled by DiI-Ac-LDL for identification of endothelial cells, magnification in D: 
x 200. 
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Healthy VECs-VICs co-culture constructs (Type 1) were compared with native 
mitral valves on immunofluorescence. Cell phenotypes and ECM related proteins 
were evaluated. Positive cells for mesenchymal marker vimentin were evenly 
distributed all through the thickness of tissue section for both valves and constructs 
(Figure 4.10A and B). SMemb, an activated mesenchymal marker, was expressed in 
a similar pattern to vimentin (Figure 4.10C and D). Positive cells were mainly seen 
in valve/construct stroma whereas endothelium was either negative or exhibited 
weaker SMemb expression. The expression pattern of α-SMA was different between 
native valves and constructs. In healthy canine mitral valve, α-SMA expression was 
limited and mainly localized to the sub-endothelial atrialis layer (Figure 4.10E). 
While in the Type 1 construct α-SMA was expressed by a number of stroma cells 
(Figure 4.10F). Usually the most prominent expression was found in the junction 
area between construct stroma and sub-endothelial dense cell layer, named as 
‘Stroma-Dense Cell Layer Junction (SDCLJ)’ (arrows in Figure 4.10F). The majority 
of cells in the densely accumulated cell layer and endothelium were negative for α-
SMA.  
Collagen type I and III are major ECM components in the native heart valve 
(Aupperle et al., 2009a; Cole et al., 1984; Latif et al., 2005) and mainly resident in 
the valve fibrosa layer (Figure 4.11A). In the Type 1 construct, weak to moderate 
collagen I and III expression was found in the stroma on immunofluorescence 
(Figure 4.11B). The expression was primarily co-localized with cells. A wavy 
staining pattern was observed on some constructs in the SDCLJ (n=2/6, ‘n’ indicates 
the number of the constructs). MMPs are important enzymes involved in valve ECM 
remodeling. Moderately diffused staining of collagenase MMP-1 was detected in 
both mitral valve and 3D construct (Figure 4.11C-D). The expression was mainly in 
valve/construct stroma. Stromelysin MMP-3 was found to be minimally expressed in 
healthy mitral valve (Figure 4.11E) and in the majority of Type 1 constructs 
examined on immunofluorescence (n=4/6, ‘n’ indicates the number of the 
constructs). Occasional and randomly dispersed MMP-3 positive cells were detected 
in stroma of the remaining constructs (n=2/6) (Figure 4.11F). 
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Primary antibody omitted negative controls for each tissue type is shown in Figure 
4.12 and only background level of staining was detected.  
 
 
Figure 4.10. Cell phenotypes in canine healthy mitral valve and fibrin based mitral 
valve construct. Valve cell markers vimentin (green in A and B), SMemb (red in C 
and D) and α-SMA (green in E and F) expression in canine mitral valves (A, C, E) 
and 3D constructs (B, D, F). Arrows in F indicate junction area between construct 
stroma and sub-endothelial dense cell layer, i.e. ‘Stroma-Dense Cell Layer Junction 
(SDCLJ)’, where prominent α-SMA is present. Construct endothelium (Endo in B, 
D and F) was identified as outer surface layer of the densely packed cell layer. 
DAPI (blue) counterstained cell nuclei. Scale bar = 100 µm.  














Figure 4.11. ECM related protein expression in canine healthy mitral valve and 
fibrin based mitral valve construct. Collagen I & III (red in A and B), MMP-1 (red 
in C and D) and MMP-3 (red in E and F) were expressed in canine mitral valves (A, 
C, E) and 3D constructs (B, D, F). Construct endothelium was identified as outer 
cell layer of the densely packed cell layer. DAPI (blue) counterstained cell nuclei. 
Scale bar = 100 µm.  
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Figure 4.12. Negative controls for healthy mitral valve and fibrin based mitral valve 
construct tissue using immunofluorescence. With primary antibodies omitted, 
fluorescence secondary antibody Alexa Fluo568 (A and B) and Alexa Fluo488 (C 
and D) only stained tissue samples at a background level. Construct endothelium 
was identified as the outer cell layer of the densely packed cell layer. DAPI (blue) 
counterstained cell nuclei. Scale bar = 100 µm.  
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4.3.3 MMVD Related Marker Expression in Healthy and 
Disease VICs Based Fibrin/VECs-VICs Co-culture 
Models 
Cell phenotype and matrix related synthesis activity (markers in Table 4.2) were 
compared between proposed healthy (Type 1) and diseased constructs (Type 2) 
constructs (n=6 respectively). Two samples were derived from one 3D construct 
fabrication experiment, and three 3D experiments were carried out. 
On immunofluorescence, no apparent differential expression pattern was observed 
between Type 1 and Type 2 constructs. Vimentin was expressed by cells all through 
construct thickness (Figure 4.13A and B). SMemb exhibited similar expression 
pattern to vimentin but was predominantly expressed by stroma cells (Figure 4.13C 
and D). Endothelial cells and the sub-endothelial dense cell layer were also positive 
for SMemb, but the expression was less pronounced than stroma. In the SDCLJ area, 
spindle shape cells strongly positive for SMemb were observed in the majority of 
constructs (n=4/6 respectively) (arrows in Figure 4.13C and D). The expression of α-
SMA was mainly found in stromal cells (Figure 4.13E and F). The expression was 
usually most prominent in SDCLJ area (n=4 respectively) (arrows in Figure 4.13E 
and F) and was not evident in outer side of the dense cellular layer closest to 
endothelial surface.  
Weak to moderate collagen I and III expression was observed in both construct types 
and predominantly localized in the construct stroma (Figure 4.14 A and B). The 
staining was diffuse and some of which was localized close to cells. On some 
constructs, wavy collagen staining was seen in the SDCLJ area (data not shown). 
MMPs expression was usually associated with cells. MMP-1 was found to be 
expressed mainly in construct stroma (Figure 4.14 C and D). Occasionally, positive 
cells were found in construct endothelium (n=2/6). MMP-3 expression was not 
apparent in the majority of Type 1 and Type 2 constructs examined by 
immunofluorescence (n=4/6 respectively) (Figure 4.14 E and F). Occasionally, weak 
to moderate MMP-3 expression was found in stromal cells (n=2/6 respectively) (Data 
not shown). 









Figure 4.13. Cell phenotype marker expression in Type 1 and Type 2 constructs. In 
general, similar cell phenotypic distribution was observed in the two construct 
types. Vimentin positive cells (green in A and B) were found all through construct 
depth in Type 1 (A) and Type 2 (B) constructs. SMemb (red in C and D) expression 
pattern was similar to vimentin in Type 1 (C) and Type 2 (D). A linear cluster of 
spindle-shaped positive cells were identified on some constructs (arrows in C and 
D). Prominent α-SMA (green in E and F) expression was generally seen in the 
SDCLJ area (arrows in E and F). Positive cells were also found in the deep stroma, 
but not commonly on the outer side of the densely packed cell layer. Construct 
endothelium was identified as the outer surface of the densely packed cell layer. 
DAPI (blue) counterstained cell nuclei. Scale bar = 100 µm  







Figure 4.14. ECM related protein expression in Type 1 and Type 2 constructs. 
Weak Collagen I&III (red in A and B), MMP-1 (red in C and D) and minimal 
MMP-3 (red in E and F) expression was found in Type 1 (A, C, E) and Type 2 
construct (B, D, F). No clear differences in expression were observed between the 
two types. Construct endothelium was identified as the outer surface of the densely 
packed cell layer. DAPI (blue) counterstained cell nuclei. Scale bar = 100 µm.  
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Primary antibody omitted negative control for each tissue type is shown in Figure 



























Figure 4.15. Negative controls for Type 1 and Type 2 constructs using 
immunofluorescence. With primary antibodies omitted, fluorescence secondary 
antibody Alexa Fluo568 (A and B) and Alexa Fluo488 (C and D) only stained 
tissue samples at the background level. Construct endothelium was identified as the 
outer surface of the densely packed cell layer. DAPI (blue) counterstained cell 
nuclei. Scale bar = 100 µm. 




The endothelial marker CD31 was used to label construct endothelium using 
immunofluorescence. However, no obvious expression was detected in both native 
valve tissue and constructs using current immunofluorescence protocols. 
Nevertheless, on Western blot CD31 protein was detected in native mitral valve 
tissue and in all constructs examined, but the expression varied between different 








Figure 4.16. Variable CD31 (130 kDa) expression was detected in Type 1 and Type 
2 constructs on protein immunoblotting (Western blot). Samples were collected 
from four separate experiments. Equal amount of total protein was loaded for each 
sample. Native mitral valve (MV) sample served as a positive control. 
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Construct cell phenotype and matrix degradation activity was also assessed using 
Western blot (Figure 4.17). Target protein band intensity did not show substantial 
difference between Type 1 and Type 2 constructs. Semi-quantitative analysis showed 
there was no statistically significant difference (P>0.01) in expression of MMP-1, 


















Figure 4.17. Representative images (results of two experiment runs) of MMVD 
related marker expression in Type 1 and Type 2 constructs on Western blot. 
Healthy and diseased VIC based constructs expressed MMVD associated markers 
MMP-1 (54 kDa), MMP-3 (54 kDa), SMemb (200 kDa) and α-SMA (42 kDa) at 
similar levels (n=4). Vimentin (58 kDa) served as an internal control for cells of 
mesenchymal origin. GAPDH (36 kDa) served as a loading control. Data was 
initially semi-quantified by normalizing protein band intensity of interest to 
GAPDH intensity, then normalised further by calculating the mean value of Type 
2/Type 1 ratio for each marker and the data are presented in the column diagram. 
One way ANOVA analysis (n=4) confirmed that statistically no significant 
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4.3.4 The Ultrastructure of Healthy and Disease VICs Based 
Fibrin/VECs-VICs Co-culture Models 
The ultrastructure of one Type 1 and Type 2 samples was examined by using TEM in 
a limited sample. Cells within both construct types were variable in morphology and 
the proposed construct endothelium appeared to be abnormal, either presenting 
atypical endothelial cells or showing evidence of cell degradation. Cell activation 
and de novo ECM production, as well as cell degeneration was detected in both 
construct types. Incomplete intercellular connections of the VICs were also observed. 
In detail, live cells with variable morphologies were identified in the Type 1 
construct medium contact surface (proposed endothelium). An elongated cell (Figure 
4.18A and B) was found highly activated displaying a complex folded nucleus with a 
high degree of euchromatin and contained large rough endoplasmic reticulum (rER) 
in the peri-nulcear region and substantial mitochondria at one edge. Incomplete 
basement membrane was also seen in the same cell. All the above cellular features 
typically are not seen in endothelial cells. Some ECM components were seen at the 
base of the cell possibly produced by the cell itself. Cell degeneration 
(apoptosis/necrosis) (Figure 4.18C) was also suggested in the proposed endothelium 
layer by the presence of cellular organelle remnants and peripheral chromatin 
aggregation in the cell nucleus. Deep to the cell, there was large accumulation of 
fibril-form ECM interspersed with cellular organelle remnants. The boundary 
between fibrin matrix and cell derived ECM were clearly seen. While in the Type 2 
construct, no cells were observed on the proposed endothelium in the selected area of 




















Figure 4.18. The ultrastructure of proposed endothelium in Type 1 and Type 2 
constructs. A. An elongated active cell was observed in proposed endothelium 
(arrow in A) of the Type 1 construct. The inset image at high magnification showed 
well-developed rER and possibly cell-derived ECM were associated with the cell. 
Accumulation of mitochondria (*in B) and patchy basement membrane (hollow 
arrow in B) were observed in the same cell. Possible cell-derived ECM was seen at 
the base of the cell (M in A); C. Cell degeneration in the proposed endothelium of 
the Type 1 construct. Peripheral chromatin aggregation in cell nucleus was 
observed (arrow in C). Substantial fibril ECM accumulated deep to this cell (M in 
C), with cellular remnants interspersed (CR in C). A clear boundary between fibrin 
matrix and de novo ECM (dash line in C) was observed. In the Type 2 construct, no 
viable cells were present in the proposed endothelium surface (arrow in D), 
however dead cell fragment was seen (CR in D). N, cell nucleus; rER, rough 
endoplasmic reticulum; M, extracellular matrix; CR, cell remnant. Magnification in 
A, 4000 x; in inset image of A and in B, 20,000 x; in C, 5,000 x; and in D, 2,000 x. 
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The VICs in both construct types were variable in morphology, particularly in the 
Type 1 construct. The VIC intercellular connection was commonly seen in the Type 
1 model (Figure 4.19A and B). A ‘lumen’ appearance formed by some connected 
cells may suggest a degree of angiogenic activity. These cells appeared to be highly 
active in matrix synthesis; well-developed rER network was observed and the cell 
was surrounded by ECM elements and patchy basement membrane. The VICs in the 
Type 2 construct were either active or appeared to undergo degeneration. Similar to 
the VICs in the Type 1 construct, not well formed intercellular junctions were seen in 
some cells in close proximity to each other in the Type 2 (Figure 4.19C). Cell 
degradation was noticed within the connected cells. De novo ECM production was 
also seen to be associated with the active cells (Figure 4.19D). Some of the VICs 
were elongated suggesting the presence of a more “smooth muscle” cell phenotype, 
though most cells in the construct were compact. Some degraded cellular fragments 
were observed in both construct types. 
  













Figure 4.19. The ultrastructure of the VICs in the Type 1 and Type 2 constructs. A. 
Intercellular connections were noticed in the Type 1 construct. A ‘lumen’ cell 
arrangement pattern (inset image in B) was observed. The cell in the lumen was in 
apoptosis and the interconnected cells appeared to be highly active. High 
magnification image of the cell in the white box inset is shown in B. Well-
developed rER, ECM synthesis (solid arrows in B) and patchy basement membrane 
(hollow arrow in B) were identified in the cell. C. The incomplete intercellular 
connections of VICs were also identified in the type 2 construct. The upper cell 
(IC1 in C) appeared to have abnormal cellular organelles and vacuolae (arrow in C) 
in cytoplasm indicating degradation. D. Active VICs in the Type 2 construct. A 
large nucleus with high euchromatin/heterochromatin ratio and de-novo ECM 
(arrow in D) was seen in one cell (IC2 in D). Highly attenuated cell morphology 
(IC-SM in the inset of D) suggested a smooth muscle phenotype. IC, interstitial 
cells; N, cell nucleus; rER, rough endoplasmic reticulum; IC-SM, smooth muscle 
phenotype interstitial cell. Magnification in A, 8,000 x; in B 20,000 x; in C 5,000 x; 
in D 7,000 x and in insets, 6,000 x. 
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4.3.5 Cell Activity Assessment in Endothelium Wounded 
Model 
 Gross Morphology Alteration   4.3.5.1
In endothelium wounding experiments, construct morphology altered after 
manipulation on macroscopic evaluation (Figure 4.20). In the wounded/adherent 
experiment (T3-1), Type 3-A constructs contracted usually within one to two days 
after insult, whereas on gross morphology adherent control constructs (Control-A) 
showed consistent morphology over the 6 day period. In wounded/floating 
experiments (T3-2 and T3-3), contraction occurred in both the control (Control-F) 
and wounded constructs (Type 3-F). Similar to the adherent constructs, the most 
dramatic change was in the first two days after detachment and endothelium damage, 
although the floating constructs appeared to have a more curled edge appearance. 





Figure 4.20. Gross morphology of adherent and floating Type 3 constructs and 
controls in culture after manipulation. Control-A construct showed consistent 
morphology during the 6 day period (Row 1). Type 3-A (Row 2), Control-F (Row 
3) and Type 3-F (Row 4) all showed contraction within the first two days.  
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 SMemb Expression in Adherent Wounded Constructs  4.3.5.2
In adherent wounded constructs (Type 3-A), α-SMA and SMemb were evaluated as 
indicative markers for VIC activation on immunofluorescence. Construct samples 
collected at Day 0, Day 1, Day 2, Day 4 and Day 6 were examined. The expression 
of α-SMA was not detected in all construct samples as well as in the positive control 
tissue (diseased canine mitral valve) (data not shown). However, increased SMemb 
expression was observed in Type 3-A constructs collected on Day 1, Day 2 and Day 
6 post wounding. Type 3-A constructs from Day 2 and Day 6 demonstrated most 
prominent SMemb up-regulation (Figure 4.21).  
In details, on Day 0, minimal to weak SMemb expression was observed in both 
Control-A (Figure 4.21A) and Type 3-A constructs (Figure 4.21B), with the latter 
having slightly higher level of expression. No expression was observed in the 
endothelium or wounded surface. On Day 1, SMemb expression in Type 3-A (Figure 
4.21D) appeared to be more intense than Control-A (Figure 4.21C). On Day 2, 
Control-A constructs showed weak to moderate SMemb expression in endothelium 
and construct stroma (Figure 4.21E), while in Type 3-A, higher SMemb expression 
was observed primarily in an area subjacent to the wounded surface (Figure 4.21F). 
On Day 4, limited SMemb expression was observed in both Control-A (Figure 
4.21G) and Type 3-A (Figure 4.21H). On Day 6, SMemb expression was minimal in 
Control-A construct (Figure 4.21I) while the expression in Type 3-A construct was 
much greater particularly in the area closed to the wounded edge (Figure 4.21J). 
Primary antibody omitted negative control for each sample was shown in Figure 
4.22. Only background level of staining was detected with Alexa 568 fluorescent 
antibody alone. 
  




Figure 4.21. SMemb up-regulation in adherent Type 3 constructs. On Day 0, 
minimal to weak SMemb (red) expression was observed in both control (A) and 
Type 3-A (B). On Day 1 slightly higher SMemb expression was observed on Type 
3-A (D) than Control-A (C). On Day 2, Type 3 constructs showed clear up-
regulation of SMemb (F) subjacent to the wounded surface compared to Control-A 
(E). On Day 4, minimal expression was detected in both construct types (G and H). 
On Day 6, higher SMemb expression was observed on Type 3-A particularly 
towards the wounded surface (J) compared to Control-A (I). White arrows 
indicating construct endothelium or wounded surface. DAPI (blue) counterstained 
cell nuclei. Scale bar = 100 µm. 









Figure 4.22. Negative controls for SMemb expression in adherent Type 3 and 
control construct on immunofluorescence. With SMemb primary antibody omitted, 
fluorescence secondary antibody Alexa Fluo568 only stained Control-A (A, C, E, 
G, I) and Type 3-A (B, D, F, H, J) constructs at background level. White arrows 
indicating construct endothelium or wounded surface. DAPI (blue) counterstained 
cell nuclei. Scale bar = 100 µm. 
.  
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 Alteration of Cell Activity on Floated Wounded Constructs 4.3.5.3
To evaluate cell phenotypic activation on Type 3-F constructs, construct protein was 
probed with α-SMA, SMemb and vimentin antibodies using Western blot. Construct 
sample collected on Day 0, Day 2 and Day 6 were analyzed. In general, reduced 
expression of the activated VIC makers SMemb and α-SMA was observed on Day 2 
and Day 6 compared to Day 0 (Figure 4.23.1 and 4.23.2). Vimentin expression was 
in a similar pattern. There were no differences between Control-F and Type 3-F 
constructs. Although protein expression was not identical between two experiments 
(T3-2 & T3-3), α-SMA and SMemb expression was similar in the same sample when 
comparing each sample with Day 0 control (without normalizing to GAPDH) (Figure 
4.23.2).  
GAPDH was used as a loading control for Type 3-F constructs Western blot, 
however it was noticed that the expression of GAPDH was not consistent between 
samples (Figure 4.23.1). When proteins of interest were normalized to GAPDH, 
expression trends altered dramatically compared to data without normalization 
(Figure 4.23.2). Triplicate experiments confirmed GAPDH inconsistent expression 
and the expression pattern was similar in each repeat. This suggested the GAPDH 
inconsistency was less likely due to a technical error. Other common loading control 
proteins such as β-actin and α-tubulin were also tried in the current study (data not 





Figure 4.23.1. Cell phenotypic alteration in floating Type 3 constructs on Western 
blot. Data for construct samples derived from two independent 3D experiments are 
shown (T3-2 and T3-3). A decreasing trend for α-SMA and SMemb expression was 
observed as culture time increased. D0, Day 0; D2, Day 2; D6, Day 6; C, Control-F; 
W, Type 3-F. 












Figure 4.23.2.  Tendency for changes in cell phenotypic markers in floating Type 3 
constructs (Western blot data). Mean value (n=3, n’ indicates the number of the 
construct protein sample in each Western blot experiment) of each sample/Day 0 
control ratio is shown. Consistent with the visual examination of immunoblots, 
there was a decreasing trend observed in α-SMA and SMemb expression in both 
Type 3-F and Control-F constructs at the different time-points. Vimentin expression 
was also decreased. Left panels show neat protein levels, while Right panels shows 
protein levels after normalization to GAPDH.  
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Cell phenotypic markers for Type 3-F and Control-F constructs were identified on 
immunofluorescence. Though expression varied between each individual sample, 
and for 4/12 constructs there was absence of endothelium/dense cellular layer 
making it difficult to identify the construct wound surface, a general description of 
any alteration can be summarized as follows. The overall expression of α-SMA and 
SMemb in floating construct was consistent with Western blot data, however the 
expression patterns were distinct for the two markers. 
On Day 0 Control-F constructs expressed α-SMA in the construct stroma, sub-
endothelial dense cell layer and typically prominent expression was found at the 
SDCLJ (Figure 4.24A). Day 0 Type 3-F constructs exhibited similar α-SMA 
expression pattern to the control and occasional positive cells were also observed on 
the wounded surface (Figure 4.24B). By Day 2 and Day 6, α-SMA positive cell 
numbers were markedly decreased in both Type 3-F and Control-F constructs (Figure 
4.24C-F). At this stage positive cells were mainly distributed in the construct stroma. 
A few positive cells were identified in SDCLJ area in some samples (arrow in Figure 
4.24C). No apparent differential expression was observed between Control-F and 
Type 3-F constructs, except for one wounded sample derived from T3-2 which 
showed prominent expression on the wounded surface and the subjacent area (data 
not shown).  
Primary antibody omitted negative control for each tissue sample is shown in Figure 











Figure 4.24. Expression of the myofibroblast marker α-SMA in floating Type 3 
constructs. Day 0, α-SMA (green) positive cells were evident in both Control-F (A) 
and Type 3-F (B); the expression was most prominent in construct stroma and the 
SDCLJ area. On Day 2 and Day 6, a minority of cells were expressing α-SMA in 
both Control-F (C and E) and Type 3-F (D and F). The staining was randomly 
distributed in the construct stroma. A few positive cells were observed in the 
SDCLJ area in some constructs (arrow in C). Construct endothelium or wounded 
surface was usually identified as the outer surface of the densely packed cell layer. 
For samples where there was complete endothelium or dense cell layer loss, two 
images along the construct long axis were captured (arrows in F indicating 
construct two surfaces parallel to the construct long axis). DAPI (blue) counter-
stained cell nuclei. Scale bar = 100 µm.  
 





Figure 4.25. Negative controls for α-SMA and vimentin immunofluorescence in 
floating Type 3 constructs. With primary antibodies omitted, fluorescence 
secondary antibody Alexa Fluo488 only provided background level staining on all 
samples examined. Construct endothelium or wounded surface was usually 
identified as the outer surface of the densely packed cell layer. For samples where 
there was complete endothelium or dense cell layer loss, two images along the 
construct long axis were captured (arrows in F indicating construct two surfaces 
parallel to the construct long axis). DAPI (blue) counterstained cell nuclei. Scale 
bar = 100 µm. 
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SMemb expression in floating constructs demonstrated a different pattern compared 
to α-SMA on immunofluorescence. On Day 0, SMemb positive cells were found all 
through the construct thickness in both Control-F and Type 3-F (Figure 4.26A and 
B). On Day 2 and Day 6, in the  Control-F, SMemb expression was predominantly in 
the stroma and expression in dense cellular layer became less evident compared to 
Day 0 (Figure 4.26C and E). Whilst in majority of Day 2 and Day 6 Type 3-F 
constructs (n=6/8, ‘n’ indicates the number of the constructs), apart from stroma 
expression, weak to moderate SMemb staining was observed in cells on or close to 
the wounded surface (Figure 4.26D and F).  
SMemb primary antibody omitted negative control for each tissue sample is shown 
in Figure 4.27. Only background level of staining was detected.  
Vimentin positive cells were distributed through the entire construct thickness from 
Day 0 to Day 6 in both Control-F and Type 3-F constructs (Figure 4.28), and the 
staining intensity did not differ appreciably between each time point. However, the 
staining was not uniform in later cultured constructs particularly evident in the 
Control-F constructs, with a number of cells being negative for vimentin staining in 
the dense cell layer which may suggest cell apoptosis (arrow in Figure 4.28E).  
Vimentin primary antibody omitted negative control for each tissue sample is shown 
in Figure 4.25. Only background level of staining was detected in control samples.  
  





Figure 4.26. Expression of the activated mesenchymal marker SMemb in floating 
Type 3 constructs. On Day 0, SMemb (red) expression was evident in the construct 
stroma and dense cell layer subjacent to the endothelium/wounded surface (A, B). 
On Day 2 and Day 6, SMemb expression was primarily observed in the construct 
stroma. Less evident expression (compared to Day 0) was detected in the dense cell 
layer in Control-F at later time points (C, E); while SMemb positive cells were 
found on (arrow point in D) or close to the wounded surface (arrow point in F) in 
several Type 3-F constructs (D, F). Construct endothelium or wounded surface was 
identified as the outer surface of the densely packed cell layer. DAPI (blue) 
counterstained cell nuclei. Inset images, scale bar = 100 µm. Other images, scale 
bar = 200 µm. 
 










Figure 4.27. Negative controls for SMemb immunofluorescence in floating Type 3 
constructs. With primary antibodies omitted, fluorescence secondary antibody 
Alexa Fluo568 only caused background level staining on all samples examined. 
Construct endothelium or wounded surface was identified as the outer surface of 
the densely packed cell layer. DAPI (blue) counterstained cell nuclei. Scale bar = 
200 µm. 





Figure 4.28. Expression of the mesenchymal marker vimentin in floating Type 3 
constructs. From Day 0 to Day 6, vimentin (green) staining intensity was consistent 
in both Control-F (A, C, E) and Type 3-F (B, D, F). It was noticed that a non-
uniform distribution existed in the sub-endothelial dense cell layer (arrow in E, a 
cluster of cells were negative for vimentin), and particularly in Control-F constructs 
at later time points. Construct endothelium or wounded surface was identified as the 
outer surface of the densely packed cell layer. Arrow in F indicating wound surface 
of Day 6 Type 3-F. DAPI (blue) counter-stained cell nuclei. Scale bar = 100 µm. 
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 Correlation of ECM Synthesis and Cell Phenotype in Floating 4.3.5.4
Constructs 
Collagen I&III and MMP-1 expression were assessed in Control-F and Type 3-F 
constructs using immunofluorescence. When evaluating ECM and cell phenotype 
markers on the same floating construct, it was noticed collagen I&III and MMP-1 
expression was not associated with α-SMA positive cells, but in a manner that was 
more similar to SMemb distribution (Figure 4.29). This finding was not evident in 
Day 0 Control-F (standard Type 1 construct) (Figure 4.29D, G, J, M). While in Day 
2 Control-F constructs, where markedly decreased α-SMA staining was observed 
(Figure 4.29H), collagen I&III (Figure 4.29K) and MMP-1 (Figure 4.29N) 
expression appeared to be not affected by this cell phenotypic alteration. Their 
distribution appeared to be more associated with SMemb positive cells (Figure 
4.29E). Examination of cultured Type 3-F (Day 2) constructs showed similar 
findings to Control-F, though SMemb expression was weaker (Figure 4.29F, I, L, O).  
Primary antibody omitted negative control for each specific construct is shown in 
Figure 4.30. Only background level of staining was detected in control samples. 
 
  




Figure 4.29. ECM related proteins and cell phenotypic markers in the same floating 
constructs. One representative construct of Day 0 Control-F, Day 2 Control-F and 
Day 2 Type 3-F are shown. ECM association with cell phenotype was not evident 
in Day 0 Control-F (D, G, J, M), but was in longer cultured floating constructs 
where collagen I&III (red in K, L) and MMP-1 (red in N, O) were more associated 
with SMemb positive cells (red in E, F) than α-SMA (green in H, I). Vimentin 
demonstrated mesenchymal cell distribution in each construct sample (green in A-
C). Construct endothelium or wounded surface was identified as the outer surface 
of the densely packed cell layer. DAPI (blue) counterstained cell nuclei. Scale bar = 
100 µm. 
























Figure 4.30. Negative controls for the three representative constructs shown in 
Figure 4.29 with immunofluorescence. With primary antibodies omitted, 
fluorescence secondary antibody Alexa Fluo568 (A-C) and Alexa Fluo488 (D-F) 
only stained tissue sample at background level. Construct endothelium was 
identified as the outer surface of the densely packed cell layer. DAPI (blue) 
counterstained cell nuclei. Scale bar = 100 µm. 
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4.3.6 The Ultrastructure of Endothelium Damaged Model 
(Floating Constructs) 
The ultrastructure of one wounded floating construct (Type 3-F) and one intact 
floating control construct (Control-F) was examined on Day 0 and Day 6 after injury. 
On Day 0, apart from the wounded area, there was no apparent difference between 
the Type 3-F and Control-F constructs. The proposed endothelial cells and the VICs 
were variable in morphologies and some degree of degradation was seen. On Day 6, 
although both samples possessed multiple layered cell mass at the wound site (in 
Type 3-F) or proposed endothelium (in Control-F), cells at the wounded site showed 
a relatively healthy appearance and were surrounded by ECM. A linear arrangement 
of cells was observed on the surface of the fibrin matrix in the examined Type 3-F 
construct. While in its counterpart, cells were generally in a degradation state in the 
proposed endothelium of the Control-F construct. The VICs in Day 6 Type 3-F 
showed relatively healthy cell profile, however the cell number was small in this 
specimen; in Day 6 Control-F construct, smooth muscle-like cells were observed and 
some of them were in degeneration state, while the others were viable and producing 
ECM. 
In detail, immediately after wounding (Day 0), the proposed endothelium surface of 
the Type 3-F construct was severely damaged with a few cells present. However, in 
some areas of the wound site, a large number of cells with varying morphology were 
observed and most of them contained large vacuoles (Figure 4.31A). Some cells 
showed distended and disrupted mitochondria and a large nucleus with fragmented 
chromatin which was evidence of degradation (Figure 4.31B). While in the intact 
Control-F construct multiple layers of cells were present in the proposed endothelium 
surface with variable morphologies. In some areas this cellular multi-layer was 
mainly consisted of highly degraded cells (Figure 4.31C). Cells in the uppermost 
layer appear to be synthetically active possessing large nuclei, obvious rER and ECM 
production (Figure 4.31D). Moreover, some cells contained filaments not typically 
seen in endothelial cells (data not shown).  












Figure 4.31. The ultrastructure of wound or proposed endothelium of the floating 
Type 3 constructs on Day 0 after manipulation. A. The proposed construct 
endothelium (arrows in A) was destroyed after wounding showing few intact cells. 
In some other areas of the wound (inset in A), multiple layered cells with variable 
morphology were observed most of which contain large vacuoles (dash arrow in the 
inset); B. A cell at wound site showed large nucleus (N in B) with fragmented 
chromatin, distended and disrupted mitochondria (* in B) were also seen. C. 
Multiple-layered cells (MCL in C) were observed on the proposed endothelium 
surface (arrow in C) of Day 0 Control-F construct. Viable cells (* in C) were 
typically lying on the uppermost surface. Most of the cell layers contained highly 
degraded cells. D. Viable cell in proposed endothelium possess large nuclei (N in 
D), obvious rER with evidence of de novo ECM production (M in D). N, nucleus; 
rER, rough endoplasmic reticulum; M, extracellular matrix. Magnification in A, 
2,500 x; in B, 6,000 x; in C, 1,500 x; in D, 8,000x; in inset of A, 2,000 x. 
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The interstitial cells in the construct stroma of both Day 0 constructs varied in 
morphology and some of them showed evidence of degradation (Figure 4.32). The 








Figure 4.32. The ultrastructure of the VICs in Day 0 floating Type 3 constructs. 
Various VIC morphologies were seen in both construct types. For example, 
compact VIC (IC in A) and elongated VIC (IC in B) were present in the Type 3-F 
construct; and pleomorphic VIC (IC in C) and smooth muscle-like VIC (IC in D) 
were observed in the Control-F construct. The presence of electron dense inclusions 
in some cells (arrow in A, C and D) suggested a degraded state. IC, interstitial cell. 
Magnification in A and B, 3,500 x; in C, 6,000 x; in D, 4,000 x.  
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Apparent differences were detected at the construct medium contact surface in the 
Day 6 Type 3-F construct compared to the Control-F. In the Type 3-F construct, 
multiple layers of cells of variable morphologies with no apparent order were 
observed at the wound site (Figure 4.33 A). These cells seemed to be surrounded by 
fibrillar ECM. Interestingly, a group of cells arranged into a monolayer lying at the 
junction between the fibrin matrix and the multiple layered cell mass (Figure 4.33 B 
and C). The monolayer cells possessed large oval nuclei and elongated profiles with 
scant organelles which were broadly fitting with endothelial-like characteristics. The 
fibrin matrix subjacent to these cells displayed an uneven surface indicating 
destruction by the prior wounding procedure. While in the Day 6 Control-F 
construct, multiple layers of cells generally in a degraded state were seen in the 
proposed endothelium (Figure 4.33 D). Most of the cells contain large vacuoles and 
lipid-like inclusion. 
In construct deep stroma of the Day 6 Type 3-F construct, only a few VICs were seen 
in the selected area of the this specimen. The cells generally displayed a relatively 
healthy profile with large nuclei, rich rER plexus and scattered mitochondria (Figure 
4.34 A). Some electron-dense inclusions are seen however, which indicates cellular 
destruction. While in Control-F construct, a number of smooth muscle phenotype 
cells were observed to be in a degraded state (Figure 4.34 B). Despite that, other cells 
remained viable and showed evidence of de novo ECM production (Figure 4.34 C 
and D). The active cells also appeared to be a smooth muscle phenotype, with 
elongated cell shape and some cytoplasmic processes.  
  














Figure 4.33. The ultrastructure of wound site or proposed endothelium in Day 6 
floating Type 3 constructs. Multiple layers of cells (MCL) were observed on the 
upper surface of both Type 3-F (A-C) and Control-F construct on Day 6. A. In the 
Type 3-F construct, cells within the wound site (arrow in A) were variable in 
morphology with no apparent order and, were surrounded by fibril ECM (M in A). 
B. Subjacent to the multiple-layered cells at the wound site (MCL in B), cells (* in 
B) in a mono layer were observed lying on the fibrin matrix (F in B). C. These cells 
possessed large oval nuclei (N in C) and elongated profiles, displaying an 
endothelial-like morphology. The fibrin matrix (F) showed an uneven surface 
which appeared had been destroyed. D. While in the proposed intact endothelium of 
the Control-F construct, majority of cells in the multiple cell layers (MCL in D) 
exhibited a degradation state showing large vacuoles and possible lipid inclusions 
(* in D). N, nucleus; M, extracellular matrix. Magnification in A, 3,500 x; in B, 
2,000 x; in C, 4,000 x; in D, 2,500 x. 













Figure 4.34. The ultrastructure of the VICs in Day 6 floating Type 3 constructs. A. 
A VIC in the Type 3-F construct with large nucleus (N), scattered mitochondria 
(dash arrow), rich rough endoplasmic reticulum (solid arrow) and some electron 
dense inclusion (hollow arrow). B. A VIC in the Day 6 Control-F construct was in 
degeneration state and showing a number of electron dense inclusions (hollow 
arrow). The selected area (in black box) is present in C. The filamentous cytoplasm 
(Cyto in C) of this cell suggested a smooth muscle phenotype. D. A viable cell in 
the Day 6 Control-F construct displayed a smooth muscle phenotype and possibly 
involved in ECM synthesis. Notice the elongated cellular process with longitudinal 
filaments in the cytoplasm (Cyto in D). There was extracellular matrix components 
(M) in proximity to the cell. N, nucleus; Cyto, cytoplasm; M, extracellular matrix. 
Magnification in A, 5,000 x; in B, 6,000 x; in C, 30,000 x; and in D, 40,000 x. 




4.4.1 The Potential for Using Fibrin Based Canine 3D Mitral 
Valve Construct as An In vitro Research Model 
As described in Section 1, though the mainstream of heart valve tissue engineering is 
for clinical transplantation, it can also be used as an in vitro model for heart valve 
research. In the present study, a 3D mitral VECs-VICs co-culture construct was 
developed using fibrin based culture system.  
Theoretically, the most ideal cell source for heart valve regeneration is primary valve 
cells. In native heart valves, the principle cell types are VECs and VICs. Therefore, a 
VECs-VICs 3D co-culture system is expected to at least partially resemble native 
mitral valve. In the present study, healthy VECs-VICs based (Type 1) 3D constructs 
were compared with native canine mitral valves. The 3D constructs possess some 
native valve like features, including tissue-like gross and histological morphology; 
expression of native cell phenotypic markers (vimentin, SMemb and α-SMA) in a 
relatively comparable manner to native valve, and cells in the co-culture constructs 
synthesized some key valve matrix components (collagen and GAGs) and also 
demonstrated ECM degradation capability (collagenase MMP-1 and stromelysin 
MMP-3 expression). These data suggested mitral valve cells in the current fibrin 3D 
model still possessed potential for organizing a native valve structure. The results are 
consistent with a previous study which also showed porcine mitral VECs and VICs 
were capable of synthesizing a native-like ECM profile in vitro (Flanagan et al., 
2006a). Similarly, aortic VICs were also found to synthesize collagenases, 
stromelysins and membrane-type MMPs on a collagen hydrogel system; ECM 
related mRNA was detected in these cells suggesting potential for matrix production 
(Dreger et al., 2006). All above findings indicate that native valve cells are capable 
of conducting ECM synthesis and remodelling in vitro. This is crucial for heart valve 
regeneration, as one of the major concerns in current heart valve tissue engineering is 
whether the seeded cell source could generate sufficient native ECM components to 
replace degraded scaffolds.   
Moreover, the expansive ability of the native mitral valve cells is another positive 
feature which make them attractive cell source for establishing 3D culture models. 
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For example, without excessive sub-culturing (i.e. cells in culture appear to be robust 
and morphologically stable), cells derived from a single middle-sized breed of dog 
mitral valve can contribute to hundreds of static constructs using the current system. 
This can provide substantial numbers of substitutes for native valve tissue which 
could improve a tissue shortage problem for research work. However, particularly in 
the current study design, an issue arose regarding cell availability: there was 
difficulty in getting sufficient number of affected young adults, since most MMVD 
cases develop the disease later in life. To overcome this issue as well as to limit 
potential inherent variability between different dogs (Stephens et al., 2010b; 
Warnock et al., 2006), pooled cells were used in one experiment. When cells were 
pooled, an equal number of cells from each individual cell culture at the same 
passage was used, and excessive passages were avoided (< 7 passages). There was no 
apparently difference in morphology between individual cultures of each group and 
no abnormal cell morphology or behaviour in the pooled cultures. 
Fibrin scaffolds have been widely used in cardiovascular tissue engineering in recent 
years (Flanagan et al., 2007; Jockenhoevel et al., 2001b; Vesely, 2005; Ye et al., 
2000). It serves as an excellent cell supporter as it is favourable for cell distribution, 
cell communication, ECM synthesis and accumulation within the 3D culture system 
(Lee et al., 2008; Pikaart, 2008; Ye et al., 2000). The most common drawback of 
hydrogel systems is cell-mediated contraction and shrinkage. The current constructs 
dramatically decreased in size within a 14 day static culture. VICs are known to have 
contractility and force generation properties, and this might be a contributing factor 
(Filip et al., 1986; Mulholland and Gotlieb, 1997; Smith et al., 2007; Stephens et al., 
2010a). Though altered macromorphology of the construct was not a major concern 
in this study (as current constructs are not used for in vivo implantation), it should be 
noted that VIC induced gel contraction must have effects on matrix configuration 
and feedback to regulate cell behaviour. Another concern for fibrin scaffolds is that 
fibrin is not a native valve ECM component. Valve cells might respond to this 
foreign protein differently than they do to native ECM. This will be discussed in 
Section 4.4.2.  
Chapter 4-Fibrin Based Canine Mitral Valve 3D Constructs in Static Culture 
187 
 
For this study the 3D valve constructs were cultured in a static system. A 3D static 
culture system is superior to 2D culture system in regards to resembling native tissue 
configuration. In native heart valve, VECs and VICs are in a sandwich like structure: 
the VECs line two surfaces of the valve leaflet and cover valve stroma which 
contains dispersed VICs and ECM. The current co-culture model created a fibrin-
VICs based stroma structure with one endothelial surface, which allows VECs and 
VICs interaction within the 3D system. On histological evaluation, cell distribution 
in the intact construct stroma appeared to be uniform. Whereas, towards the medium 
contact surface, densely accumulated cell layers were observed between the fibrin-
VICs stroma and construct endothelial surface. This phenomenon is possibly due to 
imbalanced culture nutrient and gas distribution in the culture system with VICs in 
stroma possibly tending to migrate to the medium contact surface for optimal culture 
environment. One piece of supporting evidence is in Day 0 Control-F construct 
(actually same as Type 1), TEM showed the viable cells tended to situate in the 
upper most surface of the multiple cell layers. This has been described as a common 
limit of static culture systems (Carrier et al., 1999; Kofidis et al., 2003). However, it 
cannot be ruled out that the accumulated cell mass was not from proliferation of an 
endothelial source, since multiple layer endothelium has been observed in previous 
vascular organ in vitro cultures (Gotlieb and Boden, 1984; Lester and Gotlieb, 1988; 
Merrilees and Scott, 1982). Attempts were made using endothelial markers CD31 
and vWF to detect construct endothelial cells by immunofluorescence, but both 
antibodies failed to label either constructs or endothelium of the native valve tissue. 
The endothelium formation on the construct was finally confirmed by DiI-Ac-LDL 
positively labelled live construct surface and CD31 protein expression on Western 
blot. DiI-Ac-LDL positive cells were arranged in a patchy pattern on the constructs 
which suggested uneven endothelium coverage. Additionally, variable CD31 
expression was detected between different batches of constructs. This suggests 
differences may exist between each individual VEC culture for 3D construct 
fabrication. Alternatively it might be a limitation of manual cell seeding techniques 
that resulted in uneven endothelial cell distribution between constructs. Limited 
ultrastructure examination suggested cell degradation was frequent in the static 
cultured 3D construct. It is not certain whether this is a pathological response to the 
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culture substrate (fibrin matrix/tension), or is due to (more likely) poor nutrient/gas 
perfusion. A thinner fibrin based construct is under consideration for future static 
construct experiments, which is predicted to give better gas/nutrient perfusion to 
embedded cells. It would be necessary to carry out cell viability assays in the future 
constructs.   
Investigation of valve cell behaviour in 3D culture system is not a novel concept. The 
early history of 3D culture from the 1980s used valve organ culture systems to study 
valve ECM degradation (Decker et al., 1986; Decker and Dingle, 1982) and mitral 
VIC response to wounding (Lester et al., 1993; Lester et al., 1992; Lester and 
Gotlieb, 1988). With the increased use of tissue engineering technology in 
regenerative medicine, novel TE scaffolds, such as the hydrogel system, were 
adapted to establish 3D research models for heart valve biology and disease study 
(Butcher and Nerem, 2004, 2006; Colazzo et al., 2011; Dreger et al., 2006; Flanagan 
et al., 2006b; Li et al., 2013; Smith et al., 2007). The ex-vivo 3D culture models 
provides opportunities for advanced understanding of valve cell biology and 
pathology, answering questions in heart valve tissue engineering field which will 
eventually benefit heart valve regeneration projects.  
In this study, haemodynamic factors affecting construct behaviour were not 
examined. Future designing of a more optimal tissue engineering mitral valve model 
possibly would use a combination of computed tomography based valve modelling, 
bio-printing valve fabrication and customised dynamic conditioning culture systems 
(Duan et al., 2013; Flanagan et al., 2007; Schaefermeier et al., 2008; Sodian et al., 
2010). 
4.4.2 Healthy and Diseased VICs Showed Similar Activity on 
Fibrin Based 3D VECs-VICs Co-Culture Constructs 
It is still uncertain whether canine MMVD initiates from abnormalities of VICs or 
from damage to the overlying endothelium. It has been proposed that the activated 
VICs in diseased mitral valve may be a primary initiator for pathological change of 
valve ECM structure (Prunotto et al., 2010; Walker et al., 2004). In the current study, 
the expression of a series of MMVD related markers has been compared between 
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diseased VICs and healthy VICs, to see if they contribute differently to expression of 
the selected MMVD markers in an in vitro 3D system. 
α-SMA and SMemb have been considered as hallmarks of transformed VICs and 
both of them are reported to be up-regulated in canine and human MMVD (Disatian 
et al., 2008; Disatian et al., 2010; Han et al., 2008; Rabkin-Aikawa et al., 2004b; 
Rabkin et al., 2001). Using immunofluorescence techniques, a number of α-SMA 
and SMemb positive cells were detected in both healthy and diseased VIC based 
constructs, but no apparent differential expression pattern was observed between 
these two types of models. This suggests the presence of the activated VIC 
phenotype in both models. It was also been noticed that the expression manner of α-
SMA and SMemb appeared to be different from each other: α-SMA was mainly 
expressed by stroma cells with a prominent accumulation in the SDCLJ area, while 
SMemb positive cells were distributed throughout the construct thickness, covering 
stroma, the dense cellular layer as well as surface endothelial cells. The distinct 
expression patterns between α-SMA and SMemb indicates heterogeneity existing 
within the aVICs population. Interestingly, the accumulated α-SMA positive cells 
clustered between the construct endothelium and deep stroma, and is similar to that 
observed in native samples. Even if healthy or diseased, α-SMA positive cells are 
commonly seen in the atrialis or ventricularis layers of heart valves, though with 
disease progression this can extend to the valve stroma (Bertipaglia et al., 2003; 
Chester and Taylor, 2007; Disatian et al., 2010; Han et al., 2008; Mulholland and 
Gotlieb, 1997; Taylor et al., 2003). Native valve α-SMA expression might be in 
response to mechanical stimuli (shear flow) in which cells align in response to flow 
and considering their contractile properties might also generate force to contribute to 
valve mechanical integrity. The origin of α-SMA positive cells on constructs, 
however, was not investigated. There are at least two possible explanations: VICs 
migrating from deep in the construct stroma towards the more optimal culture 
conditions or transformed VECs replenishing VIC population in a manner similar to 
EndoMT seen with embryonic heart valve development (Markwald et al., 1977; 
Oosthoek et al., 1998; Patten et al., 1948; Person et al., 2005). A recent review 
proposed that progenitor cells exist in the adult VEC populations, and that they can 
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replenish sub-endothelial VIC population through an EndoMT process triggered by 
injury or disease (Bischoff and Aikawa, 2011). 
MMPs and their inhibitors play a crucial role in valve ECM remodelling. In the 
previous studies MMP-1 and MMP-3 had been found to be up-regulated in MMVD 
(Aupperle et al., 2009c; Disatian et al., 2008; Obayashi et al., 2011; Rabkin et al., 
2001). MMP-1 is an interstitial collagenase present in heart valves in both normal 
and pathological conditions and mainly functions to cleave collagen Type I, II and III 
(Disatian et al., 2008; Dreger et al., 2002; Visse and Nagase, 2003). The up-
regulation of MMP-1 indicates increased ECM catabolic activity, presumably 
excessive degradation of collagen Type I and III. Considering Type I and III are the 
major collage types in native valve fibrosa, MMP-1 must be one principle proteinase 
that is responsible for destruction of the fibrosa and further tissue weakening in 
MMVD (Prunotto et al., 2010). Extracellular MMP-1 expression was found to 
mainly co-localize with VICs, but occasionally expressed by VECs in both healthy 
and diseased VICs based constructs. Combined with the finding that collagen Type I 
and III are present, it is clear that one of the key native valve ECM remodelling 
function was ongoing in the culture system. Stromyslin-1 MMP-3 activates a number 
of proMMPs including MMP-1 and is also involved in degradation of a range of 
ECM components (Visse and Nagase, 2003). It has been reported to be absent in 
normal canine mitral valve but present in disease valve leaflets (Obayashi et al., 
2011). Moreover, this catabolic enzyme is capable of digesting numerous ECM 
components as well as cleaving fibrin cross-link in vitro (Bini et al., 1996). 
Investigation of this MMP might be particularly important for fibrin gel-based tissue 
engineering constructs when considering achieving a balance between fibrin 
degradation and accumulation of newly synthesized ECM. In the current study 
MMP-3 was not evident in a majority of constructs on fluorescence staining. 
However, Western blot data did suggest the presence of MMP-3 on all constructs 
examined. This indicates potentially fibrin scaffolds can be degraded by native mitral 
valve cells without introducing any external proteolytic enzymes, though the efficacy 
of degradation was unknown.    
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In vivo studies have shown that diseased VICs exhibit excessive synthetic activity 
and transformed phenotypes compared to VICs in healthy mitral valves (Black et al., 
2005; Disatian et al., 2008; Disatian et al., 2010; Han et al., 2008; Rabkin-Aikawa et 
al., 2004b). The selected disease markers were expected to exhibit higher expression 
levels in constructs containing diseased VICs. However, Western blot semi-
quantification data suggested diseased VICs and healthy VICs did not contribute 
differently to all investigated markers the 3D models. Since most of the markers 
were minimally expressed in native mitral valve, clearer presence of them in both 
types of constructs suggests they are more close mimicking a MMVD valve rather 
than a health mitral valve. There are several explanations for this; construct matrix 
and cell source. Healthy VICs might be activated by the fibrin environment. Fibrin is 
not a native ECM component and in response an activated VIC phenotype is needed 
to enable production of MMPs (such as MMP-1 and MMP-3) and TIMPs in order to 
initiate ECM remodelling. Moreover, the fibrin hydrogel system is mechanically 
similar to a GAGs rich environment, which itself is a hallmark of the myxomatous 
valve (Gupta et al., 2009a; Han et al., 2010; Tamura et al., 1995). This “matrix” 
might signal to cells that they are in a pathological condition, triggering ECM 
remodelling. Substrate stiffness is also known to contribute to VIC activation (Kural 
and Billiar, 2013; Pho et al., 2008). For the cell source, the diseased VICs were 
derived from valves with mild to moderate MMVD lesions only, with cells from 
severe diseased valves not being investigated. It is possible that many VICs from 
mildly diseased valves would behave similarly in culture as those derived from 
healthy valves. One previous study compared TGF-β1 effects on canine healthy 
VICs compared to VICs from mild disease in a collagen gel compaction study and 
there was no evident differential response was observed (Waxman et al., 2012). 
Apart from the markers evaluated, other markers were also found to associate with 
MMVD (all summarized in Table 4.4). Due to time limitations, it is not possible to 
assess all the markers in the models. One important consideration that needs to be 
investigated in future studies is the potential effect of diseased VICs on healthy 
VECs. The pilot ultrastructure EM analysis suggested abnormalities existed in the 
proposed endothelium of these constructs, with atypical endothelial features and cell 
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loss somewhat similar to that observed in native MMVD (Corcoran et al., 2004; Han 
et al., 2013). Future work will evaluate endothelial function and it particular the 
question of whether the endothelium damage in MMVD is a cause or a consequence 
to sub-endothelial VIC activation.   
In summary, a MMVD-like 3D construct was obtained using either healthy or 
diseased canine mitral valve cells, and this could be a potential model for disease 
studies. For future work, studies on the combination of the current models with 
customized bioreactor maintained dynamic conditioning on construct morphology 
will be needed, and the specific effects of drugs and/or chemical components 
associated with MMVD (such as advanced glycation end product) will be 
investigated.  
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Table 4.4 MMVD associated marker review  
Category                                      Marker Roles in MMVD 
Gene Protein 
Regulation References Alteration References 
Endothelial 
function 
Endothelin-1  receptor   ↑ (Mow and Pedersen, 1999) 
Endothelin-1 ↑ (Oyama and Chittur, 2006)   
Nitric oxide synthase: ↑ (Oyama and Chittur, 2006) ↑ (Olsen et al., 2003b) 
Activated VIC 
phenotype 
α-SMA   ↑ (Rabkin et al., 2001) 
SMemb   ↑ (Rabkin et al., 2001) 
ECM components Collagen Type I   ↑ (Aupperle et al., 2009a) 
(Cole et al., 1984) 
Collagen Type III   ↑ (Aupperle et al., 2009a) 
(Cole et al., 1984) 
Collagen Type V   + (Aupperle et al., 2009a) 
↑ (Cole et al., 1984) 
Collagen Type VI   ↑ (Aupperle et al., 2009a) 
Fibronectin   ↑ (Aupperle et al., 2009a) 
laminin   ↑ (Aupperle et al., 2009a) 
proteoglycans Total   ↑ (Aupperle et al., 2009a) 
(Kogure, 1980) 
(Han et al., 2010) 
Biglycans   ↑ (Gupta et al., 2009a) 
 Decorin   ↑ (Gupta et al., 2009a) 
Versician   ↑ (Gupta et al., 2009a) 
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Table 4.4 MMVD associated marker review-continued with previous page 
 
Category Marker Roles in MMVD 
Gene Protein 
Regulation References Alteration References 
MMPs and TIMPs MMP-1 ↑ (Aupperle et al., 2009c) ↑ (Rabkin et al., 2001) 
(Disatian et al., 2008) 
MMP-2 No change (Aupperle et al., 2009c) 
(Oyama and Chittur, 2006) 
↑ (Rabkin et al., 2001) 
↓ (Aupperle et al., 2009b) 
MMP-3   + (Obayashi et al., 2011) 
MMP-9 No change (Aupperle et al., 2009c) 
(Oyama and Chittur, 2006) 
↑ (Rabkin et al., 2001) 
- (Aupperle et al., 2009b) 
MMP-13 No change (Oyama and Chittur, 2006) ↑ (Disatian et al., 2008) 
(Rabkin et al., 2001) 
MMP-14 ↑ (Aupperle et al., 2009c) ↑ (Aupperle et al., 2009b) 
TIMP-1 ↑ (Oyama and Chittur, 2006)   
TIMP-2 ↑ (Aupperle et al., 2009c) ↑ (Aupperle et al., 2009b) 
TIMP-3 ↑ (Aupperle et al., 2009c) ↑ (Aupperle et al., 2009b) 
TIMP-4 ↑ (Aupperle et al., 2009c)   
Serotonin pathways 5-Hydroxytryptamine 
receptor 2B (5-HT2B) 
↑ (Oyama and Chittur, 2006)   
Tryptophan hydroxylase 1 
(TPH1) 
  ↑ (Disatian et al., 2010) 
TGF-β3   + (Obayashi et al., 2011) 
TβR II   + (Obayashi et al., 2011) 
+, presence; -, absent
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4.4.3 Mechanical Stresses Regulate VICs Activity on Fibrin 
Based 3D VECs-VICs Co-Culture Constructs 
A potential cause of MMVD is a response to valve endothelium injury. An in vitro 
valve endothelium damage model was generated based on the fibrin 3D co-culture 
constructs, to investigate effect of endothelium injury as well as altered culture 
substrate stiffness on 3D cultured valve cells.  
With endothelium damage, there was an overall up-regulation of SMemb expression 
towards the wounded endothelial surface on adherent Type 3 (Type 3-A). On floating 
Type 3 (Type 3-F), however, overall SMemb protein expression in the constructs 
was decreased, but SMemb positive cells were still observed on the wounded surface 
of most samples. While in their counterparts (floating entire controls i.e. Control-F), 
SMemb expression was decreased on the endothelial aspect. The partial TEM results 
suggest this SMemb reduction might due to cell degradation). Overall, these results 
suggested VIC activation occurred in the wounded model and SMemb positive cells 
are presumed to be one of the important sub-population of aVICs in valve injury 
repair. Interestingly, the other common aVIC marker α-SMA, no evident differential 
response was observed between floating Type 3 and the control construct at Day 2 
and Day 6 after wounding. This further suggests distinction existing between α-SMA 
and SMemb positive cells.  
The ultrastructure analysis on EM showed that there were viable cells surrounded by 
ECM at the 3D construct wound site at 6 days after damage. Moreover, a monolayer 
of cells were observed on the uneven fibrin matrix surface which might indicate cell 
migration from the deeper stroma. Although the cells were displaying an elongated 
endothelial-like morphology, the true identity of them requires further investigation. 
Since the above features were absent in the intact control construct (which was 
generally showing a cell-degraded endothelium), it can be proposed a wound repair 
process might be occurring in the damaged construct, possibly involves cell 
migration, and proliferation and ECM production. In previous studies using valve 
organ culture or standard cell culture techniques, mitral VICs have been found to 
have wound repair ability, in response to trauma (Durbin et al., 2005; Gotlieb et al., 
2002; Lester et al., 1993; Lester et al., 1992; Tamura et al., 2000). By damaging 
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porcine mitral valve endothelium with linear wounds, VIC proliferation and 
migration was observed over a 6 day period in native valve explants (Lester and 
Gotlieb, 1988). VIC repairing processes were found to be associated with a number 
of cytokines, including FGF-2 (Gotlieb et al., 2002), NO (Durbin et al., 2005) and 
integrin (Fayet et al., 2007). The ECM component fibronectin has also been found at 
wounded sites (Fayet et al., 2007). This suggests, apart from cell proliferation and 
migration, VICs with a secretory phenotype are also involved in regulating wound 
healing. Durbin and Gotlieb (2002) suggest VIC response to valve injury, similarly 
to a vascular repair process (Clowes et al., 1983; Koo and Gotlieb, 1991), might be a 
cooperative process conducted by both motile and secretory VICs. In the early 
repairing stage, elongated VICs migrate towards wounds and proliferate; while in a 
second stage, cobblestone shape VICs secrete ECM and metabolic enzymes at the 
wounding edge while cell migration and proliferation are probably reduced by that 
point (Durbin and Gotlieb, 2002). This could explain the differences in α-SMA and 
SMemb positive aVICs observed in this study. It has been shown that the α-SMA 
phenotype is responsible for VIC migration, contractile function and force generation 
(Lester et al., 1993; Stephens et al., 2010a). However, the earliest possible response 
of VICs to endothelium damage (from Day 0-Day 2) was not examined in current 
study. And it is possible α-SMA protein up-regulation was missed in the damaged 
constructs. Apparent construct contraction ceased by Day 2 after injury, which might 
indicate cell mediated contractile activity may decrease after Day 2. Tracing changes 
in α-SMA expression at earlier time points in the future would be worthwhile. 
The exact function of SMemb is not known. As mentioned before, this non-smooth 
muscle myosin has been identified in embryonic vascular tissue including foetal 
mitral valves (Aikawa et al., 1993; Kuro-o et al., 1991). It has also been described as 
a molecular marker of undifferentiated or synthetic type smooth muscle cells (Kuro-o 
et al., 1991). In normal adult heart valves, SMemb expression is minimal and it has 
been considered as a marker of mesenchymal cell activation (Disatian et al., 2008; 
Rabkin-Aikawa et al., 2004b). In Section 3, SMemb expression was demonstrated in 
2D cultured VEC and VICs. In current endothelium injury model, SMemb positive 
cells were identified at sites close to the wounded area, moreover, their distribution 
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pattern matched that for collagen Type I and III and MMP-1, which suggests this 
phenotype might be more associated with ECM synthesis comparing to the α-SMA 
phenotype. This finding is consistent with previous studies by Disatian and 
colleagues, in which SMemb and α-SMA expression patterns were distinctly 
different and SMemb appeared to be more related to synthetic activity (Disatian et 
al., 2008; Disatian et al., 2010).  
Valve cell-matrix mechanical interactions have attracted great attention recently 
(Balachandran et al., 2011; Blevins et al., 2008; Gupta et al., 2008b; Stephens et al., 
2010b; Waxman et al., 2012). In the current study, detachment of the polystyrene 
substrate lead to decreased α-SMA and SMemb expression in the constructs. This 
effect appears to be dominant to that of endothelium wounding as it was apparent no 
matter whether endothelium damage was performed i.e. total SMemb and α-SMA 
deduction was observed in both Type 3-F and Control-F constructs. The similar 
decreasing trends between SMemb and α-SMA expression on Western blot suggest 
there might be a co-expression of these two cellular markers. A decrease in vimentin 
expression was also observed in floating constructs by Western blot and the EM 
analysis showed evident cell degradation in longer cultured floating constructs 
particularly in the proposed endothelium. These results indicate a decreased 
mesenchymal cell proliferation or presence of cell apoptosis. It might be argued that 
the reduced α-SMA and SMemb expression may be a pure result of total cell loss. 
However, it is unlikely to be the case. Immunofluorescence result showed the 
majority of cells on floating constructs were clearly positive for vimentin from Day 0 
to Day 6 after manipulation. Therefore, cell death or decreased cell growth on 
constructs cannot fully explain the apparent loss of cell phenotypic activation. A 
more likely explanation is that with decreased external mechanical tension, VICs in 
the constructs transformed from an activated contractile phenotype to a more 
quiescent phenotype or a secretory phenotype (analogue to reversal of MMVD to a 
normal valve). Rabkin-Aikawa and colleagues have proposed a hypothesis regarding 
reversal of VIC plasticity (Rabkin-Aikawa et al., 2004b; Rabkin-Aikawa et al., 
2005). They suggest during disease or physiological remodelling processes (‘a new, 
altered mechanical environment’), VICs tend to be activated and adapt to the new 
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environment in both biological and mechanical functions. When a new equilibrium is 
achieved, they will transform back to a quiescent phenotype (Rabkin-Aikawa et al., 
2004b; Rabkin-Aikawa et al., 2005). They observed in tissue engineered heart 
valves, VICs transformed gradually from a myofibroblast phenotype into fibroblast 
phenotype, particularly after 16-20 weeks in vivo remodelling at ovine pulmonary 
valve site (Rabkin et al., 2002). It is known that VICs are responsive to substrate 
stiffness (Kural and Billiar, 2013; Stephens et al., 2011; Stephens et al., 2010b). With 
exogenous mechanical force or high culture substrate stiffness, α-SMA expression 
was found to increase in vascular smooth muscle cells and aortic VICs in 3D culture 
systems (Kural and Billiar, 2013; Pho et al., 2008). Presumably decreased 
mechanical tension in the current model modulated the contractile myofibroblasts to 
a more quiescent phenotype or secretory phenotype. This assumption is supported by 
TEM images on Day 6 Control-F construct, where some smooth muscle-like VICs 
were degrading while the others were viable and synthetically active.  
The reversible phenotype plasticity of mitral VIC has been investigated in other 3D 
culture models. In a 3D collagen matrix culture system, 15% cyclic strain tended to 
regulate MMVD VICs from myofibroblast to fibroblast phenotype (Waxman et al., 
2012). Reversible GAG production by porcine mitral VIC was observed in another 
collagen hydrogel model, in which GAG level is up-regulated with cyclic stretch and 
decreased with subsequent relaxation (Gupta et al., 2008a). All these data suggest 
mitral VICs are responsive to mechanical stimulation in both phenotype and 
synthesis activity. 
There are several limitations to current study. Firstly, in the adherent Type 3 study, it 
was noticed that the construct fluorescence staining was affected by tissue fixation 
methodology. Four hour fixation in Methacarn fixative at room temperature (e.g. 
Day 2 samples) was found to be superior to 24 hour fixation at 4°C (e.g. Day 4 
samples). Antigen epitope appeared to be masked in the tissue sample fixed for 24 
hours. Control and wounded samples at each time point were collected and fixed 
using the same methodology therefore comparison results were still valid. Variation 
in construct morphology within the same group was another issue observed in T3-1 
experiment. In the later floating construct study design, sample number was 
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increased at each time point (n=2 instead of n=1) to reduce the effect of individual 
sample variation. Reasonable consistency was achieved between individual batches 
of floating constructs. Moreover, the absence of α-SMA in all Type 3-A samples as 
well as in diseased mitral valve may be due to a technical issue possibly related to 
fixation methodology or primary antibody concentration. Further optimization would 
be necessary to resolve this issue. Secondly, the floating constructs were not planned 
in the original study design. However, in the second wounding experiment, when 
conducting endothelium damage, occasionally wounded constructs detached from the 
culture plate. This is considered to be a limitation of the manual damage techniques 
used. For future fabrication of Type 3-A construct, tissue stabilizing device (such as 
sterilized pins) would be necessary to use during the wounding procedure or an 
alternative damage method devised. Lastly, the ECM response to injury were not 
systemically evaluated, although collagen I and III and MMP-1 production appeared 
to be not affected by reduced α-SMA expression on immunofluorescence. Future 
investigation in assessing ECM related markers (such as MMP-1, MMP-3 and 
fibronectin) and known cytokines modulating VIC wound repair (such FGF-2, NO 
and integrin) would be necessary. Multiple immunofluorescence staining techniques 
possibly would help to get better understanding of the correlation between cell 
phenotypic and synthetic activation. Moreover, a direct assessment of cell migration 
(e.g. scanning electron microscopy), proliferation marker expression (e.g. Ki-67) 
(Disatian et al., 2008) and cell viability will also be useful to get a more complete 
image of VIC response in the current Type 3 model.  
4.5 Conclusion 
In summary, fibrin based 3D co-culture models were successfully generated using 
canine primary mitral valve cells and it is believed they are promising tools for valve 
cell biology and MMVD pathogenesis research.  
Under static culture condition, fibrin/VECs-VICs 3D co-culture constructs assembled 
into a form more reminiscent of MMVD rather than a healthy valve, regardless if the 
VIC source was from healthy or diseased valves. This model, therefore, could be 
used to examine processes that might drive disease reversal. Mechanical stimulations 
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appeared to have apparent effects in modulating VIC phenotypes. In constructs with 
endothelium loss, cells appeared to have increased SMemb expression, which 
indicates cell activation occurred in response to the stimuli. Whereas in constructs 
challenged with endothelium injury combining decreased mechanical tension, overall 
SMemb and α-SMA expression were down-regulated. These suggest cells in 
constructs can undergo phenotypic transformation. The ultrastructure analysis 
suggests there was a degradation of some smooth muscle-like VICs when the 
mechanical tension decreased, but other cells were viable and participating in ECM 
synthesis. Moreover, it was noted that collagen Type I and III and MMP-1 
expression was more associated with SMemb positive cells than α-SMA cells. This 
finding indicates heterogeneity existing in the aVICs population, and the SMemb 
positive cell population might be involved in ECM synthesis and catabolism. 
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Chapter 5: Tissue-Engineered Mitral Valve 
Tubular Construct Models under Dynamic 
Conditioning 
Abstract  
Tissue engineering has become an important technology recently in the field of heart 
valve regeneration. An application of this technology in establishing in vitro 3D 
research models has been considered as being of great value in contributing to the 
understanding of valve biology and pathology. In this study, the aim was to generate 
a tubular canine mitral valve construct using tissue engineering techniques. To date 
the feasibility of fabricating a prototype fibrin based mitral valve tubular construct, 
as well as construct endothelialisation has been determined. A customised bioreactor 
system has been designed to use for future dynamic conditioning. These preliminary 
data establish a foundation for future experiments and the model will be of benefit in 
researching of MMVD pathogenesis.  
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5.1 Introduction 
Tissue engineering (TE) has recently become an important technology in the field of 
heart valve regeneration. Using a variety of cells, tissue scaffolds and bioreactor 
systems, attempts at developing tissue engineered valves have been made by research 
groups worldwide (Baraki et al., 2009; Flanagan et al., 2009; Jockenhoevel et al., 
2001a; Kim et al., 2001; Shinoka et al., 1995; Steinhoff et al., 2000). Although 
substantial efforts have been made in artificial heart valve development, only a few 
have been applied to clinical usage in human medicine and the results have been 
controversial (Konertz et al., 2005; Simon et al., 1993). Inadequate understanding of 
valve cell biology as well as tissue ex-vivo development influences the progress of 
valve tissue engineering (Butcher and Nerem, 2006). Therefore, artificial three 
dimensional (3D) tissues have been proposed to be used as pre-clinical research 
models for answering fundamental questions of tissue physiology and 
pathophysiology in vitro (Gibbons et al., 2012; Griffith and Swartz, 2006).  
Mitral valve tissue engineering has been investigated less compared to the aortic and 
pulmonic valve, mainly due to the complexity of the mitral valve apparatus (Black et 
al., 2009; Grande-Allen and Liao, 2011). Previous studies related to mitral valve 
tissue engineering mainly includes investigation of mitral valve cell biology and 
mechanobiology (Flanagan et al., 2006a; Grande-Allen and Liao, 2011), heart valve 
embryonic development biology and signalling pathways (Butcher and Markwald, 
2007; Chiu et al., 2010; Stock and Vacanti, 2001), and bioreactor system 
development of mitral organ cultures in vitro (Barzilla et al., 2010; Gheewala and 
Grande-Allen, 2010; Lieber et al., 2010). To our knowledge, so far there have been 
no reported studies investigating the pathogenesis of myxomatous mitral valve 
disease (MMVD) utilising a tissue-engineered mitral valve model.  
Canine MMVD is the most common cardiac disease in dog and the pathogenesis of 
this disease is not fully understood. A popular hypothesis of MMVD is long term 
shear stress of the valve leaflet causing valve endothelium denudation, which triggers 
sub-endothelial valve interstitial cell (VIC) activation and further extracellular matrix 
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(ECM) remodelling (Corcoran et al., 2004; Durbin and Gotlieb, 2002; Pedersen and 
Haggstrom, 2000; Prunotto et al., 2010; Stein et al., 1989). In this study, we aimed to 
develop a fibrin based canine mitral valve tubular construct using tissue engineering 
technology, that could be used to test the shear stress hypothesis in the aetiology of 
MMVD.  
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5.2 Materials and Methods 
5.2.1 Fibrin Based Mitral Valve Tubular Construct Fabrication 
Fibrin based canine mitral valve constructs were produced using a similar moulding 
methodology previously described for a vascular structure fabrication (Tschoeke et 
al., 2009). Details of protocols have been covered in Section 2.10.1 and 2.10.3. The 
cell source used for tubular construct generation was identical to the cultures used 
previously for 3D static cultures as described in Section 4. The schematic image in 
Figure 5.1 illustrates the fabrication process and the key devices involved in 
construct production are shown in Figure 5.2. The tubular construct mould and the 
medium reservoir for construct culture were kindly provided by the collaborators in 
RWTH Aachen University, Germany. Fabricated constructs were cultured in a 30 
rpm continuous flow circulation system (Figure 5.3) for one week before 






Figure 5.1. Schematic illustration of fibrin based canine mitral valve tubular 
construct fabrication process. Similar to static constructs, fibrin/VICs hydrogel was 
first generated in a dual cylinder mould (Figure 5.2 B). Endothelial cells were 
subsequently seeded on the luminal surface of the tubular constructs by manual 
rotation (Figure 5.2 D). Fabricated constructs were removed from the mould and 
transferred to a low rate flow circulation system (Figure 5.3) and cultured for one 
week before measurement and evaluation. 
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Figure 5.2. Key equipment for canine mitral valve tubular construct fabrication. A. 
Dual chamber syringe was used for simultaneously injection of VICs suspension/ 
thrombin/CaCl2 and fibrinogen. A customised syringe was used in the current 
experiments (syringe on bottom) and a commercial product will be used in future 
fabrication (inset photo, kindly provided by Dr Tom Flanagan, University College 
Dublin, Ireland). B. Customised silicone moulding device composed of a sealing 
cap, a core cylinder and outer cylinder with lumen. C. Fibrin/VICs gel moulding 
process. Mixed solutions were injected in the mould lumen space at a constant 
speed (image was provided by RWTH Aachen University, Germany). D. 
Customised endothelial seeding device. Inner cylinder was removed subsequent to 
fibrin/VICs hydrogel polymerization, VEC suspension was added to the construct 
lumen (dash arrow in D) and filled up to the top of the mould. Seeding device was 
sealed with a T80 flask filter cap and secured with parafilm (solid arrow in D). The 
device was placed in standard tissue culture incubation and rotated by 90
o
 (in first 
experiment) or 45
o
 (in second experiment) every 15 min for 2 h or 4 h respectively 
following marked directions on the cap.  
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Figure 5.3. Equipment for canine mitral valve tubular construct culture at low rate 
flow circulation system. After endothelial cell seeding, constructs were removed 
from the mould and placed on a 5 ml supporting syringe to prevent collapsing. The 
tubular construct was then transferred to a sterile reservoir containing bioreactor 
culture medium and connected to a MCP process pump by rubber and silicone 
tubes. A sterile 0.2 µm venting filter was placed on the cap of the medium reservoir 
to allow gas exchange in the culture system. One direction continuous flow was set 
at a rate of 30 rpm. The assembled culture system was kept in a standard tissue 
culture incubator for 7 days.  
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5.2.2 Constructs Evaluation 
 Construct Contraction Assessment 5.2.2.1
After 7 days low rate flow circulation culture, constructs were harvested and 
measured for length, thickness and lumen diameter using an electronic vernier 
caliper. These parameters were compared to values obtained on Day 0 culture (right 
after fabrication). Details of the measurements are described in Table 5.1.  
Table 5.1 Measurement of tubular construct length, thickness and lumen diameter 
Construct Length Thickness Inner diameter 
Day 0 Direct 
measurement 
Indirect measurement 
=½ (mould outer cylinder 
inner diameter – mould 
inner cylinder diameter) 
Indirect measurement 
= mould inner cylinder 
diameter 
Day 7 Direct 
measurement 
Direct measurement Indirect measurement 
= supporting syringe 
diameter 
 
 Endothelium Formation Assessment 5.2.2.2
Harvested tubular constructs were divided in to three parts and a 0.5 mm length 
tissue ring of the middle third of the construct was used for endothelium assessment. 
The ring was cut vertically and dissected into two strips. Luminal surface of 
construct strips was incubated with 0.5-1 ml diluted DiI-Ac-LDL for 4 h at 37°C and 
5% CO2, rinsed with 3 x 5 times sterile PBS and transferred construct strips to an 
invert glass slide for confocal microscopy (with endothelium side facing down). 
Constructs were maintained in small amount of sterile PBS during analysis. All 
treatments were carried out in a dark room to reduce light exposure. Stack images 
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were captured with Zen imaging software and the maximum intensity image is 
presented in Section 5.3.2. 
5.3 Results 
5.3.1 Tubular Construct Gross Morphology and Contraction 
Assessment  
The current study demonstrated the feasibility of utilizing canine mitral VECs and 
VICs to fabricate a tubular construct. Constructs (n=2, ‘n’ indicates the number of 
construct fabrication experiment) cultured under low rate flow circulation were 
harvested on Day 7. They dramatically had shrunk in size and became less 
transparent compared to Day 0 (Figure 5.4). The length, thickness and inner diameter 
values of the two constructs are summarized in Table 5.2. After 7 days culture, the 
constructs showed a  29.1% and 33.7% decrease in length, 55% and 69% decrease in 
thickness and 0.7% decrease in inner diameter respectively. 
 
  
Figure 5.4. Mitral valve tubular construct morphology on gross inspection. 
Construct at 7 day culture (B) shrank in size compared to Day 0 culture (A), and 
demonstrated a more tissue-like less translucent appearance.  
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Day 0 30.6 2.0 16.1 
Day 7 20.3 0.9 15.5 










Day 0 36.5 2.0 16.1 
Day 7 29.5 0.62 15.5 
Ratio (Day 7:Day 0)  80.9% 31% 96.3% 
 
5.3.2 Construct Histology and Endothelium Formation 
Assessment  
Cultured tubular construct showed tissue-like morphology on histology (Figure 5.5). 
Compared to static constructs (Figure 4.9), cells on tubular construct were more 
evenly distributed and a sub-endothelial dense cell-matrix layer was not observed. A 
number of lacunae were found interspersed between stromal cells, which may be 
caused by cell loss. Monolayer cells were found to line the construct luminal surface, 
however the coverage was not even between different areas within the same 
construct (Figure 5.5 B and C) 
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Tubular construct endothelium was assessed by up-take of DiI-Ac-LDL. Uneven 
positive cell coverage was observed on the luminal surface of both constructs 
examined (Figure 5.6).  
  
Figure 5.5. Histology of fibrin based mitral valve tubular construct cultured under a 
low rate continuous flow conditioning. Construct lumen surface is indicated by 
solid arrows. A. compared to static constructs in culture plate (Figure 4.9), the 
tubular construct demonstrated more even cell distribution and the sub-endothelial 
dense cell-matrix layer of the static construct was not observed in the tubular 
construct. B. cavernous areas were found in valve stroma (dash arrow). C. A 
monolayer of cells was observed on part of the construct luminal surface (presumed 
endothelium). Scale bar in A = 400 µm; scale bar in B and C =100 µm. 
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Figure 5.6. DiI-Ac-LDL labelled endothelial cells in one tubular construct luminal 
surface. Three separate area as shown in A, B and C. Uneven endothelial cell 
distribution was observed between different areas of the construct. Magnification x 
200. 
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5.4 Discussion and Future Plan 
The study design of the dynamic conditioned tubular construct comprises two stages 
and is shown in detail in Table 5.1. Results of the fabrication of the tubular construct 
in Stage 1 are presented in the current chapter, due to time constraints the results of 
Stage 2 have not been presented as part of this thesis and further work is planned and 
discussed in Section 5.4.2 and 5.4.3.    
Table 5.3 Study design of dynamic conditioned tubular construct experiments 
Stage Experiments 
Stage 1 Preparation for dynamic conditioning: testing the feasibility of 
generating a mitral tubular construct by using canine primary 
mitral valve cells and evaluating construct shrinkage and 
mechanical properties when cultured in a low rate flow circulation 
system for a 7 day period; and designing of a customised 
bioreactor system for Stage 2 pulsatile flow conditioning. 
Stage 2 Applying dynamic conditionings to the tubular constructs. Three 
types of construct models will be generated: 
Dynamic Type 1 (pulsatile control)-constructs cultured in low rate 
flow loop for 14 days, which serve as ‘static’ controls for pulsatile 
flow conditioning; 
Dynamic Type 2 (physiological model)-constructs cultured in 
pulsatile flow condition in the bioreactor system for 14 days; 
Dynamic Type 3 (pathological model)-damage luminal 
endothelium of Dynamic Type 2 constructs and condition the 
constructs within the pulsatile flow bioreactor for another 7 days. 
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5.4.1 Development of A Fibrin Based Prototype Valve Tubular 
Construct  
To date, a prototype valve tubular construct model using primary canine mitral valve 
cells has been generated. Preliminary data has shown the feasibility of tubular 
construct fabrication. Histologically morphology of the construct under low rate 
continuous flow conditioning demonstrated tissue-like morphology and relatively 
even cell distribution throughout the constructs. A number of lacunae existed in 
construct stroma possibly due to cell loss. This incidence of this phenomenon might 
be reduced or prevented by dynamic conditioning as it has been shown that this can 
enhance cell adherence to tissue engineering substrates (Flanagan et al., 2007; 
Schenke-Layland et al., 2003). By using a customised manual cell seeding device, 
endothelial lining of the construct lumen was partially achieved. The uneven 
endothelial cell distribution in the current method is not ideal. Dynamic seeding at 
low rotating speed would likely improve endothelial surface seeding (Flanagan et al., 
2009; Lichtenberg et al., 2006; Tschoeke et al., 2009), which will be carried out in 
future experiments.  
Cell contractility mediated construct shrinkage as well as tissue weakness are 
common concerns in hydrogel based tissue-engineered structures (Jockenhoevel et 
al., 2001b; Mol et al., 2005). In the current study design it was essential to obtain a 
tubular construct with relatively stable structure geometry and tissue strength prior to 
dynamic conditioning. Therefore, the shrinkage of the fibrin based tubular constructs 
was initially evaluated after a 7-day period low rate flow circulation culture. Pilot 
results from the two tubular constructs demonstrated that the construct contraction 
occurred in three dimensions: construct size decreased in length, thickness as well as 
luminal space. The ratios of construct parameters on Day 7 compared to Day 0 were 
fairly consistent between the two experimental runs: approximate 30% decrease in 
length (29.1% and 33.7% respectively) and 60% decrease in thickness (55% and 
69% respectively). The shrinkage extent of constructs provides guidance for 
optimizing mould choice, as an appropriate construct configuration will be necessary 
for cyclic motion in the pulsatile flow bioreactor system. Moreover, in the future, it 
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will be necessary to test tissue strength of the tubular constructs prior to dynamic 
conditioning to get an idea of the maximum force the fibrin construct can withstand 
(Tschoeke et al., 2008).   
5.4.2 Design of a Customized Bioreactor for Dynamic 
Conditioning  
A bioreactor system for dynamic conditioning has been designed and produced by 
collaborators in RWTH Aachen University, Germany. The main body of the 
bioreactor is a silicone chamber (Figure 5.7A). It connects with a medium reservoir 
(Figure 5.7E) and a MCP processing pump (Figure 5.7D). Biochemical and flow 
mechanical parameters in the culture system can be programmed by a computer 
(Figure 5.7B) and monitored through a sensor (Figure 5.7C). By generating pulsatile 
flow with the pump, the flexible opening of the tubular construct (demonstrated by a 
plastic tube model in Figure 5.7A-1-3) is expected to open and close in response. 
This imitates native mitral valve motion in the systolic and diastolic phase of the 
cardiac cycle in vivo. 
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Figure 5.7. A bioreactor system (model) provides dynamic conditioning for a 
tubular construct. The customised dynamic conditioning system is composed of a 
MCP process pump (D) for generating cyclic flow, a bioreactor chamber (A) for 
construct culture, a medium reservoir (E) for nutrient supply and gas exchange, a 
sensor (C) and a computer (B) for culture condition monitoring and parameter 
control. The movement of the construct is expected to mimic native mitral valve 
movement during the cardiac cycle. An open-close-open cyclic motion (A-1-3) is 
demonstrated by a plastic tube model and the images are from a video file provided 
by collaborators in RWTH Aachen University, Germany. Arrows in A-1-3 
indicated two mental stands which are supporting the plastic tube model to avoid 
collapsing. 
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Details of the planned design of the tubular constructs under dynamic culture 
conditions are summarized as follows: one opening of the tubular construct will be 
sutured to the silicone tube base of the bioreactor. The distal one third of the 
construct relative to the suture ring will represent mitral valve leaflets and the 
remainder will represent the left atrial wall (Figure 5.8). The distal one third flexible 
opening of the construct will mimic valve leaflet motion during the cardiac cycle. 
The luminal aspect of the construct represents the atrial part of the valve leaflet and 
the outer part of the construct the ventricular aspect of the valve leaflet. The atrial 
aspect of valve leaflet will experience physiological flow across the mitral orifice. 
When flow moves from the proximal opening of the construct to the distal end, 
‘tubular MV leaflets’ in an open position will mimic the diastole phase of native 
cardiac cycles (Figure 5.8A); when flow moves from the distal part of tubular 
constructs to the proximal opening, ‘leaflets’ will close which imitates a systolic 
phase (Figure 5.8B), in which the flow direction within the tubular constructs is 
opposite to a native valve. As endothelium is absent on the construct outer surface it 
will not be investigated in the current study design.  
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Figure 5.8. Schematic illustration of the design of pulsatile flow conditioned tubular 
constructs. The red arrows indicate flow directions in the bioreactor system; while 
the blue arrows indicate flow directions in native adult heart left atrium. During 
‘diastole’, the flexible end of the tubular construct  (represents MV leaflets) is in an 
open position with shear flow passing across (A); during ‘systole’, the flow reverses 
in direction and the ‘MV leaflets’ close (B).  
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To date, though basic design of the pulsatile flow bioreactor system has been 
developed, the detailed conditioning parameters have not been determined so far. In 
previous studies, dynamic conditioning systems have been developed for mitral valve 
organ culture (Barzilla et al., 2010; Gheewala and Grande-Allen, 2010; Lacerda et 
al., 2012a; Lacerda et al., 2012b; Lieber et al., 2010).  
Typically adult heart physiological flow conditions were aimed to be reproduced in 
these systems as the cultivated organs were mature animal heart valves. For tissue-
engineered valves, however, the application of physiological dynamic conditions for 
adult hearts would not necessarily be applicable for the early tissue development 
construct models. It has been suggested any type of TE cardiovascular structure 
should be conditioned following a foetal cardiac developmental protocol, which is 
less than 5% radial strain, low oxygen tension and a crescendo heart rate (Stock and 
Vacanti, 2001).  
Gradually increased pulse rate dynamic conditioning as well as low shear stress 
conditioning has been found to enhance cell attachment and alignment as well as 
ECM remodeling in tissue engineered heart valves (Flanagan et al., 2007; Flanagan 
et al., 2009; Jockenhoevel et al., 2002; Weston and Yoganathan, 2001). Once a 
relatively mature neo structure is achieved, it would be reasonable to gradually adjust 
conditions towards a physiological level. In adult dog heart, maximum early diastolic 
transmitral pressure gradient (ETPmax) is 2.8+0.8 mmHg (Courtois et al., 1988). 
Normal diastolic flow velocity peak across mitral valves is considered as a range of 
in 0.8-1.0 m/sec (Belanger, 2010). Adult dog heart rate is about 70-160 beats/min 
(Cote, 2010). All these physiological parameters should ideally be reproduced in 
vitro for mature canine tissue engineered mitral valve construct cultivation.  
In summary, an integration of construct mechanical properties and general criteria of 
tissue engineered construct dynamic conditioning as well as native adult 
physiological cardiac flow parameters will determine the specific values of the 
dynamic conditioning in future experiments involving this model. 
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5.4.3 Potential Application of the Valve Tubular Construct for 
MMVD Pathogenesis Investigation  
The initial application current valve tubular construct is planned to test the shear 
stress hypothesis in the aetiology of MMVD. As has been described in Table 5.1 
(Stage 2), three types of tubular construct models will be generated in next step of 
this project. By utilizing pulsatile shear flow conditioning, it is predicted a superior 
physiological model will be achieved showing greater resemblance to native mitral 
valve compared to static 3D cultures. A pathological model (endothelial damage) 
will also be produced based on normal dynamic conditioned constructs. It is expected 
that myxomatous mitral valve disease related changes will occur in the wounded 
model, such as endothelial dysfunction, VIC phenotype transformation, proliferation 
and migration as well as ECM remodeling.  
Potential further applications of this model could include application in drug 
discovery and therapeutic investigation, as well as MMVD putative marker 
examination. Potential examples include antagonists of endothelin receptors (Mow 
and Pedersen, 1999), serotonin receptor blockers (Orton et al., 2012; Oyama and 
Levy, 2010) and advanced glycation end products.  
5.5 Conclusion  
A tubular mitral valve construct has been developed and the principal and the 
feasibility of construct fabrication and endothelialisation has been confirmed. A 
customized bioreactor system has been designed and specific conditioning values 
will be decided at a later date. In future work, the dynamic conditioned valve tubular 
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Chapter 6: Expression of Advanced Glycation 
End Product Carboxymethyllysine in Canine 
Myxomatous Mitral Valve Disease 
Abstract 
In the current study, fibrin based mitral valve constructs have been developed. It is 
believed these in vitro models can be a research platform to investigate the role of a 
wide range of molecules with biochemical effects in valve function and disease. In 
this project the intention was firstly to investigate the role of advanced glycation end 
products (AGEs) in MMVD pathogenesis. Prior to the 3D construct based 
investigation, it was necessary to know if there is a link between AGEs and naturally 
developed MMVD.  
The aim of this study was to determine the expression of the advanced glycation end 
product-carboxymethyllysine (CML) in native valve tissue and blood samples of 
dogs with myxomatous mitral valve disease, and to investigate the potential role of 
AGEs in canine MMVD, using a combination of protein immunoblotting (Western 
blot), immunohistochemistry and ELISA techniques. 
CML expression was clearly identified in canine mitral valves. Comparing normal 
(n=3) and diseased valves (n=3), there was a clear difference with marked increased 
expression of CML in the diseased valves. When serum expression of CML in 
normal dogs (n=8) and dogs with confirmed MMVD (n=15) was compared, there 
was no difference in expression (1.15 ± 0.16 µg/ml vs 1.18 ± 0. 12µg/ml). There was 
a tendency for weak negative correlation between CML serum values and age.  
These findings suggest CML might contribute to the pathogenesis of MMVD, and 
the role of CML in MMVD can be further investigated utilising current 3D static 
mitral valve construct model. This will be under-taken in future studies. 
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6.1 Introduction  
In previous chapters, tissue engineered canine mitral valve 3D constructs have been 
developed. It is believed these are promising research tools for investigation of 
MMVD aetiology. They can be particularly useful in examining putative chemicals 
related to MMVD. For example, the advanced glycation end products.  
Advanced glycation end products (AGEs), examples include pentosidine and 
carboxymethyllysine (CML), are complexes produced in the Maillard reaction that 
have important effects on extracellular matrix (ECM) biology. Once formed, AGEs 
are persistent compounds and natural age-associated accumulation has been found in 
many tissues including skin, bone and cartilage, and heart and blood vessels (Singh 
et al., 2001). AGEs can also be dietary in origin, with the main source being high 
heat processing or cooking of food which is also known to contribute to diabetic 
nephropathy in humans (Semba et al., 2010; Yamagishi, 2011). AGEs have high 
affinity for long-living proteins such as present in ECM and can impair tissue 
functions through a variety of pathways, including forming glucose-mediated 
intermolecular cross-links (Hartog et al., 2007). These cross-links are considered as 
having a primary effect on aging of collagen, increased biomechanical stiffness and 
enzyme-resistance, and reduced collagen turnover. AGEs also react with their 
receptor (RAGE) resulting in induction of oxidative stress, up-regulation of 
inflammatory signals and connective tissue growth factors which can then lead to 
expansion and remodelling of the ECM and endothelial dysfunction (Twigg et al., 
2001).  
The study of AGEs in cardiac disease has concentrated on diabetes mellitus and the 
consequent damaging effects on cardiac function, the increased risk of cardiovascular 
events, and atherosclerosis as part of the metabolic syndrome (Barlovic et al., 2011). 
In ageing and the diabetic heart, collagen acts as a target protein for AGEs 
accumulation. The reduced compliance of cardiovascular tissue in heart failure may 
be a result of AGEs cross-linking collagen and elastin, increased collagen production 
and reduced collagen degradation. Indeed, soluble RAGE and serum pentosidine are 
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recognised as independent risk factors for heart failure in human patients, and plasma 
CML level has been found to be associated with severity and prognosis of chronic 
heart failure in human patients (Koyama et al., 2007; Koyama et al., 2008). In the 
dog AGEs accumulation has been found in cerebellar neurons, aorta, cartilage, blood 
and atherosclerotic lesions of dogs, but not in myocardium (Chiers et al., 2010; 
Comazzi et al., 2008; DeGroot et al., 2004; Shapiro et al., 2008; Weber et al., 1998).  
Myxomatous mitral valve disease (MMVD) involves changes in extra-cellular matrix 
components, including a disorganization of valve collagen and increased 
glycosaminoglycan (GAG) content. The extent and severity of connective tissue loss 
is closely associated with age-dependent disease status (Hadian et al., 2007; Han et 
al., 2010). An alteration in collagen fibril alignment and failure of maturation of 
newly produced collagen has been observed in canine MMVD previously (Hadian et 
al., 2010; Hadian et al., 2007). Since MMVD clearly involves changes in ECM 
production and organisation and alteration in collagen cross-links have previously 
documented with this disease, the aim of this pilot study was to investigate the 
possible role of CML in canine MMVD, by determining expression in valve tissue 
and measuring circulating CML levels. It has been hypothesized that the expression 
of CML is increased in myxomatous mitral valves. 
6.2 Materials and Methods 
6.2.1 Animals and Tissue Samples  
Mitral valve samples (Table 6.1) from three adult dogs with gross pathological 
evidence of MMVD (Whitney grading 1/4-4/4), and three normal dogs were 
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Table 6.1 Animals used for CML Western blot and immunohistochemistry 
Animal Age Gender Breed MMVD Severity (Whitney Grade) 
D-1 4Y F Mongrel 3/4 
D-2 5Y F Mongrel 4/4 
D-3 1Y M beagles 1/4 
H-1 <1Y M beagles 0/4 
H-2 1Y F beagles 0/4 
H-3 1Y F beagles 0/4 
 
Twenty three whole blood samples (15 MMVD cases and 8 dogs with no evidence of 
MMVD (control group)) were collected for ELISA analysis and the details are 
shown in Table 6.2. All blood samples were collected as part of an individual dog’s 
clinical care and only unused remnant of a sample was retained for analysis in 
accordance with accepted institutional and national guidelines, and with informed 
owner consent. Detail of blood sample preparation is described in Section 2.1. All 
dogs were checked for evidence of diabetes mellitus and renal failure using standard 
biochemical tests, and found to be unaffected. Either serum or plasma sample of each 
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Table 6.2 Animal cases used for CML ELISA study 
Group Age (Year) Gender Breed  Blood 
Glucose Level 
(mmol/l) 









Labrador Retriever (1) 































F, female; M, male 
6.2.2 Western Blot 
Related protocols of protein sample preparation and immunoblotting are described in 
Section 2.2. Protein samples derived from three MMVD valve and three normal 
mitral valves were probed with CML antibody (ab27684, Abcam, UK) at a 
concentration of 1 in 1,000 and the secondary antibody was same swine anti-rabbit 
antibody in Table 4.3 and the working concentration was 1 in 1,000. Ponceau S 
staining of the proteins on the membranes was carried out as loading control. 
6.2.3 Immunohistochemistry  
Detail of tissue section preparation and immunohistochemistry protocols are 
described in Section 2.11.5. Primary CML antibody was same as for immunoblotting 
at a concentration of 1 in 250. The rest of the reaction solutions including a 
secondary antibody were provided in the R.T.U. VECTASTAIN Elite ABC Kit. 
Detailed information has been described in Section 2.11.5. Canine skin tissue section 
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was used as a positive control for CML. Images were captured by using a Leica 
DMRB microscope. Representative images at magnification x 200 are presented in 
this chapter.  
6.2.4 ELISA 
A CycLex CML ELISA Kit (CY-8066, CycLex Co, Japan) was used to detect 
circulating CML levels. Prior to the assay, all reagents were brought to room 
temperature. First Antibody, 10 x Wash Buffer and CML-human serum albumin 
(HAS) Standard were provided in kit and the solutions were reconstituted according 
to manufacture instruction. CML-HAS Standard solution was prepared in a dilution 
series at concentration of 5.0 µg/ml, 2.5 µg/ml, 1.25 µg/ml, 0.63 µg/ml, 0.31 µg/ml, 
0.16 µg/ml, 0.08 µg/ml and 0 µg/ml. Canine serum or plasma samples were 1 in 4 
diluted with Sample Dilution Buffer (provided in the kit) in appropriate wells of a 96 
well sample preparation microplate. 60 µl CML-HAS Standards and diluted samples 
were added in appropriate wells of the preparation microplate. 60 µl First Antibody 
working solution was added and mixed in each well. 100 µl prepared mixture was 
transferred to an Antigen Coated Microplate (provided in the kit) and incubated at 
room temperature for 1 h on an orbital microplate shaker. The microplate was 
washed by adding 350 µl Wash Buffer for 4 times. Subsequent to the washing step, 
100 µl Substrate Reagent (provided in the kit) was added to each well and incubated 
for 20 min. The reaction ceased by adding 100 µl Stop Solution (provided in the kit). 
After all reactions, optical density (OD) value of each well was measured at 450nm 
using a VICTOR3™ V Multilable Counter (Perkin Elmer). A standard curve was 
obtained by plotting the optical density for the standard versus the concentration of 
the standard. The sample CML concentrations were then determined by a sigmoidal 
five parameter logistic equation calculated by using MasterPlex® EX 2010- 
Multiplex Expression Data Analysis Software (Hitachi Solutions America, Ltd. 
MiraiBio Group, USA). Dr.Uemoto Yoshinobu kindly provided help for statistical 
analysis with R program (The R Foundation, Austria). ANOVA test was performed 
to determine the data difference between normal and MMVD groups. Correlations 
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between CML level and age were obtained using the Pearson’s product-moment 
correlation. 
6.3 Results 
6.3.1 Western Blot Analysis 
When comparing CML modified protein expression in MMVD and normal dogs 
there were marked differences: CML modified proteins were clearly detected in three 
MMVD dogs, with band sizes between 20 and 105 kDa; While in the three normal 
mitral valves, very weak or no expression of CML was found (Figure 6.1).  









Figure 6.1. CML modified protein expression in canine MMVD and normal mitral 
valves on Western blot. Differential CML expression was observed between 
MMVD and normal group. CML modified protein bands between 20 and 105 kDa 
were detected in MMVD, while minimal CML expression was found in normal 
mitral valves. Ponceau S stained proteins were used as an equal loading control.  
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6.3.2 Immunohistochemistry  
Consistent with findings of immunoblotting, there was marked difference of CML 
expression between MMVD and normal mitral valves on immunohistochemistry 
(Figure 6.2). In normal mitral valves from three young dogs, the CML expression 
was weak to absent. All three healthy valves showed no evidence of CML expression 
in valve distal edge (Figure 6.2A). In normal valve base, some cardiomyocytes were 
positive for CML and a faint stroma staining was observed in one valve (Figure 6.2 
B). While in MMVD group, strong CML expression was detected in all three 
diseased valves. The CML staining in MMVD valve was present all through the 
valve leaflet length, from distal edge to valve base. The CML expression was evident 
in endothelium and interstitial cells in stroma of the valve distal edge (Figure 6.2D). 
In the proximal area, CML expression was prominent in cardiomyocytes as well as 
deep stroma, presumably the fibrosa lamina (Figure 6.2E).  
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  Figure 6.2. CML modified protein expression in canine MMVD and normal mitral 
valves on immunohistochemistry. In normal mitral valve, CML expression is absent 
in valve distal edge (A); weak to minimal staining was observed in myocytes (solid 
arrow in B) and weak stroma staining was observed in one valve (dash arrow in B); 
canine skin tissue was used as a positive staining control for normal valve CML 
immunohistochemistry (C), arrow in C indicates a stained blood vessel-like 
structure; while in MMVD valves, marked CML expression was observed in 
endothelium (solid arrow in D) and stroma interstitial cells (dash arrow in D) of 
valve distal area; towards to valve base, the CML staining was prominent in 
myocytes (solid arrow in E) and deep stroma (dash arrow in E); CML primary 
antibody omitted tissue section (F) was used as a negative control for MMVD valve 
CML immunohistochemistry. Scale bar =100 µm. 
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6.3.3 ELISA  
The circulating CML ELISA results are shown in Figure 6.3. The mean CML level 
in blood sample was 1.18 ± 0.12 µg/ml in the MMVD group (n=15) and 1.15 ± 0.16 
µg/ml in the control group (n=8). There was no statistically significantly difference 
between the two groups when comparing means or the variances. There was a 
tendency for weak negative correlation (r = -0.39) between circulating CML values 
and age for the combined groups (n=23), where MMVD cases were considered alone 
(r = -0.46), and for the control dogs only (r = -0.37), but these Pearson’s product-
moment correlations did not have associated p values less than 0.05 indicating a 








Figure 6.3. Circulating CML level in MMVD and normal control dogs. Statistically, 
the CML concentration in blood was not different between the two groups. The 
circulating CML level in MMVD group (n=15) was 1.18 ± 0.12 µg/ml, and was 
1.15 ± 0.16 µg/ml in the control group (n=8). 
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Figure 6.4. Correlation of circulating CML level and animal age. There was a 
tendency of weak negative correlation between CML level and age in the combined 
group, MMVD only and control only. However, statistically these correlations were 
not significant (P>0.05).  
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6.4 Discussion 
This is the first study to demonstrate CML modified protein expression in the mitral 
valve of dogs. There were clear differences in expression between diseased and 
normal mitral valves. Apparently increased CML expression was found in MMVD 
valves, while the expression in normal valves was minimal. While the main interest 
in AGE products is their possible interaction with ECM, this study has shown clear 
evidence of intra-cellular expression of CML with staining of endothelial and stroma 
interstitial cells. CML positive endothelial and interstitial cells were observed in 
canine mitral valves which matches previously reported findings in human tissues 
(Baidoshvili et al., 2004). It should be noticed that the CML expression was 
prominent in predisposed myxomatous region (valve edge) in MMVD valves but not 
in normal valves, which indicates the AGEs may play a role in myxomatous lesion 
development. 
AGEs interact with long-lived proteins through different pathways. CML is a non-
crosslink AGE product and affects tissues by binding to the receptor of AGEs 
(RAGE) to cause oxidative modification. It is also known as a “dominant AGE 
product” and CML would appear to be one of the most important AGEs participating 
in disease processes (Yamagishi, 2011). Aberrant ECM remodeling is known to be a 
key feature of MMVD (Aupperle et al., 2009a; Hadian et al., 2010; Hadian et al., 
2007), involves a complex series of events for which transforming growth factor beta 
(TGF-β) and serotonin signaling are thought to play major roles (Disatian et al., 
2010; Disatian and Orton, 2009; Oyama and Levy, 2010; Zhong et al., 2006). AGEs 
have been shown to up-regulate TGF-β expression and are also associated with 
serotonin and, therefore, their presence in MMVD is not surprising.  
The exact mechanism by which AGEs might interact with the valve ECM is 
unknown, but appears to involve stimulation of production of vascular endothelial 
growth factor (VEGF) which in turn allows stimulation of production of other 
growth factors, such as TGF-β and insulin like growth factor-1. These then 
contribute to increasing production of collagen, laminin and fibronectin (Yamagishi, 
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2011; Yamagishi et al., 2007). Furthermore AGEs interfere with matrix-to-matrix 
and matrix-to-cell interactions and reduce nitric oxide production by endothelial 
cells; functions that are important in life-long connective tissue remodelling and 
maintaining a healthy valve ECM (Yamagishi et al., 2007).  
Since AGEs accumulate at sites of long-lived proteins it can be hypothesized that the 
endogenous production of AGEs or exogenous delivery through diet would increase 
in the valve where there is a large quantity of collagen. Furthermore, the documented 
changes in collagen cross-linkages in MMVD might suggest a role for AGEs 
(Hadian et al., 2010). However, ECM remodelling in MMVD differs from fibrosis as 
would occur in kidney, lung and myocardium. The matrix changes found with 
MMVD involve a loss rather than an increase in collagen content in overtly 
myxomatous areas of the valve (Hadian et al., 2010; Han et al., 2010). The data from 
this study shows there is increased expression of CML particularly in deep stroma 
(presumably collagen-rich fibrosa lamina) of MMVD valves, but whether this 
accumulation is a disease cause or consequence remain uncertain.  
Raised circulating CML cannot be considered to be an independent risk factor for 
MMVD (Koyama et al., 2007; Koyama et al., 2008) as differences were not observed 
between dogs with MMVD and control dogs. This study has also shown that the 
circulating concentration for CML in dogs is approximately double that reported for 
normal human subjects and chronic renal failure human patients (Semba et al., 2010). 
There was a negative correlation between age and blood AGE levels, but this was too 
weak to be of any significance. Increased circulating AGEs concentrations have been 
shown to be associated with nephropathy in diabetes mellitus, renal failure and 
Alzheimer’s disease in human patients (Mostafa et al., 2007; Sanaka et al. 2000; Bär 
et al., 2003). However, in the present study, there was no significant difference 
between mean circulating CML levels in MMVD and non-MMVD dogs, despite the 
clear differences in tissue expression. One explanation of this discrepancy is the 
elimination of circulating AGEs is dependent on renal function (Singh et al., 2001; 
Miyata et al., 1998). All dogs used for the CML ELISA study were unaffected by 
diabetes mellitus and renal failure, which indicate they must have adequate renal 
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function. Effective excretion of systemic AGEs therefore can be achieved. The 
discrepancy of systemic AGE level and local tissue AGE expression has been 
discussed previously in an Alzheimer’s disease and vascular dementia study (Bär et 
al., 2003). CML level in cerebrospinal fluid of Alzheimer patients have been found 
be elevated and this change was not correlated with the serum values. It is believed 
the local tissue AGE expression can reveal the role of AGEs in specific tissue 
pathology, while the systemic AGE level is a less specific indicator that can be 
affected by many factors (for example, concurrent diseases). Therefore, the 
circulating AGE levels should be interpreted with cautions.  
One limitation of this study is a small number of dog valves were examined. 
Moreover, the distinct age difference (two old dogs and one young dog) within the 
diseased animal group used for immunohistochemistry and Western blot induced a 
variation and may potentially affect the experimental results. Though in this study, 
there were no differences observed between the results from the young diseased dog 
and from the two old ones. Additional canine valve samples would be worthy to be 
investigated to confirm the current findings in the future. 
6.5 Conclusion 
This study has found CML modified protein expression increased in canine MMVD 
valves compared to normal dogs using a combination of protein immunoblotting and 
Immunohistochemistry. Circulating CML concentrations of MMVD dogs were not 
significantly different from normal dogs. On the basis of the current data it would 
appear that AGEs may play a role in canine MMVD pathogenesis. The intention in 
future studies is increase the native valve sample size and to challenge the 3D mitral 





  234 
Chapter 7: Discussion  
The pathogenesis of MMVD is only partially understood. However, it is known that 
the major pathological changes of this disease include valve cell phenotype 
transformation as well as ECM remodelling (Barth et al., 2005; Black et al., 2005; 
Corcoran et al., 2004; Disatian et al., 2008; Disatian et al., 2010; Han et al., 2008) 
(Aupperle et al., 2009a; Cole et al., 1984; Hadian et al., 2010; Mow and Pedersen, 
1999; Prunotto et al., 2010; Rabkin-Aikawa et al., 2004a; Stein et al., 1989; Tamura 
et al., 1995). In the current study, fibrin based canine mitral valve constructs were 
developed utilising primary cells and tissue engineering techniques. The intended 
aim will be to use these artificial models as in vitro platforms for studying MMVD 
pathogenesis, particularly focusing on the contribution of diseased VICs and/or 
damaged VECs. The findings of the study were as follows. 
Characteristics of primary canine mitral valve endothelial and interstitial cells 
possess in vitro 2D culture 
Prior to 3D mitral valve construct fabrication, primary canine mitral VECs and VICs 
were successfully isolated, cultivated and characterized in 2D culture. This provides 
an important platform for primary mitral valve cell biology studies as well as 
benefiting other aspects of valve research and tissue engineering. 
Overall, relatively pure canine mitral VECs and VICs were obtained. With 
mesenchymal features having been found in both populations, endothelial marker 
expression enabled differentiation of VECs from VICs. 
Canine mitral VECs were found to possess common endothelial properties, such as 
forming a predominantly cobblestone morphology in culture, expressing the marker 
CD31 and up-taking acetylated low density protein (DiI-Ac-LDL). These features 
differentiate them from mitral VICs. Cell pleomorphism was also observed within 
the VEC culture. In addition to the different cell morphologies, RT-PCR showed 
expression of myofibroblast markers in VEC cultures. These “myofibroblasts” in the 
VEC culture could either come from differentiated VECs or contaminating VICs. 
The activated mesenchymal marker SMemb was widely expressed in VEC cultures. 
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Previous in vivo studies have shown SMemb is highly expressed by embryonic 
VECs, but minimally expressed by adult VECs (Aikawa et al., 2006). To our 
knowledge, this is the first study showing apparent SMemb expression in adult VECs 
from any species. This suggests the VEC cultures are activated in vitro and possibly 
still possess developmental EndoMT potential, which is consistent with a VEC 
progenitor cell theory proposed previously (Bischoff and Aikawa, 2011). The 
EndoMT transformation of adult VECs have been investigated in a number of 
studies, and this mechanism is believed to be one of the key remodelling processes in 
valve diseases (Bischoff and Aikawa, 2011; Mahler et al., 2013; Paranya et al., 2001; 
Paruchuri et al., 2006). The hypothesis is that a subset of adult VECs possessing 
embryonic differentiation potential and could be a ‘stock’ cell source for replenishing 
VICs in disease or normal remodelling situations; similar to a foetal EndoMT 
development (Bischoff and Aikawa, 2011; Paruchuri et al., 2006).  
The VIC contamination in VEC cultures has been discussed in previous reports, 
which has been considered as a common problem in primary isolated VECs using 
enzymatic digestion techniques (Butcher et al., 2004; Cheung et al., 2008). 
Additional VEC purification methods such as magnetic or fluorescence activated cell 
sorting or single clonal expansion appear to be effective solutions for the VIC 
contamination issue (Cheung et al., 2008; Gould and Butcher, 2010; Hoerstrup et al., 
1998; Paranya et al., 2001). Moreover in purified VECs, using CD146 FACs as well 
as endothelial basal medium cultured VECs, the myofibroblast marker expression 
dramatically decreased. This suggests the proliferation of contaminating VICs and/ 
or differentiation of VECs were suppressed by both processes. To obtain a purer 
VEC population, a combination of cell sorting followed by endothelial specific 
medium culture should give optimal outcomes. 
The VICs are the major cell type in all heart valves. It has been well known that sub-
populations exist in this versatile population (Durbin and Gotlieb, 2002; Liu et al., 
2007). However, there is no clear marker panel for differentiating VIC sub-
populations. In this study, the entire VIC population has been defined as expressing 
vimentin but negative for endothelial markers (Heaney et al., 2009). Regarding sub-
populations, cells in 2D VIC cultures have been found to express activated VIC 
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markers α-SMA, SM22 and SMemb (Blevins et al., 2006; Della Rocca et al., 2000; 
Disatian et al., 2008; Disatian et al., 2010; Han et al., 2008; Rabkin et al., 2001; 
Stephens et al., 2011; Wiester and Giachelli, 2003). This is distinct from healthy 
mitral VICs in vivo, which are predominantly a quiescent phenotype (vimentin 
positive only). The VIC phenotypic activation has been observed in a number of 
valve diseases such as the MMVD (Disatian et al., 2008; Han et al., 2008; Rabkin-
Aikawa et al., 2004b; Rabkin et al., 2001). In pathological conditions, these activated 
myofibroblast-like cells  (aVICs) have been implicated as a major player in ECM 
synthesis, remodelling (Aupperle et al., 2009a; Gupta et al., 2009a; Han et al., 2010) 
and degradation (Aupperle et al., 2009b; Disatian et al., 2008; Rabkin et al., 2001), 
and also responsible for cell proliferation and migration in the valve repair process 
(Black et al., 2005; Durbin et al., 2005; Lester et al., 1993; Lester and Gotlieb, 1988). 
Cell phenotypic markers in 2D VIC cultures were assessed in this study. Moreover 
SMemb protein was found in all cells in VIC culture, while α-SMA expression 
varied between different cultures. This is consistent with in vivo studies in which α-
SMA and SMemb demonstrate differential distribution patterns in diseased valve 
(Disatian et al., 2008; Disatian et al., 2010; Rabkin et al., 2001). All this suggests 
heterogeneity exists even within the aVICs population. Future investigations of the 
aVICs phenotypic plasticity would be necessary to gain clearer understanding of 
valve disease or remodeling mechanisms.  
Other future work directions using the 2D valve cell culture system may include 
identification of embryonic differentiation potential in the VECs, and comparison of 
ECM synthesis profile in healthy and diseased VICs. As has been mentioned before, 
cells in the adult VEC cultures have been found widely expressing SMemb protein. 
Counterstaining of SMemb and endothelial markers in the VECs would be necessary 
to carry out in order to confirm cell identity. If SMemb positive cells in the VEC 
culture were actually endothelial in nature, it can be proposed embryonic-like 
differentiation potential (EndoMT) may exist in the current VEC culture system. 
EndoMT pathways such as notch signalling would be worthwhile examining in the 
model in future studies (Orton et al., 2012). 
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Since ECM weakness is a cardinal feature in MMVD, it can be presumed that the 
diseased VICs may possess differential ECM remodelling capability to normal VICs.  
Although in the current study, when comparing mild diseased VICs to healthy VICs, 
there were no apparent differences in the cell activation and matrix catabolism 
markers. In future studies, it would be necessary to evaluate a panel of the native 
valve ECM markers (such as proteoglycan and GAGs, collagen and elastin) in these 
two cell populations. VICs from late stage MMVD valves should also be 
investigated. 
The potential for using tissue-engineered mitral constructs as an in vitro 
platform for valve research, particularly for MMVD pathogenesis 
Tissue engineering is fast becoming a commonly used technology in regenerative 
medicine. Though the majority of the attempts are focusing on generating artificial 
organs for clinical usage, the value of using TE constructs as preclinical research 
tools has also been recognized (Gibbons et al., 2012; Griffith and Swartz, 2006). 
Fibrin hydrogel systems are a relatively novel scaffold in the tissue engineering area. 
It has been described as ‘excellent cell carrier’ as they are favorable for cell 
distribution, cell communication and synthesis of ECM in a 3D culture system (Lee 
et al., 2008; Pikaart, 2008; Ye et al., 2000). Fibrin based canine mitral valve 
constructs in static culture were found to possess some native mitral valve properties 
including tissue-like gross and histological morphology, expression of native cell 
phenotypic markers and, demonstration of ECM synthesis and degradation 
capability. This suggests cultured mitral valve cells still have potential for organizing 
a native valve structure, which makes them an attractive cell source for heart valve 
tissue engineering. The good cell replication, without excessive cell number 
expansion, is another positive feature, such that cells derived from a medium size 
dog mitral valve can generate hundreds of static 3D constructs using current 
technologies. This could ameliorate the problems of native tissue shortage in valve 
research, in which the tissue engineered constructs could serve as partial substitutes 
for native valves.  
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Recently, the application of tissue engineered/3D culture models in valve research 
has attracted great attention. A numbers of fundamental questions were allowed to be 
examined through these models, examples including valve cell-cell interaction 
(Butcher and Nerem, 2006), cellular response to mechanical strain (Gupta et al., 
2009b; Lacerda et al., 2012a; Lacerda et al., 2012b) and signaling pathways involved 
in valve embryonic development (Butcher and Markwald, 2007; Chiu et al., 2010; 
Stock and Vacanti, 2001).  
In this project, the fibrin based tissue engineered VECs-VICs co-culture models have 
been particularly used for studying the pathogenesis of MMVD. The MMVD 
pathogenesis has been partially understood. Cellular transformation and interaction, 
mechanical stimuli and developmental-like signaling pathways are three major 
aspects in recent research of MMVD. The first two areas were examined in the 
current study.  
Healthy and diseased VICs contribute similarly to MMVD marker expression in 
3D static constructs 
The most clearly identifiable cellular alteration in MMVD is VIC phenotype 
transformation and endothelium denudation over the lesion area (Barth et al., 2005; 
Black et al., 2005; Corcoran et al., 2004; Disatian et al., 2008; Disatian et al., 2010; 
Han et al., 2008; Mow and Pedersen, 1999; Prunotto et al., 2010; Rabkin-Aikawa et 
al., 2004b; Stein et al., 1989). However, it is uncertain if disease is initiated from 
abnormalities of VICs or from endothelial damage. It has been proposed the 
activated/diseased VICs might be a primary initiator for ECM alteration during 
disease development (Prunotto et al., 2010; Walker et al., 2004). In the current study, 
diseased VIC based mitral valve constructs were generated and compared with 
constructs containing VICs from healthy valves. Previous in vivo studies have shown 
the VICs in diseased valves are phenotypically activated and expressing excess ECM 
catabolic enzymes (Disatian et al., 2008; Disatian et al., 2010; Han et al., 2008; 
Rabkin et al., 2001). However, the diseased VICs and healthy VICs were found to 
show similar phenotypic and ECM remodeling behaviour in the fibrin based 3D 
culture system.  In contrast to a native mitral valve (predominantly vimentin positive 
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cells), mesenchymal marker vimentin, activated VIC phenotypic marker α-SMA and 
SMemb were all evidently expressed in both diseased and healthy VIC based 
constructs. Collagenase MMP-1 and stromyslin MMP-3 expression have been found 
to be up-regulated in MMVD (Aupperle et al., 2009c; Disatian et al., 2008; Obayashi 
et al., 2011; Rabkin et al., 2001). The similar expression levels of MMP-1 and MMP-
3 in diseased and healthy VICs based constructs suggest ECM synthesis and 
degradation activity is not different in both construct types. As most of the markers 
typically used to examine MMVD are minimally expressed in healthy mitral valves, 
but up-regulated in the diseased condition, their clear expression in both types of 
constructs suggests they are more closely modelling MMVD rather than the normal 
valve. The ultrastructure analysis results supporting the above assumption (variable 
cell morphology, cell degradation and activation as well as ECM synthesis) were 
observed which suggested a remodeling process.  
The culture environment is likely to be the major contributor to cell activation in 
these tissue-engineered systems. Firstly, fibrin is not a native ECM component and 
there is a need for cells to ‘clean up’ this foreign protein and rebuild a more typical 
matrix environment which surrounds them in vivo. Activation of VICs is necessary to 
accomplish this remodeling process. It has been shown that MMP-3 is capable of 
cleaving fibrin cross links in vitro and MMP-3 is important in valve remodeling (Bini 
et al., 1996). Inadequate gas and nutrient perfusion into the deeper construct stroma 
is another possible cause which might lead to cell changes. Secondly, the mechanical 
properties of the culture system might trigger cell activation. Fibrin hydrogel has 
similar mechanical properties to a GAG environment, which is a characteristic of 
myxomatous lesions (Gupta et al., 2009a; Han et al., 2010; Tamura et al., 1995). 
Cells might be reacting as if they are in a “pathological” stroma and so begin to 
initiate ECM remodeling processes. Furthermore, it has been shown that a stiff 
culture substrate can also contribute to cell activation (Kural and Billiar, 2013; Pho et 
al., 2008). Further work is planned to examine the effects of movement on construct 
morphology using a custom built bioreactor system. 
Though cell activation has been observed in the current model, the exact activation 
mechanism was not investigated. Previous reports have suggested the VIC activation 
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and repair in diseased heart valves as well as the tissue engineering heart valves 
share similar signaling pathways to embryonic heart valve development (Butcher and 
Markwald, 2007; Chiu et al., 2010; Goodwin et al., 2005; Orton et al., 2012). 
Serotonin/TGF-β signaling pathway has been proposed to be an initiator for the VIC 
activation (Merryman et al., 2007; Walker et al., 2004). Therefore, examination of 
this pathway would be necessary in future work examining this model.  
An additional consideration is the potential effect of diseased VICs on overlying 
VEC function, but this has not been fully examined so far due to time constraints. 
Indeed, the ultrastructure study on the construct suggested morphological 
abnormality was present in the proposed endothelium. Future work will be necessary 
to functionally assess the endothelial layer in these constructs, which should help to 
examine the question of endothelium loss as a contributor to in MMVD.  
This model could be used to examine the potential for disease reversal and to 
evaluate effects of mechanical and biochemical activation or therapeutic reagents on 
disease manifestation. As an example, since it is known that VIC activation involves 
the TGF-β signalling pathway, the effect of interference with that pathway can be 
examined, and in a controlled sequential manner. 
Additionally, putative chemical triggers for MMVD could be applied to the 
constructs, and examined to see if characteristics of MMVD become more evident. 
For example, the advanced glycation end product (AGE) carboxymethyline (CML) is 
a biochemical compound known to affect long living protein such as collagen. 
Distinct CML expression in canine MMVD valves, examined in this project, 
suggests AGEs might be a putative regulator of MMVD pathogenesis. In future 
work, the role of AGEs in MMVD can be analyzed by introducing exogenous CML 
to the 3D construct system, followed by evaluation of changes on MMVD related 
markers. 
Wound site changes in static 3D constructs after endothelium damaged 
Endothelial damage is commonly observed in the MMVD lesion area (Corcoran et 
al., 2004; Stein et al., 1989). One possible hypothesis of MMVD pathogenesis is that 
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long term shear stress induced endothelial damage triggers sub-endothelial VIC 
activation and further ECM remodeling (Corcoran et al., 2004; Durbin and Gotlieb, 
2002; Pedersen and Haggstrom, 2000; Prunotto et al., 2010; Stein et al., 1989). In 
this study, an endothelial damage model was developed (Type 3) based on the Fibrin/ 
VECs-VICs 3D co-culture mitral constructs in static culture condition. Depending on 
different manipulation techniques applied, the Type 3 constructs had been further 
divided in to adherent Type 3 (Type 3-A) and floating Type 3 (Type 3-F). After 
endothelial damage, the constructs were followed for a 6 day period. The hypothesis 
was that, in response to endothelial injury the VICs in the construct stroma would be 
activated and initiate a repair-like process. Indeed, increased expression of the 
activated mesenchymal marker SMemb was detected in Type 3A constructs when 
compared to intact control constructs, especially on Day 2 and Day 6. In the majority 
of Day 2 and Day 6 Type 3-F constructs, although total SMemb expression 
decreased (presumed due to mechanical alteration), some SMemb positive cells were 
found to be associated with the wounded surface. Transmission electron microscopy 
examination showed viable cells with ECM components surrounded at the wound 
site and also there was evidence of cells appearing to migrate from the deep stroma. 
These results suggest VICs have been activated in the wounding model and SMemb 
positive aVICs possibly play a role in valve injury repair. Interestingly, in contrast to 
SMemb, another aVIC marker α-SMA appears not to increase in response to the 
injury in Type 3-F constructs on Day 2 and Day 6. Moreover, any changes in α-SMA 
expression did not affect the expression of ECM related proteins (collagen Type I 
and III and MMP-1), whereas SMemb expression pattern appeared to be more 
associated with the ECM related proteins.  
Mitral VIC repair has been investigated in previous organ culture or cell culture 
studies (Durbin et al., 2005; Gotlieb et al., 2002; Lester et al., 1993; Lester et al., 
1992; Tamura et al., 2000). The repairing process involves cell proliferation and 
migration (Lester and Gotlieb, 1988), and expression of cytokines (e.g FGF-2, NO 
and integrin) (Durbin et al., 2005; Fayet et al., 2007; Gotlieb et al., 2002) and ECM 
products (e.g. fibronectin) (Fayet et al., 2007). It has been proposed both motile VICs 
and secretory VICs are required in the wound repair process; the former in an early 
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response mainly involving cell proliferation and migration towards the wound, while 
the latter being responsible for ECM synthesis and catabolism at the wound sites, 
which is believed to be subsequent to cell proliferation and migration (Durbin and 
Gotlieb, 2002). Based on the results of the current study it might be presumed that 
the α-SMA positive population is the motile phenotype, while the SMemb positive 
cells are more related to secretory activity. Similar findings have been reported in 
previous studies in which α-SMA and SMemb have shown distinct expression 
patterns in diseased canine mitral valves, and where the SMemb expression appears 
to be more related to synthesis (Disatian et al., 2008; Disatian et al., 2010).  Previous 
reports also support the α-SMA association with motile activity and it has been 
shown the α-SMA positive VICs are responsible for cell migration, contractility and 
valve internal force generation (Lester et al., 1993; Stephens et al., 2010a). Given the 
fact that Type 3 constructs contraction mainly occurred within 48 hours, it is very 
likely the current study missed α-SMA up-regulation when assessed at the time 
points selected. It would be necessary to examine α-SMA protein alteration, cell 
proliferation and migration at earlier time points in future studies.  
The SMemb protein has been identified to associate with undifferentiated or 
‘synthetic state’ smooth muscle cells (Koo and Gotlieb, 1991; Sluiter et al., 2012), 
and it is likely SMemb positive VICs are the major synthetic cell population in heart 
valves. The signaling pathways involved in the repair process were not investigated 
in the current study due to time constraints, but several developmental pathways have 
been identified in the VIC wound healing process such as TGF-β/smad signaling 
(Han and Gotlieb, 2011) and Wnt/β-catenin signaling pathway (Xu and Gotlieb, 
2013). This is of interest considering the similarity of the VICs in response to valve 
injury and the myxoid changes typical of MMVD and features of foetal valve 
development.  
Apart from the VIC activation close to wound sites, it was also found that decreased 
mechanical tension resulted in down-regulation of total expression of the aVIC 
markers (SMemb and α-SMA) in Type 3F constructs. Ultrastructure analysis 
suggests there was smooth muscle-like phenotype cell degradation, which was likely 
to be a response to the decreased mechanical stretch. It is known that the VICs are 
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responsive to substrate stiffness (Kural and Billiar, 2013; Stephens et al., 2011; 
Stephens et al., 2010b), and α-SMA expression has been found to be up-regulated by 
exogenous mechanical forces or high culture substrate stiffness in vascular smooth 
muscle cells and aortic VICs (Kural and Billiar, 2013; Pho et al., 2008). In the 
current study, it is likely the decreased exogenous tension on the constructs 
modulated the activated VICs, especially their contractile phenotype, to a more 
quiescent and/or synthetic phenotype.  
The reversal of phenotypic plasticity of mitral valve VICs has been discussed in 
previous studies. Rabkin and colleagues proposed VICs tend to be activated in 
response to novel altered mechanical environment (such as disease or physiological 
remodeling process) and once a steady-state equilibrium has been achieved the 
aVICs will then transform back to a quiescent phenotype (Rabkin-Aikawa et al., 
2004b; Rabkin-Aikawa et al., 2005). VICs in tissue engineering heart valves 
transform gradually from activated myofibroblasts back to fibroblasts (quiescent 
VICs), particularly after implantation (Rabkin et al., 2002). Furthermore, applying 
15% cyclic strain to a collagen hydrogel model has been shown to modify aVICs 
from myxomatous diseased mitral valves to a quiescent fibroblast phenotype 
(Waxman et al., 2012). Reversing GAG production by VICs has also been observed 
in a 3D collagen model in which the GAGs level was increased with cyclic stretch 
and decreased with subsequent relaxation (Gupta et al., 2008a). These data from 
various studies suggest mitral VICs have reverse plasticity capacity in both terms of 
cell phenotype and synthetic activity, potentially allowing strategies for disease 
reversal to be identified.  
Advanced model-dynamic conditioned tissue engineered mitral valve construct 
A major limitation of the static 3D constructs produced is that the effect of flow is 
excluded. Knowing that dynamic flow conditions are important to native valve 
functions and tissue-engineered heart valve development, a pulsatile flow 
conditioned tubular construct model has also been designed. Future work will use a 
bioreactor for accommodating the constructs and to allow tissue-flow interaction in 
the system, aimed to mimic as far as is possible physiological cardiac conditions. To 
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date, the study has preliminarily proved the feasibility of tubular construct 
fabrication and endothelisation. A customised bioreactor has also been developed 
and specific conditioning values will be determined based on tissue mechanical 
properties and tissue engineering conditioning criteria. In the next stage, both a 
physiological and a pathological (endothelium damage) tubular construct model will 
be generated and exposed to the dynamic conditioning. It is believed this would be a 
superior model to the static constructs in resembling naturally developed tissue. It 
has been shown that the dynamic conditioning of a tissue engineered construct can 
overcome the common gas/nutrient perfusion issue limitation in static culture, 
improve cell proliferation and viability and enhance extracellular matrix production 
and organization in tissue engineered heart valves (Flanagan et al., 2007; Schenke-
Layland et al., 2003; Sodian et al., 2000; Wendt et al., 2009; Weston and 
Yoganathan, 2001). Moreover, a pulsatile flow system would allow examining the 
shear flow/stress effects on the mitral valve tubular construct endothelium, which 
may go some way to improving understanding of the role of shear stress induced 
VEC damage in the MMVD pathogenesis. 
Conclusion 
In summary, tissue-engineered mitral valve research models have been generated in 
the current project. MMVD-like features (i.e. VIC activation and excessive ECM 
catabolism) have been observed in the current model regardless of using VICs 
derived from healthy or MMVD valves. External mechanical stimuli have been 
found to modulate the VICs behaviour in the current 3D static model: the VICs are 
activated in response to endothelial damage, whereas the decreased mechanical 
tension appears to down-regulate the VIC activation. Moreover, in later stage of this 
project, a tissue engineered tubular construct model and a pulsatile shear flow 
conditioning bioreactor system have been generated for future work. By utilizing 
pulsatile shear flow conditioning, it is predicted a superior physiological and a shear 
stressing endothelial damage model will be achieved showing greater resemblance to 
naturally occurred biological processes compared to static 3D constructs. 
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It is believed the tissue engineered models developed in this project are promising 
research platforms for heart valve in vitro research. These will particularly benefit 
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